Note: Descriptions are shown in the official language in which they were submitted.
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
TITLE OF THE INVENTION
SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S
DISEASE
FIELD OF THE INVENTION
The invention is directed to spiropiperidine compounds which are useful as
inhibitors of the beta
secretase enzyme, and are useful in the treatment of diseases in which the
beta secretase enzyme is
involved, such as Alzheimer's Disease.
BACKGROUND OF THE INVENTION
Alzheimer's disease is characterized by the deposition of amyloid in the brain
in the form of
extra-cellular plaques and intra-cellular neurofibrillary tangles. The rate of
amyloid accumulation is a
combination of the rates of formation, aggregation and egress from the brain.
It is generally accepted
that the main constituent of amyloid plaques is the 4kD amyloid protein ((3A4,
also referted to as A(3, (3-
protein and (3AP) which is a proteolytic product of a precursor protein of
much larger size. The amyloid
precursor protein (APP or APPP) has a receptor-like structure with a large
ectodomain, a membrane
spanning region and a short cytoplasmic tail. The Ap domain encompasses parts
of both extra-cellular
and transmembrane domains of APP, thus its release implies the existence of
two distinct proteolytic
events to generate its NH2- and COOH-termini. At least two secretory
mechanisms exist which release
APP from the membrane and generate soluble, COOH-truncated forms of APP
(APPS). Proteases that
release APP and its fragments from the membrane are termed "secretases." Most
APPs is released by a
putative a-secretase which cleaves within the A(3 protein to release a-APPs
and precludes the release of
intact A(3. A minor portion of APPS is released by a P-secretase ("(3-
secretase"), which cleaves near the
NH2-terminus of APP and produces COOH-terminal fragments (CTFs) which contain
the whole A(3
domain.
Thus, the activity of (3-secretase or (3-site amyloid precursor protein-
cleaving enzyme ("BACE")
leads to the cleavage of APP, production of Ap, and accumulation of (3 amyloid
plaques in the brain,
which is characteristic of Alzheimer's disease (see R. N. Rosenberg, Arch.
Neurol., vol. 59, Sep 2002,
pp. 1367-1368; H. Fukumoto et al, Arch. Neurol., vol. 59, Sep 2002, pp. 1381-
1389; J.T. Huse et al, J.
Biol. Chein., vol 277, No. 18, issue of May 3, 2002, pp. 16278-16284; K.C.
Chen and W.J. Howe,
Biochem. Bioplzys. Res. Comm, vol. 292, pp 702-708, 2002). Therefore,
therapeutic agents that can
inhibit (3-secretase or BACE may be useful for the treatment of Alzheimer's
disease.
The compounds of the present invention are useful for treating Alzheimer's
disease by inhibiting
the activity of P-secretase or BACE, thus preventing the formation of
insoluble A(3 and arresting the
production of A(3.
-1-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
SUMMARY OF THE INVENTION
The present invention is directed to spiropiperidine compounds represented by
general formula
m
Y
R1,H N,R2
N
\ R4
R3
(I)
or its tautomer (I')
Y
R,
N N, R2
N R4
.Q
R3
(I')
and individual enantiomers and diastereomers thereof, and pharmaceutically
acceptable salts thereof,
which are useful as inhibitors of the (3-secretase enzyme.
The invention is also directed to pharmaceutical compositions which include a
therapeutically
effective amount of a compound of formula (I), or pharmaceutically acceptable
salts thereof, and a
pharmaceutically acceptable carrier. The invention is also directed to methods
of treating mammals for
diseases in which the (3-secretase enzyme is involved, such as Alzheimer's
disease, and the use of the
compounds and pharmaceutical compositions of the invention in the treatment of
such diseases.
DETAILED DESCRIPTION OF THE INVENTION
In one embodiment, the present invention is directed to spiropiperidine
compounds represented
by general formula (I)
-2-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Y
R1,H N.R2
N R4
\
R3
(~)
or its tautomer (I')
Y
RN N,R2
N R4
.Q
R3
(I')
wherein
X is selected from the group consisting of
(1) N; and
(2) CR5, wherein R5 is selected from the group consisting of
(a) hydrogen,
(b) -C1-6 alkyl,
(c) -C3-7 cycloalkyl,
(d) - C1-6 alkyl,
(e) -C0-6 alkyl-aryl,
(f) -C0-6alkyl-heteroaryl,
(g) halo, and
(h) a heterocyclic group having 4 to 8 ring atoms, wherein one ring atom is a
heteroatom selected from the group consisting of nitrogen and oxygen,
wherein said alkyl, cycloalkyl, aryl or heteroaryl R5 moiety is optionally
substituted with one or more
(1) halo,
(II) -C1-6 alkyl,
-3-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
(III) -O-C1-6 alicyl, and
(IV) -N02;
X' is selected from the group consisting of
(1) NR5; and
(2) CRSRS', wherein R5' is selected from the same group as R5;
Y is selected from the group consisting of
(1) 0, and
(2) S;
Rl is selected from the group consisting of
(1) hydrogen,
(2) -C 1-10 alkyl,
(3) -C2_10 alkenyl,
(4) -C2-10 alkynyl,
(5) -C3-12 cycloalkyl, wherein one or two of the ring carbon atoms is
optionally replaced by a
-Si(C1-6 alkyl)2- group,
(6) -C3-12 cycloalkenyl,
(7) a heterocyclic group having 4 to 8 ring atoms, wherein one ring atom is a
heteroatom selected from the group consisting of nitrogen, sulfur or oxygen,
(8) aryl,
(9) heteroaryl,
wherein said alkyl, cycloalkyl, heterocyclic, alkenyl, alkynyl, aryl or
heteroaryl Rl moiety is
optionally substituted with one or more
(a) halo,
(b) -OH,
(c) -CN,
(d) -C1-10 alkyl
(e) -C3_12 cycloalkyl,
(f) -0-C1-10 alkyl,
(g) -O-CH2-aryl,
(h) aryl,
(i) heteroaryl,
G) -NR5R5'
(k) NC(=0)R5,
-4-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
(1) a heterocyclic group having 4 to 8 ring atoms, wherein one ring atom is a
heteroatom
selected from the group consisting of nitrogen, sulfur and oxygen,
(m) - SO2C 1-3 allcyl,
(n) - SO2NR5R5',
(o) -NR5SO2C1-3alkyl,
(p) - C02R5,
(q) - CONR5R5',
(r) - COR5, and
(s) -Si(C1-6 a11cYl)3
wherein said aryl or heteroaryl moiety is optionally substituted with one or
more
(I) halo,
(II) -C1-6 alkyl, wherein said alleyl is optionally substituted with one or
more halogen,
(III) -O-C 1 _6 alkyl, and
(IV) -N02;
R2 is selected from the group consisting of
(1) hydrogen,
(2) -C1-10 alkyl,
(3) -C2-10 alkenyl,
(4) -C2-10 alkynyl,
(5) -C3-12 cycloalkyl, wherein one or two of the ring carbon atoms is
optionally replaced by a
-Si(C1-6 allcyl)2- group,
(6) a heterocyclic group having 4 to 8 ring atoms, wherein one ring atom is a
heteroatom selected from the group consisting of nitrogen and oxygen,
(7) aryl,
(8) heteroaryl,
wherein said alkyl, cycloalkyl, heterocyclic group, alkenyl, alkynyl, aryl or
heteroaryl R2
moiety is optionally substituted with one or more
(a) halo,
(b) -OH,
(c) -CN,
(d) -CI-10 alkyl
(e) -C3_12 cycloalkyl,
(f) -O-C1-10 alkyl,
-5-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
(g) -C0-6 alkyl-aryl, wherein said aryl is optionally substituted with one or
more
(i) halo,
(ii)-OH,
(iii) -CN,
(iv) -C 1-6 alkyl,
(v) -C2-6 alkenyl,
(vi) -OC1-6 alkyl,
(vii) - C 1-6 haloalkyl,
(viii) - S02C1-3 alkyl,
(ix) - SO2N R5R5', or
(x) - CONR5R5;
(h) -C0-6 allcyl-heteroaryl,
(i) NC(=0)-NR5R5';
(j) NC(=O)-C1-3 alkyl-NR5R5';
(k) -NC(=O)R5
(1) -NR5R5',
(m) a heterocyclic group having 4 to 8 ring atoms, wherein one ring atom is a
heteroatom
selected from the group consisting of nitrogen and oxygen, and
(n) -Si(C1-6 alkYl)3
and said alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic moiety is
optionally substituted with one or more
(i) halo,
(ii)-OH,
(iii) -CN,
(iv) -C1-10 alkyl,
(v) -OC1-10 alkyl,
(vi)-S02C1-3 alkyl,
(vii) - SO2N R5R5',
(viii) NR5SO2C1-3alkyl,
(ix) - C02R5, and
(x) - CONR5R5;
Q is -C1_6 alkylene, wherein said alkylene is optionally substituted with one
or more
(a) halo,
(b) -OH,
(c) -CN,
(d) -C1-10 alkyl
-6-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
(e) -C3_12 cycloalkyl,
(f) -O-C 1-10 alleyl,
(g) aryl, and
(h) heteroaryl;
R3 is selected from the group consisting of
(1) hydrogen,
(2) -C1-10 alkyl,
(3) -C2-10 alkenyl,
(4) -C2-10 allcynyl,
(5) -C3-12 cycloallryl, wherein one or two of the ring carbon atoms is
optionally replaced by a
-Si(C1-6 alkyl)2- group,
(6) -C3_12 cycloalkenyl,
(7) aryl, and
(8) heteroaryl,
wherein said alkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aryl or
heteroaryl R3 moiety is
optionally substituted with one or more
(a) halo,
(b) -OH,
(c) -CN,
(d) -C1-10 alkyl,
(e) -C2-10 alkenyl,
(f) -C3_12 cycloalkyl,
(g) -O-C3_12 cycloalkyl,
(h) -0-C1-10 alkyl,
(i) -0-C3_12 heterocyclic, wherein said heterocyclic group has from 4 to 8
ring atoms,
wherein one ring atom is a heteroatom selected from the group consisting of
nitrogen,
sulfur and oxygen,
G) aryl,
(k) heteroaryl,
(1) -NR5R5', and
(m) -Si(Cl-6 alkyl)3;
and said alkyl, cycloalkyl, aryl and heteroaryl moiety is optionally
substituted with one or more
(i) halo,
(ii)-OH,
-7-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
(iii) -CN,
(iv) -C3-12 cycloalkyl,
(v) -C 1-10 allcyl,
(vi) -OC1-10 alkyl,
(vii) - NR5R5'
(viii) -C2-6 alkenyl,
(ix) - C1-6 haloallcyl,
(x) - SO2C1-3 allcyl,
(xi) - SO2NR5R5', or
(xii) - CONR5R5;
R4 is -C1-10 alkyl or -C2-4 allcenyl, wherein said allcyl or alkenyl R4 group
is optionally substituted
with one or more
(a) halo,
(b) -OH
(c) -C1-6 alkyl,
(d) -CN,
(e) -O-C1-10 alkyl,
(f) NR8R9, wherein R8 and R9 are selected from the group consisting of
(i) hydrogen, and
(ii) -C1-6 alkyl,
(g) -S(O)n C1-6 alkyl, wherein n is 0, 1 or 2,
(h) -C(=O)-R7, wherein R7 is selected from the group consisting of
(i) hydrogen,
(ii) OH,
(iii) -C 1-6 alkyl, and
(iv) -OC 1-6 alkyl, and
(v) aryl;
and pharmaceutically acceptable salts thereof, and individual enantiomers and
diastereomers thereof.
In preferred embodiments of the compounds of formula (1), Y is O.
In preferred embodiments of the compounds of formula (I), X is N.
In preferred embodiments of the compounds of formula (I'), X' is NH.
In preferred embodiments of the compounds of formula (I) and (I'), Rl is
selected from the group
consisting of optionally substituted C1-10 alkyl, preferably optionally
substituted C1-6 alkyl, or
optionally substituted C3-12 cycloalkyl, preferably optionally substituted C3-
6 cycloalkyl.
-8-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
In preferred embodiments of the compounds of formula (I) and (I'), R2 is
phenyl, wherein the
phenyl is optionally substituted with one or more
(i) halo,
(ii) -OH,
(iii) -CN,
(iv) - C1-10 alkyl, and
(v) phenyl optionally substituted with
(A) halo,
(B)-OH,
(C) -CN,
(D) -C1-10 alkyl,
(E) -OC 1-10 alkyl,
(F) - S02C1-3 alkyl,
(G) - SO2NR5R5',
(H) NR5SO2C1-3alkyl,
(I) - C02R5, and
(J) - CONR5R5'.
In preferred embodiments of the compounds of formula (I) and (I'), Q is C1-3
alkylene, most
preferably -CH2-, and R3 is phenyl, wherein the phenyl is optionally
substituted with one or more
(A) halo,
(B)-OH,
(C) -CN,
(D) -C1-10 alkyl,
(E) -OC1-10 alkyl, and
(F) phenyl, optionally substituted with
(i) -C1-6 alkyl,
(ii) -OC1-6 alkyl,
(iii) NR5R5'.
In preferred embodiments of the compounds of formula (I) and (I'), R4 is -C1-6
alkyl, most
preferably methyl or ethyl.
In another embodiment, R4 is -C24 alkenyl.
Within the genus of compounds of formula (I) and (I'), there is a sub-genus of
compounds of
formula (II)
-9-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
0
X
R1,H N,R2
N R4
R1o
(II)
or its tautoiner (II')
O
1
R, N N-W
N R4
R1o
(11')
wherein X, X', Rl, R2, and R4 are as defined above, and R10 is selected from
the group consisting of
(1) halo,
(2)-OH,
(3) -CN,
(4) -C1-10 alkyl, wherein said alkyl is optionally substituted with one or
more halogen,
(5) -C3-6 cycloalkyl, wherein said cycloalkyl is optionally substituted with
one or more halogen,
(6) -C2-10 alkenyl, and
(7) -OC1-10 alkyl,
and pharmaceutically acceptable salts thereof, and individual enantiomers and
diastereomers thereof.
In preferred embodiments of the compounds of formula (II), X is N.
In preferred embodiment of the compounds of formula (II'), X' is NH.
In preferred embodiments of the compounds of formula (II) and (II'), R2 is
phenyl, wherein the
phenyl is optionally substituted with one or more
-10-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
(i) halo,
(ii) -OH,
(iii) -CN,
(iv) - C1-10 allryl, or
(v) phenyl, optionally substituted with
(A) halo,
(B)-OH,
(C) -CN,
(D) -C1-10 alkyl,
(E) -OC1-10 allcyl,
(F) - SO2C1-3 allcyl,
(G) - SO2NR5R5',
(H) NR5S02C1-3alkyl,
(1) - C02R5, and
(J) - CONR5R5'.
In preferred embodiments of the compounds of formula (II) and (II'), R4 is C1-
6 allcyl, most
preferably methyl or ethyl.
In one embodiment of the compounds of formula (II) and (II'), R10 is phenyl,
which is optionally
substituted with one or more R13 groups selected from
(A) halo,
(B)-OH,
(C) -CN,
(D) -C 1-6 alkyl,
(E) -C2-6 alkenyl,
(F) -OC 1-6 alkyl,
(G) - C 1-6 haloalkyl,
(H) - SO2C1-3 alkyl,
(1) - SO2N R5R5', or
(J) - CONR5R5.
Within the genus of compounds of formula (1), there is a sub-genus of
compounds of formula
(M)
-11-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
X
O
R"
H
- R11
N R4
\
Q
R3
(III)
or its tautomer (III')
0
R1,
N~
R11
N R4
k
Q
R3
(III')
wherein X, X', Q, Rl, R3, and R4 are as defined above, and Rl 1 is selected
from the group consisting of
(1) halo,
(2)-OH,
(3) -CN,
(4) -C1-10 alkyl, and
(5) optionally substituted phenyl,
and pharmaceutically acceptable salts thereof, and individual enantiomers and
diastereomers thereof.
In preferred embodiments of the compounds of formula (III), X is N.
In preferred embodiment of the compounds of formula (III'), X' is NH.
In preferred embodiments of the compounds of formula (III) and (III'), Q is C1-
3 alkylene, most
preferably -CH2-, and R3 is phenyl, wherein the phenyl is optionally
substituted with one or more
(A) halo,
(B)-OH,
-12-
CA 02615656 2008-01-16
WO 2007/011833
PCT/US2006/027594
(C) -CN,
(D) -C1-10 allcyl,
(E) -OC1-10 allcyl, or
(F) phenyl, optionally substituted with
(i) -C1-6 alkyl,
(ii) -OC1_6 alkyl,
(iii) NR5R5'.
In preferred embodiments of the compounds of formula (lII) and (III'), R4 is
C1-6 alkyl, most
preferably methyl or etliyl.
In one embodiment of the compounds of formula (III) and (TII'), Rl 1 is
phenyl, which is
optionally substituted with one or more R12 groups selected from
(A) halo,
(B)-OH,
(C) -CN,
(D)-C1-6 alkyl,
(E) -OC1-6 alkyl,
(F) -C2-6 alkenyl,
(G) - C1-6 haloalkyl,
(H) - S02C1-3 alkyl,
(I) - SO2N R5R5', or
(J) - CONR5R5.
In still another embodiment, the invention is directed to spiropiperidine
compounds
represented by general forrnula (N)
0
R1~N N
H _R2
CH3
R3
(IV)
;5
-13-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
-)r its tautomer (IV')
0
HN-~ R1, N
~ -R2
N CH3
R3
(IV')
wherein
Rl is selected from the group consisting of
(1) hydrogen,
(2) -C1-10 alkyl,
(3) -C3-12 cycloalkyl,
(4) a heterocyclic group having 4 to 8 ring atoms, wherein one ring atom is a
heteroatom selected from the group consisting of nitrogen, sulfur or oxygen,
and
(5) phenyl,
wherein said alkyl, cycloalkyl, heterocyclic or phenyl Rl moiety is optionally
substituted with
one or more
(a) hydrogen,
(b) halo,
(c) -OH,
(d) -CN,
(e) -C1-10 alkyl
(f) -C3-12 cycloalkyl,
(g) -O-C1-10 alkyl, or
(h) phenyl;
R2 is optionally present at one or more of the ring carbon atoms, and is
selected from the group
consisting of
(1) halo,
(2)-OH,
(3) -CN, and
(4) -C1-10 alkyl;
-14-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
R3 is selected from the group consisting of
(1) hydrogen,
(2) -C1-10 alkyl,
(3) -C3-12 cycloalkyl,
(4) phenyl, and
(5) heteroaryl,
wherein said alleyl, cycloalkyl, phenyl or heteroaryl R3 moiety is optionally
substituted with one
or more
(a) halo,
(b) -OH,
(c) -CN,
(d) -C1-10 alkyl,
(e) -C3_12 cycloalkyl,
(f) -O-C3-12 cycloalkyl,
(g) -0-C1-10 alkyl,
and said alkyl, cycloalkyl and phenyl moiety is optionally
substituted with one or more
(i) halo,
(ii)-OH,
(iii) -CN,
(iv) -C3_12 cycloalkyl,
(v) -C1-10 alkyl, or
(vi) -OC1-10 alkyl;
and pharmaceutically acceptable salts thereof, and individual enantiomers and
diastereomers thereof.
In preferred embodiments, the invention is directed to compounds of the
invention of Examples
1-10, as follows:
Racemic 5(R,S)7(R,S)-8-benzyl-4-(cy.clohexylamino)-1-(3-fluorophenyl)-7-methyl-
1,3,8-
triazaspiro[4.5]dec-3-en-2-one diastereomer A;
Racemic 5(R,S)7(S,R)-8-benzyl-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-
1,3,8-
triazaspiro[4.5]dec-3-en-2-one Diastereomer B;
Racemic 5(R,S)7(R,S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3-
isopropoxybenzyl)-7-methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one Diastereomer A;
Racemic 5(R,S)7(S,R)-4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3-
isopropoxybenzyl)-7-methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one Diastereomer B;
Racemic 5(R,S)7(R,S)-8-benzyl-4-(cyclohexylamino)-7-methyl-l-phenyl-1,3,8-
triazaspiro[4.5]dec-3-en-
2-one Diastereomer A;
-15-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Racemic 5(R,S)7(S,R)-8-benzyl-4-(cyclohexylamino)-7-rnethyl-l-phenyl-1,3,8-
triazaspiro[4.5]dec-3-en-
2-one Diastereomer B;
Racemic 5(R,S)7(R,S)-8-(3-isopropoxybenzyl)-4-(isopropylamino)-7-methyl-l-(3-
methylphenyl)-1,3,8-
triazaspiro[4.5]dec-3-en-2-one Diastereomer A;
Racemic 5(R,S)7(S,R)-8-(3-isopropoxybenzyl)-4-(isopropylamino)-7-methyl-l-(3-
methylphenyl)-1,3,8-
triazaspiro[4.5]dec-3-en-2-one Diastereomer B;
(R,S)7(R,S)-8-benzyl-4-(cyclohexylamino)-1,7-dimethyl-1,3, 8-triazaspiro [4.5]
dec-3-en-2-one
Diastereomer A; and
5(R,S)7(S,R)-8-benzyl-4-(cyclohexylamino)-1,7-dimethyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one
Diastereomer B; and
enantioiners thereof, and pharmaceutically acceptable salts thereof.
In other preferred embodiments, the invention is directed to compounds of the
invention identified
in Examples 11-80, as follows:
(5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-7-methyl-
1,3, 8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-8-(3-thienylmethyl)-
1,3,8-triazaspiro[4.5]dec-
3-en-2-one;
(5R,7S)-4-(cyclohexylamino)-8-(2-fluorobenzyl)-1-(3-fluorophenyl)-7-methyl-
1,3,8-triazaspiro[4.5]dec-
3-en-2-one;
(5R,7,S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-8-[3-(1H-pyrrol-1-
yl)benzyl]-1,3,8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-8-[3-
(trifluoromethyl)benzyl]-1,3, 8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S')-8-(3-tert-butoxybenzyl)-4-(cyclohexylamino)-1-(3 -fluorophenyl)-7-
methyl-1,3, 8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4-(cyclohexylamino)-8-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-1-(3-
fluorophenyl)-7-methyl-1,3, 8-
triazaspiro[4.5]dec-3-en-2-one;
(5R, 7S)-4-(cycl ohexylamino)-1-(3 -fluorophenyl)-7-methyl-8-(3 -methylbut-2-
en-1-yl)-1, 3, 8 -
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-8-
[(trimethylsilyl)methyl]-1,3,8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-8-[2-
(trimethylsilyl)ethyl]-1,3,8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4-(cyclohexylamino)-8-[3-(1-cyclopropylethoxy)benzyl]-1-(3-
fluorophenyl)-7-methyl-1,3,8-
tri azaspiro [4.5 ] de c-3 -en-2-one;
(5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-8-(3-{ [(1R)-1-
methylpropyl]oxy}benzyl)-
1,3,8-triazaspiro[4.5]dec-3-en-2-one;
-16-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
(5R,7S)-4-(cyclohexylamino)-8-(2-fluoro-5-{ [(1R)-1-methylpropyl]oxy}benzyl)-1-
(3-fluorophenyl)-7-
methyl-1,3,8-triazaspiro [4.5] dec-3-en-2-one;
(5R,7S)-4-(cyclohexylamino)-8-[3-(cyclopropylmethyl)benzyl]-1-(3-fluorophenyl)-
7-methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-8-[(2E)-3-methylpent-2-
en-1-yl]-1,3,8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4-(cyclohexylamino)-8-[3-(cyclopropyloxy)benzyl]-1-(3-fluorophenyl)-7-
methyl-1,3, 8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4-(cyclohexylamino)-8-{3-[(1S)-1-cyclopropylethyl]benzyl}-1-(3-
fluorophenyl)-7-methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4-(cyclohexylamino)-8- {3-[(1R)-1-cyclopropylethyl]benzyl}-1-(3-
fluorophenyl)-7-methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-8-(cyclohex-l-en-l-ylmethyl)-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-
methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one;
(5R, 7S)-4-(cycl ohexyl amino)-8 -(cyclopent-l-en-l-ylmethyl)-1-(3 -
fluorophenyl)-7-methyl-1, 3, 8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-8-[(1-isopropyl-lH-indol-6-
yl)methyl]-7-methyl-1,3, 8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-8-[(2-methylcyclopent-
l-en-l-yl)methyl]-
1,3,8-triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4-[(1R,4R)-bicyclo[2.2.1]hept-2-ylamino]-1-(3-fluorophenyl)-7-methyl-8-
(3-{ [(1R)-1-
methylpropyl]oxy}benzyl)-1,3,8-triazaspiro [4.5] dec-3-en-2-one;
(5R,7S)-4-[(1S,4S)-bicyclo[2.2.1]hept-2-ylamino]-1-(3-fluorophenyl)-7-methyl-8-
(3-{ [(1R)-1-
methylpropyl]oxy}benzyl)-1,3, 8-triazaspiro [4.5] dec-3-en-2-one;
(5R,7S)-4-(cyclobutylamino)-1-(3-fluorophenyl)-7-methyl-8-(3- { [(1 S,2R)-2-
methylcyclopropyl] oxy}benzyl)-1,3,8-triazaspiro[4.5] dec-3-en-2-one;
(5R,7S)-4-(cyclobutylamino)-1-(3 -fluorophenyl)-7-methyl-8-(3- { [(1 R,2S)-2-
methylcyclopropyl] oxy } benzyl)-1, 3, 8-triazaspiro [4.5 ] de c-3 -en-2-one;
(5R,7S)-8-(cyclopentylmethyl)-4- { [(1 S,2S)-2-fluorocyclohexyl] amino) -1-(3 -
fluorophenyl)-7-methyl-
1,3,8-triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-8-(cyclopentylmethyl)-4-{ [(1R,2R)-2-fluorocyclohexyl]amino}-1-(3-
fluorophenyl)-7-methyl-
1,3,8-triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4-(cyclopentylamino)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-7-
methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-8-benzyl-l-(3-fluorophenyl)-7-methyl-4-(spiro [2.5]oct-6-ylamino)-1,3,
8-triazaspiro [4.5]dec-3-
en-2-one;
(5R,7S)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-7-methyl-4-{ [(5S,6R)-6-
phenylspiro[2.4]hept-5-
yl]amino}-1,3,8-triazaspiro[4.5]dec-3-en-2-one ;
-17-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
(5R,7S)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-7-rnethyl-4-{ [(5R,6S')-6-
phenylspiro[2.4]hept-5-
yl] amino } -1,3, 8-triazaspiro [4.5] dec-3 -en-2-one;
(5R,7S)-4-[(4,4-difluorocyclohexyl)amino]-1-(3-fluorophenyl)-8-(3-
isopropoxybenzyl)-7-methyl-1,3, 8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7,S)-8-benzyl-4-[(4,4-difluorocyclohexyl)amino]-1-(3-fluorophenyl)-7-
methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-8-(cyclobutylmethyl)-4- { [(3R)-1,1-dimethylsilolan-3-yl]amino} -1 -(3-
fluorophenyl)-7-methyl-
1,3,8-triazaspiro[4.5]dec-3-en-2-one;
(5R, 7S)-8 -(cycl obutylmethyl)-4- { [ (3 S)-1,1-dimethyl silol an-3 -yl]
amino } -1 -(3-fluorophenyl)-7-methyl-
1,3,8-triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-8-(cyclobutylmethyl)-4- { [(1R,2R)-2-fluorocyclohexyl] amino} -1-(3 -
fluorophenyl)-7-methyl-
1,3,8-triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-8-(cyclobutylmethyl)-4-{ [(1S,2S)-2-fluorocyclohexyl]amino} -1 -(3-
fluorophenyl)-7-methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4- { [(1R)-1,2-dirnethylpropyl]amino} -1-(3-fluorophenyl)-7-methyl-8-
(3-methylbut-2-en-1-yl)-
1,3,8-triazaspiro[4.5]dec-3-en-2-one;
(5R, 7S)-4- { [(1 S)-1,2-dimethylpropyl] amino } -1-(3 -fluorophenyl)-7-methyl-
8 -(3 -methylbut-2-en- 1 -yl)-
1,3,8-triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-1-(3-chlorophenyl)-8-(cyclobutylmethyl)-4-(cyclohexylamino)-7-methyl-
1,3,8-
triazaspiro [4.5]dec-3-en-2-one;
(5R, 7S)-1-(3 -bromophenyl)-8 -(cyclobutylmethyl)-4-(cyclohexyl amino)-7-
methyl-1, 3 , 8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-7-methyl-
1,3, 8-
triazaspiro [4,5]dec-3-ene-2-thione;
(5R,7S)-4-(cyclohexylamino)-8-[(2,2-dimethyl-1,2-dihydroquinolin-8-yl)methyl]-
1-(3-fluorophenyl)-7-
methyl-1,3, 8-triazaspiro [4.5] dec-3-en-2-one;
(5R,7S)-4-(cyclohexylamino)-8-[(2,2-dimethyl-1,2,3,4-tetrahydroquinolin-8-
yl)methyl]-l -(3-
fluorophenyl)-7-methyl-1,3, 8-triazaspiro[4.5]dec-3-en-2-one;
(5R,7R)-4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-7-vinyl-
1,3,8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7R)-8-benzyl-4-(cyclohexylamino)-1-(3 -fluorophenyl)-7-vinyl-1,3, 8-
triazaspiro [4.5] dec-3-en-2-one;
(5R,7R) -4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3-{[(1R)-1-
methylpropyl]oxy}benzyl)-7-vinyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7R) -4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-7-[(lE)-
prop-l-en-l-yl]-1,3,8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7R) -4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-7-[(1Z)-
prop-l-en-l-yl]-1,3,8-
triazaspiro[4.5]dec-3-en-2-one;
-18-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
(5R,7S)-1-(3-fluorophenyl)-7-methyl-4-(methylamino)-8-[(2'-methylbiphenyl-3-
yl)methyl]-1,3,8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-8-(cyclobutylmethyl)-4-(cyclohexylamino)-1-[4'-
(isopropylsulfonyl)biphenyl-2-yl]-7-methyl-
1,3,8-triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)- 8-benzyl-4-(cyclohexylamino)-1-(cyclopropylmethyl)-7-methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-
one;
(5R,7S)-( 5 S, 7R) -8 -b enzyl-4-(cyclohexylamino)-1-cyclopropyl-7-methyl-1,
3, 8-tri aza spiro [4.5 ] dec-3 -en-2-
one;
(5R,7S)-(5S,7R)-8-benzyl-l-cyclobutyl-4-(cyclohexylamino)-7-methyl-1,3, 8-
triazaspiro[4.5]dec-3-en-2-
one;
(5R,7S)-(5S,7R)-8-benzyl-4-(cyclohexylamino)-1-cyclopentyl-7-methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-
one;
(5R,7S)-(5S,7R)-8-benzyl-l-cyclohexyl-4-(cyclohexylamino)-7-methyl-1,3, 8-
triazaspiro [4.5]dec-3-en-2-
one;
(5R,7S)-(5S,7R)-8-benzyl-4-(cyclohexylamino)-7-methyl-l-(2-methylprop-2-en-1-
yl)-1,3, 8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-(5S, 7R)-8-benzyl-4-(cyclohexylamino)-7-methyl-l-(tetrahydrofuran-3 -
yl)-1, 3, 8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-7-methyl-4-{ [(3S)-1-
(methylsulfonyl)pyrrolidin-3-
yl] amino }-1, 3, 8-triazaspiro [4.5 ] de c-3 -en-2-one;
(5R,7S)-4-[(3,3-difluorocyclohexyl)amino]-1-(3-fluorophenyl)-8-(3-
isopropoxybenzyl)-7-methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)- (5S,7R)-4-[(2-fluoro-l-methylethyl)amino]-1-(3-fluorophenyl)-8-(3-
isopropoxybenzyl)-7-
methyl-1,3,8-triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)- (5S,7R)-4-{[(1S)-1,2-dimethylpropyl]amino}-1-(3-fluorophenyl)-8-(3-
isopropoxybenzyl)-7-
methyl-1, 3, 8-triazaspiro [4.5 ] dec-3 -en-2-one;
(5R,7S)-4- { [(1R,2R)-2-fluorocyclohexyl] amino } -1-(3 -fluorophenyl)-8-(3 -
isopropoxybenzyl)-7-methyl-
1,3,8-triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4-{ [(1S,2S)-2-fluorocyclohexyl]amino}-1-(3-fluorophenyl)-8-(3-
isopropoxybenzyl)-7-methyl-
1,3,8-triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-4-[(2-
isopropylcyclopropyl)amino]-7-methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4-{ [(1R,2R)-2-fluorocyclopentyl]amino}-1-(3-fluorophenyl)-8-(3-
isopropoxybenzyl)-7-methyl-
1,3,8-triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4-{[(1S,2S)-2-fluorocyclopentyl]amino}-1-(3-fluorophenyl)-8-(3-
isopropoxybenzyl)-7-methyl-
1,3,8-triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-7-methyl-4-[(2-
propylcyclopropyl)amino]-1,3, 8-
triazaspiro[4.5]dec-3-en-2-one;
-19-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
(5R,7S)-4-{[(1R)-2,2-difluorocyclohexyl]amino} -1-(3-fluorophenyl)-8-(3-
isopropoxybenzyl)-7-methyl-
1,3,8-triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4-{[(1S)-2,2-difluorocyclohexyl]amino} -1-(3-fluorophenyl)-8-(3-
isopropoxybenzyl)-7-methyl-
1, 3, 8-triazaspiro [4. 5] dec-3 -en-2-one;
(5R,7S')-4-{ [(1R)-2,2-difluorocyclopentyl]amino}-1-(3-fluorophenyl)-8-(3-
isopropoxybenzyl)-7-methyl-
1,3,8-triazaspiro[4.5]dec-3-en-2-one;
(5R,7}S)-4-{ [(1S)-2,2-difluorocyclopentyl]amino}-1-(3-fluorophenyl)-8-(3-
isopropoxybenzyl)-7-methyl-
1,3,8-triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4- { [(1R,2S)-2-fluorocyclohexyl]amino}-1-(3-fluorophenyl)-8-(3-
isopropoxybenzyl)-7-methyl-
1,3,8-triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4- { [(1 S,2R)-2-fluorocyclohexyl] amino } -1-(3 -fluorophenyl)-8-(3 -
isopropoxybenzyl)-7-methyl-
1,3,8-triazaspiro[4.5]dec-3-en-2-one;
(5R,7,S)-S-benzyl-l-(3-fluorophenyl)-7-methyl-4-{[(1S')-1,2,2-
trimethylpropyl]amino} -1,3,8-
triazaspiro[4.5]dec-3-en-2-one;
(5R,7S)-4-(cyclohexylimino)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-3,7-
dimethyl-1,3, 8-
triazaspiro[4.5]decan-2-one; and
pharmaceutically acceptable salts thereof.
The invention is also directed to methods of treating a patient (preferably a
human) for diseases
in which the (3-secretase enzyme is involved, such as Alzheimer's disease, by
administering a
therapeutically effective amount of a spiropiperidine compound of formula (I),
(I'), (II), (II'), (IlI), (III'),
(IV) or (IV') or a pharmaceutically acceptable salt thereof, and a
pharrnaceutically acceptable carrier.
The invention is also directed to methods of inhibiting BACE1 enzyme activity,
by adniinisteriing
a therapeutically effective amount of a spiropiperidine compound of formula
(I), (I'), (lI), (II'), (III),
(I1I'), (IV) or (IV'), or a pharmaceutically acceptable salt thereof, and a
pharmaceutically acceptable
carrier, to a mammal or patient in need thereof. In another embodiment, the
invention is directed to
methods of inhibiting BACE2 enzyme activity, by administering a
therapeutically effective amount of a
spiropiperidine compound of formula (1), (I'), (Il), (fI'), (I1T), (III'),
(IV) or (IV'), or a pharmaceutically
acceptable salt thereof, and a pharmaceutically acceptable carrier, to a
mammal or patient in need
thereof.
The invention is also directed to methods of treating a patient (preferably a
human) for diseases
in which the (3-secretase enzyme is involved, such as Alzheimer's disease, by
administering a
therapeutically effective amount of a spiropiperidine compound of formula (I),
(I'), (II), (II'), (III), (III'),
(IV) or (IV'), or a pharmaceutically acceptable salt thereof, in combination
with a P450 inhibitor, such as
ritonavir, and a pharmaceutically acceptable carrier.
The invention is also directed to pharmaceutical compositions for the
treatment of diseases in a
patient (preferably a human) in which the (3-secretase enzyme is involved,
such as Alzheimer's Disease,
which include a therapeutically effective amount of a compound of formula (1),
(I'), (lI), (II'), (III), (III'),
(IV) or (IV') or a pharmaceutically acceptable salt thereof, and a
pharmaceutically acceptable carrier.
-20-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
The invention is also directed to pharmaceutical compositions for the
treatment of diseases in
mammals (preferably humans) in which the (3-secretase enzyme is involved, such
as Alzheimer's
Disease, which include a therapeutically effective amount of a compound of
formula (I), (I'), (II), (II'),
(III), (III'), (IV) or (IV'), or a pharmaceutically acceptable salt thereof,
together with a P450 inhibitor,
such as ritonavir, and a pharmaceutically acceptable carrier.
The invention is further directed to a method for the manufacture of a
medicament or a
composition for inhibiting (3-secretase enzyme activity in mammals (preferably
humans) and animals
comprising combining a therapeutically effective amount of a compound of
formula (I), (I'), (II), (II'),
(III), (III'), (IV) or (IV'), or a pharmaceutically acceptable salt thereof,
with a pharmaceutically
acceptable carrier.
The invention is also directed to a method for the manufacture of a medicament
or a composition
for treating diseases in which the (3-secretase enzyme is involved, such as
Alzheimer's Disease, in
mammals (preferably humans), comprising combining a therapeutically effective
amount of compound
of formula (I), (I'), (II), (II'), (III), (III'), (IV) or (IV'), or a
pharmaceutically acceptable salt thereof, with
a pharmaceutically acceptable carrier.
The invention is also directed to a method for the manufacture of a medicament
or a composition
for treating diseases in which the P-secretase enzyme is involved, such as
Alzheimer's Disease, in
mammals (preferably humans), comprising combining a compound of formula (I),
(I'), (II), (II'), (III),
(III'), (IV) or (IV'), or a pharmaceutically acceptable salt thereof, and a
P450 inhbitor, such as ritonavir,
with a pharmaceutically acceptable carrier.
As used herein, the term "alkyl," by itself or as part of another substituent,
means a saturated
straight or branched chain hydrocarbon radical having the number of carbon
atoms designated (e.g., C1-
alkyl means an alkyl group having from one to ten carbon atoms). Preferred
alkyl groups for use in
the invention are C1-6 alkyl groups, having from one to six carbon atoms.
Exemplary alkyl groups
include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl,
pentyl, hexyl, and the like.
The term "CO alkyl," for example in the term "-COalkyl-C6-12 aryl", refers to
a bond.
As used herein, the term "alkylene," by itself or as part of another
substituent, means a saturated
straight or branched chain divalent hydrocarbon radical having the number of
carbon atoms designated.
As used herein, the term "alkenyl," by itself or as part of another
substituent, means a straight or
branched chain hydrocarbon radical having a single carbon-carbon double bond
and the number of
carbon atoms designated (e.g., C2-10 alkenyl means an alkenyl group having
from two to ten carbon
atoms). Preferred alkenyl groups for use in the invention are C2-6 alkenyl
groups, having from two to six
carbon atoms. Exemplary alkenyl groups include ethenyl and propenyl.
As used herein, the term "alkynyl," by itself or as part of another
substituent, means a straight or
branched chain hydrocarbon radical having a single carbon-carbon triple bond
and the number of carbon
atoms designated (e.g., C2-10 alkynyl means an alkynyl group having from two
to ten carbon atoms).
Preferred alkynyl groups for use in the invention are C2-6 alkynyl groups,
having from two to six carbon
atoms. Exemplary alkynyl groups include ethynyl and propynyl.
-21-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
As used herein, the term "cycloalkyl," by itself or as part of another
substituent, means a
saturated cyclic hydrocarbon radical having the number of carbon atoms
designated (e.g., C3-12
cycloalkyl means a cycloalkyl group having from three to twelve carbon atoms).
The term cycloalkyl as
used herein includes mono-, bi- and tricyclic saturated carbocycles,
spirocycles, and bridged and fused
ring carbocycles.
Preferred cycloalkyl groups for use in the invention are monocyclic C3-8
cycloalkyl groups,
having from three to eight carbon atoms. Exemplary monocyclic cycloalkyl
groups include cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl and the lilce. Exemplary bridged
cycloalkyl groups include
adamantly and norbomyl. Exemplary fused cycloalkyl groups include
decahydronaphthalene.
As used herein, the term "heterocyclic," by itself or as part of another
substituent, means a
cycloallcyl group as defined above, in which one or more of the ring carbon
atoms is replaced with a
heteroatom (such as N, S or 0). Suitable non-aromatic heterocyclic groups for
use in the invention
include piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl,
tetrahydrofuranyl, pyrrolidinyl,
pyrazolidinyl and imidazolildinyl. Preferred heterocyclic groups for use in
the invention have four to
eight ring atoms and a single nitrogen or oxygen heteroatom.
When a heterocyclic group as defined herein is substituted, the substituent
may be bonded to a
ring carbon atom of the heterocyclic group, or to a ring heteroatom (i.e., a
nitrogen, oxygen or sulfur),
which has a valence which permits substitution. Preferably, the substituent is
bonded to a ring carbon
atom. Similarly, when a heterocyclic group is defined as a substituent herein,
the point of attachment
may be at a ring carbon atom of the heterocyclic group, or on a ring
heteroatom (i.e., a nitrogen, oxygen
or sulfur), which has a valence which permits attachment. Preferably, the
attachment is at a ring carbon
atom.
As used herein, the term "aryl," by itself or as part of another substituent,
means an aromatic or
cyclic radical having the number of carbon atoms designated (e.g., C6-10 aryl
means an aryl group
having from six to ten carbons atoms). The term "aryl" includes multiple ring
systems (such as fused
ring systems) as well as single ring systems, and includes multiple ring
systems wherein part of the
molecule is aromatic and part is non-aromatic. The preferred single ring aryl
group for use in the
invention is phenyl. Preferred fused ring aryl groups include naphthyl,
tetrahydronaphthyl and indanyl.
The term "halo" or "halogen" includes fluoro, chloro, bromo and iodo.
As used herein, the term "heteroaryl," by itself or as part of another
substituent, means an
aromatic cyclic group having at least one ring heteroatom (0, N or S). The
term "heteroaryl" includes
multiple ring systems as well as single ring systems, and includes multiple
ring systems wherein part of
the molecule is aromatic and part is non-aromatic. Preferred heteroaryl groups
have from 5 to 12 ring
atoms. Exemplary heteroaryl groups include pyrazinyl, pyrazolyl, pyridazinyl,
pyridyl, pyrimidinyl,
pyrrolyl, tetrazolyl, furanyl, imidazolyl, indazolyl, triazinyl, pyranyl,
thiazolyl, thienyl, thiophenyl,
triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl,
isoquinolinyl, benzimidazolyl,
benzofuranyl and benzoxazolyl. More preferred heteroaryl groups include
indolyl, thienyl, pyridinyl,
dihydroquinolinyl and tetrahydroquinolinyl.
-22-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
When a heteroaryl group as defined herein is substituted, the substituent may
be bonded to a ring
carbon atom of the heteroaryl group, or on a ring heteroatom (i.e., a
nitrogen, oxygen or sulfur), which
has a valence which permits substitution. Preferably, the substituent is
bonded to a ring carbon atom.
Similarly, when a heteroaryl group is defined as a substituent herein, the
point of attachment may be at a
ring carbon atom of the heteroaryl group, or on a ring heteroatom (i.e., a
nitrogen, oxygen or sulfur),
which has a valence which permits attachment. Preferably, the attachment is at
a ring carbon atom.
As used herein, the term "beta-secretase" or ",6-secretase" refers to an
enzyme that is sometimes
known in the literature as "BACE", "BACEl" (see, e.g., Vassar et al., 1999,
Science 286:735-741), or
"BACE2" (see, e.g., Farzan et al., 2000, PNAS 97:9712-9717). BACE1 is a 501
amino acid membrane-
bound aspartic protease. BACE1 has all the known functional properties and
characteristics of (3-
secretase. BACE2, also called Asp-1 or memapsin-1, is a second member of the
BACE family of
membrane-bound aspartic proteases. See Roggo, Curf-ent Topics in Medicinal
Chefnistry, 2002, 2:359-
370, for a further discussion of the differences between BACE1 and BACE2.
The compounds of the invention are inhibitors of both the BACE1 and BACE2
enzyme.
The compounds of the invention have at least two asymmetric centers.
Additional asymmetric
centers may be present depending upon the nature of the various substituents
on the molecule.
For example, for the compounds of formula (I) and (I'), the 5-carbon and 7-
carbon of the
spiropiperidine ring are chiral. As a result, the compounds of formula (I) may
be present as two racemic
diastereomers, or in four stereochemically pure forms. The diastereomeric
forms for compounds of
formula (I) are depicted below, as diastereomers (IA) (diastereomer A), where
the amine of the spiro
center and the R4 group are cis to one another, and (IB) (diastereomer B),
where the amine of the spiro
center and the R4 group are trans to one another.
Y
X~
~
R1,1
H NR2
N ~'R4
i
QR3
(IA)
-23-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Y
x
R1,N\ 2
H R
N ~'R4
i
QR3
(IB)
When R4 is methyl or ethyl, the diastereomer (IA) is the 5(S,R),7(S,R)
configuration, the diastereomer
(IB) is the 5(R,S),7(S,R) configuration. An alternative convention is to refer
to diastereomer IA as
having the (5S,7S) (5R,7R) configuration, and to refer to diastereomer 1B as
having the (5R,7S)(5S,7R)
configuration.
Each of (IA) and (IB) may be present in tautomeric form, as shown below as
(IA') and
(1B'):
Y
1
R, N
N ~'R4
i
QR3
(IA')
or
~Y
X'
1
N ~'R4
QR3
(IB')
In a preferred embodiment, the compounds of the invention are compounds of
formula
(IB) and its tautomer (IB').
-24-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
The compounds of each of formulas (II), (II'), (III), (III'), (IV) and (IV')
are also present
as diastereomeric forms, as diastereomers (IIA), (IIIA) and (NA), where the
amine of the spiro center
and the R4 group are cis to one another, and diastereomers (IIB), (IIIB ) and
(NB), where the amine of
the spiro center and the R4 group are trans to one another. In a preferred
embodiment, the compounds of
formulas (II), (II'), (III), (III'), (IV) and (IV') are present as the
diastereomeric forms (IIB), (II1B ) and
(IVB), and their respective tautomers, as depicted below:
0
x
R1,
R2
H N
N "'R4
R1o
(IIB)
or its tautomer (IIB')
0
X' R1, NN
R2
N ~'R4
R1o
(iiB')
- 25
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
X
~O
R1,N
H I _ R11
N
\
p
R3
(IIIB)
or its tautomer (IIIB')
O
X
R1, N N
-R11
N "'R4
Q
R3
(IIIB')
and
0
N~
R1~N
H I -R2
N ''CH3
R3
(IVB)
-26-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
or its tautomer (IVB')
0
R11% N-/
N ~-. N ~
I -R2
~
N "'CH3
~
R3
(IVB')
In addition, each of (IA) and (IB) may be present as a racemic mixture, or in
one of two
enantiomeric forms, as shown below with compound (IA), as compounds (IA) and
(IA*):
Y
1
R~H
N ~'R4
QR3
(IA)
or
Y
1
R~H
R4~ N
QR3
(IA*)
wherein when R4 is methyl or ethyl, the enantiomers IA is the 5(S),7(S)
configuration and the
enantiomers IA* is the 5(R),7(R) configuration.
Similarly, compounds of formula 1B may exist as the separate enantiomeric
compounds
IB and IB*
-27-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Y
x
R"N, ~
H R
N
QR3
(IB)
or
~Y
x
R1ll
NN\ 2
H R
\Jf'
R4~'
N
QR3
(IB*)
wherein when R4 is methyl or ethyl, the enantiomers IB is the 5(R),7(S)
configuration and the
enantiomers IB* is the 5(S),7(R) configuration.
In a preferred enantiomeric embodiment, the compounds of the invention are
compounds of
formula (IB).
Compounds with asymmetric centers give rise to enantiomers (optical isomers),
diastereomers
(configurational isomers) or both, and it is intended that all of the possible
enantiomers and
diastereomers in mixtures and as pure or partially purified compounds are
included within the scope of
this invention. The present invention is meant to encompass all such isomeric
forms of these compounds.
Compounds described herein may contain one or more double bonds, and may thus
give rise to
cis/trans isomers as well as other configurational isomers. The present
invention includes all such
possible isomers as well as mixtures of such isomers.
Formulas (I), (I'), (II), (II'), (III), (III'), (IV) or (IV') are shown above
without a definite
stereochemistry at certain positions. The present invention includes all
stereoisomers of formulas (I),
(I'), (11), (II'), (III), (III'), (IV) or (IV') and pharmaceutically
acceptable salts thereof.
The independent syntheses of the enantiomerically or diastereomerically
enriched compounds, or
their chromatographic separations, may be achieved as known in the art by
appropriate modification of
the methodology disclosed herein. Their absolute stereochemistry may be
determined by the x-ray
-28-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
crystallography of crystalline products or crystalline intermediates that are
derivatized, if necessary, with
a reagent containing an asymmetric center of known absolute configuration.
If desired, racemic mixtures of the compounds may be separated so that the
individual
enantiomers or diastereoiners are isolated. The separation can be carried out
by metliods well lmown in
the art, such as the coupling of a racemic mixture of compounds to an
enantiomerically pure compound
to form a diastereomeric mixture, followed by separation of the individual
diastereomers by standard
methods, such as fractional crystallization or chromatography. The coupling
reaction is often the
formation of salts using an enantiomerically pure acid or base. The
diastereomeric derivatives may then
be converted to the pure enantiomers by cleavage of the added chiral residue.
The racemic mixture of the
-ompounds can also be separated directly by chromatographic methods using
chiral stationary phases,
which methods are well known in the art.
Alternatively, any enantiomer or diastereomer of a compound may be obtained by
stereoselective
;ynthesis using optically pure starting materials or reagents of known
configuration by methods well
mown in the art.
As used herein, the term "tautomer" refers to a compound which exists in an
equilibrium mixture
nd which can be isolated in either form and react through either form. The
tatutomers may differ in
inkage, bond, or connections between atoms, and the position or distribution
of the atoms in the
iolecule. One common form of tautomerism occurs when an enamine group, for
example a group
:2C=CR-NHR, exists in equilibrium with its tautomeric imine form, for example
R2CH-CR=NR. In the
Dntext of this invention, compounds of formula (I) may be present in the
enamine form as shown below:
~Y
X
R1,H ~ N,R2
N
\ W
.Q
R3
(1)
d pharmaceutically acceptable salts thereof, and individual enantiomers and
diastereomers thereof,
ierein X, Q, Rl, R2, R3 and R4 are as defined above, or in the tautomeric
imine form (I'), as shown
low:
-29-
~
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Y
1
R,1
N' N,R2
N R4
.Q
R3
(11)
and pharmaceutically acceptable salts thereof, and individual enantiomers and
diastereomers thereof,
wherein X', Q, Rl, R2, R3 and R4 are as defined above.
The compounds claimed in this invention can be prepared according to the
following general
procedure methods.
General Scheme 1 depicts a method for preparing 1-benzyl-2-methylpiperidin-4-
one
intermediates useful for making compounds of the invention. The commercially
available 1-1 may be
alkylated with an appropriate alkyl halide like benzyl chloride using a
suitable base like potassium
carbonate in a suitable solvent like acetonitrile. A similar method is
described by M. E. Kopach et. al. J.
Or=g.Chena. 2003 68 5739-5741.
General Scheme 1
O O
base
N R4 N R4
H CI
1-2 R10
Alternatively, as shown below in General Scheme 2, an intermediate like 1-2
may be prepared
using a procedure similar to the one outlined in J. Blanco-Pilado et al, in
W02004/094380. Vinyl
trimethylsilane and an acyl chloride are condensed with A1C13 to give an
intermediate that is then reacted
with an amine like benzylamine to give the alkylated piperidinone 1-2.
-30-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
General Scheme 2
O
0 O R10 1 NH2
AiCI
1SLc1
3 -_
+ ~ N 4
R4 R
~ ~
/~
R'o
1-2
General Scheme 3 below depicts a four-component coupling reaction between a
piperidinone
derivative, amine, isonitrile, and cyantate, which assembles the core
structure 3-1. A similar method is
described in. Chung et al, U.S. Patent No. 5,221,675. Further elaboration of 3-
1 is possible, for example,
by removal of a temporary R3 group to give 3-2, followed by alkylation with a
different R3 to give new
structure 3-3, using methods similar to that described above for 1-1.
General Scheme 3
KOCN
Rs (D -CI+H3N ~ ~ N 0
N0 R Rl
H N-'R2
N R4 LNR4
Q Rs"Q
R3
3-1
l
N 0 O
R
H N-R2 R'
N N- R2
<---- H
N Q R4
H R4
R3
3-3 3-2
-31-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
General Scheme 4 depicts the formation of compounds of the invention where
X/X'
CR5/CR5R5'. Similar to methods found in R. Jones et al, Tetrahedron Letters,
24 (43), 1983, 4751-
4754, Streclcer reaction on a suitably substituted intermediate 1-1 gives
nitrile 4-1, which can be acylated
to give 4-2 and then cyclized to 4-3 by first treatment with a base lilce
NaOMe followed by treatment
with a strong aqueous acid like 6 N HCI. 4-3 may then be treated with a
suitable amine to give 4-4 and
substituted with a fluorine to give 4-5 upon treatment with a fluorinating
agent.
General Scheme 4
H2N, R2 O
H 0
0
TMSCN O \\R2
-~~
N N-R2
4
N R N R4
R 3 Q N R4
R3
,Q
R3
4-2
4-1
F O O O
R\N N-R2 RN / N-R2 O 7 N- R2
H H
N R4 N R4 N R4
,Q ,Q P
R3 R3 R3
4-5 4-4 4-3
General Scheme 5 depicts an alternative route that allows the formation of
compounds of the
vention where Rl may be varied.toward the end of the synthesis. Similar to
methods found in P.L.
ldman et al, J.Org.Cherra. 1990 55, 4207, 1983, 4751-4754, Strecker reaction
on a suitably substituted
ermediate 1-1 gives nitrile 5-1, which can be deprotected to give the
unsubstituted piperidine 5-2 and
;n derivitized in a manner similar to that described for 1-2 to give nitrile 5-
3. 5-3 may be acylated to
,e 5-4 and then cyclized to 5-5 by treatment with water. 5-5 may then be
treated with a sulfur source
hydrogen sulfide to give 5-6 and then reacted with a suitable amine to give 5-
7.
-32-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
General Scheme 5
H2N,Rz
N
- 2 N\ H
TMSCN 0 N\\ H I >cNR
N-R2 N
-R2
------~ -~ --~-
N R4 N R4 H R4 N R4
W,O~O W-O--~O R3"Q
5-2 5-3
5-1
CISO2N=C=0
O O
HNO HNCIlS~O
HN N-R2 HN O
S N-R2 H2S H20
N N-R2
~
N R4 ~~ N R4
Q Q
R3 0
N R4
5-6 Q
RINH2 R3
5-5 5-4
0
N
R,H N1R2
N R4
Nn
R3~.i
5-7
General Scheme 5a depicts a similar route that allows the formation of
compounds of the
invention where Rl may be varied toward the end of the synthesis. Here the
nitrile 5-3 may be acylated to
give 5a-1 and then cyclized to 5a-2 by treatment with water. 5a-2 may then be
directly reacted with a
suitable amine to give 5a-3.
-33-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
General Scheme 5a
N CCI3~0
HNR2 HN~O HN~O
CI3CCON=C=O N' nI,,R2 HN N'-R2
N
R3'Q N R4 N R4
5-3 Rs'Q R3 Q
5a-1 5a-2
O
N
N ~ N1R2
RI
H
N R4
i
R3.Q
5a-3
General Scheme 5b depicts an alternative route that allows the formation of
compounds of the
invention where R2 is substituted with additional groups. Similar to methods
found in P.L. Feldman et al,
.I.Org.Chem. 1990 55, 4207, 1983, 4751-4754, Strecker reaction on a suitably
substituted
biphenylanaline gives nitrile 5b-1, which can be acylated to give 5b-2 and
then cyclized to 5b-3 by
treatment with water. Addition of a suitably substituted R'amine then gives 5b-
4, which can be
deprotected and derivitized on the piperidine nitrogen with a suitable QR3
group as described above.
-34-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
General Scheme 5b
H2N, R2 CC13--f 0
TMSCN 0 N~ H HN-~/O
N'R2
N N-R2
N R4 LN R' CI33CCON=C=O
N R4
W" O O W,O~O
w,
~
(iR11 O O
R2 = N
~R11 5b-1 5b-2
~ 11
I H2O
p R11 RHNR\ yo
H N -~' HN N-R2
H N R11 ~-
R11 N R4 RjNH2 LN R4
H R4 W,O O W,
O-'~-1O
5b-6 5b-4 5b-3
I
QR12
RIN H
R'l
N R4
.Q
R3
5b-7
General Scheme 6 depicts an alternative route, which allows the formation of
compounds of the
invention where R3 is substituted with additional groups. Preparation similar
to that outlined above
-35-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
illows formation of the bromo-substituted intermediate 6-1, which may be
coupled with a suitable
)oronic acid using a suitable catalyst lilce palladium acetate and a suitable
ligand lilce 3,3',3"-
?hosphinidynetris(benzene sulfonic acid). Alternatively, the boronic acid
intermediate 6-3 may be
=eacted with an appropriate aryl halide under the same type of conditions to
give 6-2.
General Scheme 6
~O
O N
N~ R~N N
N ,R2
R1
, N-R2 H
H
N R4
H Br
3-2 or 7-9 6-1
O O
~~
N R 2 R1, N R
hN ~ hN
2
H H
N R4 N R4
(HO)2B 3
6-3 R1 6-2
General Scheme 7 depicts an alternative route, which allows efficient
variation of Rl and QR3
groups in compounds of the invention. In this scheme, a piperidinone protected
with a suitable removable
protecting group like CBZ (where W is CH2-phenyl) can take part in a Strecker
reaction in the presence
of Zn(CN)2 to give the desired stereoisomeric Strecker product as the major
isomer. Alternatively, the
Strecker reaction similar to that described by J. Cossy in Synthesis 1995 11
1368-1370 may be done with
TMSCN/HOAC and the resulting mixture of diastereomeric products can be treated
with TMSCN in
EtOH with heat to equilibrate the mixture so that the major isomer is the
desired one. Acylation with a
suitable agent like trichloroacetylisocyanate followed by cyclization with
methanol/water in a procedure
similar to that described by R. Sarges, et.al. in JOC 1982, 47 4081-4085 leads
to the isolable
intermediate iminohydantoin 7-6 that can be converted directly to the Rl
substituted intermediate 7-8 by
heating with a suitable amine. The nitrogen protecting group may then be
removed and a suitable
alkylating agent with a suitable base like potassium carbonate may used to
incorporate the QR3
substituent.
-36-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
General Scheme 7
Conditions A
Zn(CN)2
0 HOAc
0 rt
H3C, 0 1,CBZCI overnight
R4MgBr
resolution (~N-"W
N R4 AD W\ ~ or
N HOAC W, ~ chiral 0 0
Conditions B.
O O column 1= TMSCN
7-3 7-3S HOAc RT
7-1
2. Epimerization
0 0
N~ HN-R2 N~ HN-R2 1.CI3CCON=C=O HN~NR2 HN~N-R2
f
2. MeOHI H20 / TEA HN HN neat
R4 C'1R4 * * cyclohexylamine
W. ~
C~
W~O/O 0 0 W, 0___0 W\00
7-4 7-5 7-6 7-7
0 0 O
N~ DMF ~
N-R2 N~ K2C03 jNR2
R~\H2/ Pd/C R~\ J~n,. N-R2 Heat R"
H H =~, HCtI MeOH H X
N R4 ~ , N R4
N 'R4 I
W, 0_~_10 H R3. R3.0
7-9 7-10
7-8
General Scheme 8 depicts an alternative route to the preparation of compounds
of the invention
utilizing a sulfur-containing reagent like thiocyanate in the Ugi reaction
similar to conditions described
by I.Ugi et.al. Ann. 1963, 666 54-61 to give the thiohydantoin 8-2, and then
conversion of 8-2 to the
iminohydantoin 8-3 in a manner similar to that described by K. Senga et.al.
Chem. Phaf m. Bull. 26(3)
765-769 by activation with thionyl chloride followed by reaction with a
suitable alcohol like methanol
and acid like acetic acid.
-37-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
General Scheme 8
R3NH2HCI 0
O R1NC J-)~
K+S-CN R\ N~N-RZ 1) thionyl chloride, R tNN R
H 2) methanol H
C'N' Ra 3) acetic acid, methanol
R3,Q N Ra N R4
I
R3.Q R3,Q
8-1 8-2 8-3
The term "substantially pure" means that the isolated material is at least 90%
pure, and
preferably 95% pure, and even more preferably 99% pure as assayed by
analytical techniques known in
the art.
By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient
must be compatible
with the other ingredients of the formulation and not deleterious to the
recipient thereof.
The term "pharmaceutically acceptable salts" refers to salts prepared from
pharmaceutically
acceptable non-toxic bases or acids including inorganic or organic bases and
inorganic or organic acids.
The compounds of the invention may be mono, di or tris salts, depending on the
number of acid
functionalities present in the free base form of the compound. Free bases and
salts derived from
inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous,
lithium, magnesium,
manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly
preferred are the
arnmonium, calcium, magnesium, potassium, and sodium salts. Salts in the solid
form may exist in more
than one crystal structure, and may also be in the form of hydrates. Salts
derived from pharmaceutically
acceptable organic non-toxic bases include salts of primary, secondary, and
tertiary axnines, substituted
amines including naturally occurring substituted amines, cyclic amines, and
basic ion exchange resins,
such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylene-diamine,
diethylamine, 2-
diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-
ethyl-morpholine, N-
ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine,
isopropylamine, lysine,
methylglucamine, morpholine, piperazine, piperidine, polyamine resins,
procaine, purines, theobromine,
triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
When the compound of the
present invention is basic, salts may be prepared from pharmaceutically
acceptable non-toxic acids,
including inorganic and organic acids. Such acids include acetic,
trifluoroacetic, benzenesulfonic,
benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic,
hydrobromic, hydrochloric,
isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric,
pamoic, pantothenic,
phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the
like. Particularly preferred salts
are the sulfate, phosphate, citrate, malate, mandelate, hippurate,
trifluoroacetate and hydrochloric acid
salts.
-38-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
The present invention is directed to the use of the compounds of formulas (I),
(I'), (II), (II'), (III),
(III'), (IV) or (IV') disclosed herein as inhibitors of (3-secretase enzyme
activity or (3-site amyloid
precursor protein-cleaving enzyme ("BACE") activity, in a patient or subject
such as a manunal in need
of such inhibition, comprising the administration of an effective amount of
the compound. The terms
secretase enzyme," "(3-site amyloid precursor protein-cleaving enzyme," and
"BACE" are used
interchangeably in this specification. In addition to humans, a variety of
other mammals can be treated
according to the method of the present invention.
The compounds of the present invention have utility in treating, ameliorating,
controlling or
reducing the risk of Alzheimer's disease. For example, the compounds may be
useful for the prevention
of dementia of the Alzheimer's type, as well as for the treatment of early
stage, intermediate stage or late
stage dementia of the Alzheimer's type. The compounds may also be useful in
treating, ameliorating,
controlling or reducing the risk of diseases mediated by abnormal cleavage of
amyloid precursor protein
(also referred to as APP), and other conditions that may be treated or
prevented by inhibition of P-
secretase. Such conditions include mild cognitive impairment, Trisonly 21
(Down Syndrome), cerebral
amyloid angiopathy, degenerative dementia, Hereditary Cerebral Hemorrhage with
Amyloidosis of the
Dutch-Type (HCHWA-D), Creutzfeld-Jakob disease, prion disorders, amyotrophic
lateral sclerosis,
dementia associated with Parkinson's Disease, progressive supranuclear palsy,
head trauma, stroke,
pancreatitis, inclusion body myositis, other peripheral amyloidoses, diabetes
and atherosclerosis. The
compounds may also be useful in enhancing cogntion in patients suffering from
diseases mediated by
abnormal cleavage of the amyloid precursor protein.
The subject or patient to whom the compounds of the present invention is
administered is
generally a human being, male or female, in whom inhibition of (3-secretase
enzyme activity is desired,
but may also encompass other mammals, such as dogs, cats, mice, rats, cattle,
horses, sheep, rabbits,
monkeys, chimpanzees or other apes or primates, for which inhibition of (3-
secretase enzyme activity or
treatment of the above noted disorders is desired.
The compounds of the present invention may be used in combination with one or
more other
drugs in the treatment of diseases or conditions for which the compounds of
the present invention have
utility, where the combination of the drugs together are safer or more
effective than either drug alone.
Additionally, the compounds of the present invention may be used in
combination with one or more other
drugs that treat, prevent, control, ameliorate, or reduce the risk of side
effects or toxicity of the
compounds of the present invention. Such other drugs may be administered, by a
route and in an amount
commonly used therefor, contemporaneously or sequentially with the compounds
of the present
invention. Accordingly, the pharmaceutical compositions of the present
invention include those that
contain one or more other active ingredients, in addition to the compounds of
the present invention. The
combinations may be administered as part of a unit dosage form combination
product, or as a kit or
treatment protocol wherein one or more additional drugs are administered in
separate dosage forms as
part of a treatment regimen.
-39-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Examples of combinations of the compounds of the present invention with other
drugs in either
unit dose or kit form include combinations with anti-Alzheimer's agents, for
example other beta-secretase
inhibitors; glycine transport inhibitors; alpha 7 nicotinic agonists, such as
SSR 180711, MEM3454 and
MEM63908; gamma-secretase inhibitors, such as LY450139, LY411575 and TAK 070;
gamma secretase
modulators, such as E2012; tau phosphorylation inhibitors; blockers of A,li
oligomer formation; 5-HT4
agonists, such as PRX 03140; 5HT6 antagonists, such as GSK 742457, SGS-518,
SAM315, E6795, SL-
65.0155, SRA-333 and xaliproden; p25/CDK5 inhibitors; HMG-CoA reductase
inhibitors; NK1/NK3
receptor antagonists; NSAID's including ibuprofen; vitamin E; anti-amyloid
antibodies (including anti-
amyloid humanized monoclonal antibodies), such as bapineuzumab, AAB002,
RN1219, ACC001,
CAD 106 and AZD3 102; 5-HT1A antagonists, such as lecozotan; COX-2 inhibitors;
anti-inflammatory
compounds, such as (R)-flurbiprofen, nitroflurbiprofen, rosiglitazone, ND-
1251, VP-025, HT-0712 and
EHT-202; CB-1 receptor antagonists or CB-1 receptor inverse agonists, such as
AVE 1625; antibiotics
such as doxycycline and rifampin; N-methyl-D-aspartate (NMDA) receptor
antagonists, such as
memantine, neramexane and EVT101; NR2B antagonists; androgen receptor
modulators;
acetylcholinesterase inhibitors such as galantamine, rivastigmine, donepezil,
tacrine, phenserine,
ladostigil and ABT-089; mGluR5 modulators; growth hormone secretagogues such
as ibutamoren,
ibutamoren mesylate, and capromorelin; histamine H3 receptor antagonists, such
as ABT834, ABT239,
GSK 189254 and CEP16795; AMPA agonists or AMPA modulators, such as CX717,
LY404187 and S-
18986; PDE IV inhibitors, such as MEM141, HT0712 and AVE8112; GABAA inverse
agonists;
iABAA a 5 receptor ligands; GABAB receptor ligands; potassium channel
blockers; neuronal nicotinic
igonists, such as ABT089; plasminogen activator inhibitors, such as PAZ417;
cathepsin B inhibitors;
sSK3,6 inhibitors, such as AZD1080, SAR502250 and CEP 16805; selective Ml
agonists; neuronal
iicotinic agonists, microtubule affinity regulating kinase (MARK) ligands; P-
450 inhibitors, such as
itonavir; or other drugs that affect receptors or enzymes that either increase
the efficacy, safety,
;onvenience, or reduce unwanted side effects or toxicity of the compounds of
the present invention. The
7oregoing list of combinations is illustrative only and not intended to be
limiting in any way.
The compounds of the invention, like many protease inhibitors, are believed to
be metabolized in
rivo by cytochrome P-450 monooxygenase. Cytochrome P-450 is a family of
isozymes which impact
[rug metabolism. Cytochrome P-450 isozymes (including the CYP3A4 isozyme)
transform drug
aolecules in vivo, typically via oxidation. Metabolism by cytochrome P-450
often leads to unfavorable
,harmacokinetics, and the need for more frequent and higher doses than are
desirable. Administration of
uch drugs with an agent that inhibits metabolism by cytochrome P-450 may
improve the
harmacokinetics (i.e., increase half-life, increase time to peak plasma
concentration, increase blood
,vels) of the drug.
In one embodiment, the invention is directed to the combination or co-
administration of a
Dmpound of the invention and a cytochrome P-450 inhibitor. The invention is
also directed to a method
>r improving the pharmacokinetics of a compound of the invention which is
metabolized by cytochrome
-450 monooxygenase, by administering a compound of the invention with a
cytochrome P-450 inhibitor.
-40-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
The combination of a P-450 inhibitor and a compound of the invention may be
administered as
part of a unit dosage form combination product, or as a kit or treatment
protocol wherein one or more
p450 inhibitors are administered in separate dosage forms as part of a
treatment regimen.
Exemplary p450 inhibitors include ketoconazole, clarithromycin, erythromycin,
isoniazid,
fluoxetine, midazolam, delavirdine, indinavir, ritonavir, dihydralazine,
verapamil, troleandomycin,
tamoxifen and irinotecan. Other p450 inhibitors are disclosed in Pea et al,
Clin Pharnzacokinet 2001,
40(11), 833-868; Zhou et al, Cun=entDrugMetabolisna 2004, 5, 415-442; and
Wienkers, J. Plaarnz
Toxicol Metltods 2001, 45: 79-84. A preferred p450 inhibitor is ritonavir.
The term "composition" as used herein is intended to encompass a product
comprising specifled
ingredients in predetermined amounts or proportions, as well as any product
which results, directly or
indirectly, from combination of the specified ingredients in the specified
amounts. This term in relation
to pharmaceutical compositions is intended to encompass a product comprising
one or more active
ingredients, and an optional carrier comprising inert ingredients, as well as
any product which results,
directly or indirectly, from combination, complexation or aggregation of any
two or more of the
ingredients, or from dissociation of one or more of the ingredients, or from
other types of reactions or
nteractions of one or more of the ingredients.
In general, pharmaceutical compositions are prepared by uniformly and
intimately bringing the
ctive ingredient into association with a liquid carrier or a finely divided
solid carrier or both, and then, if
iecessary, shaping the product into the desired formulation. In the
pharmaceutical coniposition the
ictive compound, which is a compound of the invention (of formulas (I), (I'),
(II), (II'), (III), (III'), (IV)
r (IV')), is included in an amount sufficient to produce the desired effect
upon the process or condition
f diseases. Accordingly, the pharmaceutical compositions of the present
invention encompass any
omposition made by admixing a compound of the invention and a pharmaceutically
acceptable carrier.
The carrier may take a wide variety of forms depending on the form of
preparation desired for
dministration, e.g., oral or parenteral (including intravenous). Thus, the
pharmaceutical compositions of
ie invention can be presented as discrete units suitable for oral
administration such as capsules, cachets
r tablets each containing a predetermined amount of the active ingredient.
Further, the compositions
in be presented as a powder, as granules, as a solution, as a suspension in an
aqueous liquid, as a non-
lueous liquid, as an oil-in-water emulsion or as a water-in-oil liquid
emulsion. In addition to the
)mmon dosage forms set out above, the compounds of the invention, may also be
administered by
>ntrolled release means and/or delivery devices.
Pharmaceutical compositions intended for oral use may be prepared according to
any method
iown to the art for the manufacture of pharmaceutical compositions and such
compositions may contain
ie or more agents selected from the group consisting of sweetening agents,
flavoring agents, coloring
;ents and preserving agents in order to provide pharmaceutically elegant and
palatable preparations.
iblets may contain a compound of the invention in admixture with non-toxic
pharmaceutically
ceptable excipients which are suitable for the manufacture of tablets. These
excipients may be, for
ample, inert diluents, such as calcium carbonate, sodium carbonate, lactose,
calcium phosphate or
-41-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
sodium phosphate; granulating and disintegrating agents, for example, corn
starch, or alginic acid;
binding agents, for example starch, gelatin or acacia, and lubricating agents,
for example magnesium
stearate, stearic acid or talc. The tablets may be uncoated or they may be
coated by known techniques to
delay disintegration and absorption in the gastrointestinal tract and thereby
provide a sustained action
over a longer period.
A tablet containing a compound of this invention may be prepared by
compression or molding,
optionally with one or more accessory ingredients or adjuvants. Compressed
tablets may be prepared by
compressing, in a suitable machine, a compound of the invention in a free-
flowing form such as powder
or granules, optionally mixed with a binder, lubricant, inert diluent, surface
active or dispersing agent.
Molded tablets may be made by molding in a suitable machine, a mixture of the
powdered compound
moistened with an inert liquid diluent. Each tablet preferably contains from
about 0.1 mg to about 500
mg of a compound of the invention and each cachet or capsule preferably
contains from about 0.1mg to
about 500 mg of a compound of the invention.
Compositions for oral use may also be presented as hard gelatin capsules
wherein the compound
of the invention is n7ixed with an inert solid diluent, for example, calcium
carbonate, calcium phosphate
or kaolin, or as soft gelatin capsules wherein the compound of the invention
is mixed with water or an oil
medium, for example peanut oil, liquid paraffin, or olive oil.
Other pharmaceutical compositions include aqueous suspensions, which contain
the active
naterials in admixture with excipients suitable for the manufacture of aqueous
suspensions. In addition,
)ily suspensions may be formulated by, suspending the compound of the
invention in a vegetable oil, for
;xample arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil
such as liquid paraffin. Oily
;uspensions may also contain various excipients. The pharmaceutical
compositions of the invention may
Llso be in the form of oil-in-water emulsions, which may also contain
excipients such as sweetening and
lavoring agents.
The pharmaceutical compositions may be in the form of a sterile injectable
aqueous or
-leaginous suspension, or in the form of sterile powders for the
extemporaneous preparation of such
terile injectable solutions or dispersions. In all cases, the final injectable
form must be sterile and must
ie effectively fluid for easy syringability. The pharmaceutical compositions
must be stable under the
onditions of manufacture and storage; thus, preferably should be preserved
against the contaminating
ction of microorganisms such as bacteria and fungi.
Pharma.ceutical compositions of the present invention can be in a form
suitable for topical use
uch as, for example, an aerosol, cream, ointment, lotion, dusting powder, or
the like. Further, the
ompositions can be in a form suitable for use in transdermal devices. These
formulations may be
repared via conventional processing methods. As an example, a cream or
ointment is prepared by
iixing hydrophilic material and water, together with about 5 wt% to about 10
wt% of the compound of
ie invention, to produce a cream or ointment having a desired consistency.
- 42 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Pharmaceutical compositions of this invention can also be in a form suitable
for rectal
administration wherein the carrier is a solid. It is preferable that the
niixture forms unit dose
suppositories. Suitable carriers include cocoa butter and other materials
conunonly used in the art.
The terms "administration of' or "administering a" compound should be
understood to
mean providing a compound of the invention to a patient in need of treatment
in a form that can be
introduced into the patient's body in a therapeutically useful form and
therapeutically useful amount,
including, but not limited to: oral dosage forms, such as tablets, capsules,
syrups, suspensions, and the
like; injectable dosage forms, such as IV, IM, or IP, and the lilce;
transdermal dosage forms, including
-reams, jellies, powders, or patches; buccal dosage forxns; inhalation
powders, sprays, suspensions, and
:he like; and rectal suppositories.
The terms "effective amount" or "therapeutically effective amount" means the
amount of the
;ubject compound that will elicit the biological or medical response of a
tissue, system, animal or human
hat is being sought by the researcher, veterinarian, medical doctor or other
clinician.
As used herein, the term "treatment" or "treating" means any administration of
a compound of
he invention and includes (1) inhibiting the disease in an animal that is
experiencing or displaying the
,athology or symptomatology of the diseased (i.e., arresting further
development of the pathology and/or
ymptomatology), or (2) ameliorating the disease in an animal that is
experiencing or displaying the
athology or syxnptomatology of the diseased (i.e., reversing the pathology
and/or symptomatology). The
;rm "controlling" includes preventing treating, eradicating, ameliorating or
otherwise reducing the
;verity of the condition being controlled.
The compositions containing compounds of the invention may conveniently be
presented in unit
)sage form and may be prepared by any of the methods well known in the art of
pharmacy. The term
init dosage form" is taken to mean a single dose wherein all active and
inactive ingredients are
-mbined in a suitable system, such that the patient or person administering
the drug to the patient can
-en a single container or package with the entire dose contained therein, and
does not have to mix any
,mponents together from two or more containers or packages. Typical examples
of unit dosage forms
- tablets or capsules for oral administration, single dose vials for
injection, or suppositories for rectal
ministration. This list of unit dosage forms is not intended to be limiting in
any way, but merely to
)resent typical examples of unit dosage forms.
The compositions containing compounds of the invention may conveniently be
presented as a kit,
tereby two or more components, which may be active or inactive ingredients,
carriers, diluents, and the
e, are provided with instructions for preparation of the actual dosage form by
the patient or person
ninstering the drug to the patient. Such kits may be provided with all
necessary materials and
redients contained therein, or they may contain instructions for using or
making materials or
nponents that must be obtained independently by the patient or person
administering the drug to the
ient.
When treating, ameliorating, controlling or reducing the risk of Alzheimer's
disease or other
;ases for which compounds of the invention are indicated, generally
satisfactory results are obtained
-43-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
when the compounds of the invention are administered at a daily dosage of from
about 0.1 mg to about
100 mg per kg of animal body weight, preferably given as a single daily dose
or in divided doses two to
six times a day, or in sustained release form. The total daily dosage is from
about 1.0 mg to about 2000
mg, preferably from about 0.1 mg to about 20 mg per kg of body weight. In the
case of a 70 kg adult
human, the total daily dose will generally be from about 7 mg to about 1,400
mg. This dosage regimen
may be adjusted to provide the optimal therapeutic response. The compounds may
be administered on a
regimen of 1 to 4 times per day, preferably once or twice per day.
The amount of the compound of the invention that may be combined with the
carrier materials to
produce a single dosage form will vary depending upon the host treated and the
particular mode of
administration. For example, a formulation intended for the oral
administration to humans may
conveniently contain from about 0.005 mg to about 2.5 g of a compound of the
invention, compounded
with an appropriate and convenient amount of carrier material. Unit dosage
forms will generally contain
between from about 0.005 mg to about 1000 mg of the compound of the invention,
typically 0.005 mg,
0.01 mg, 0.05 mg, 0.25 mg, 1 mg, 5 mg, 25 mg, 50mg, 100 mg, 200 mg, 300 mg,
400 mg, 500 mg, 600
mg, 800 mg or 1000 mg, administered once, twice or three times a day.
. It will be understood, however, that the specific dose level and frequency
of dosage for any
particular patient may be varied and will depend upon a variety of factors
including the activity of the
specific compound employed, the metabolic stability and length of action of
that compound, the age,
body weight, general health, sex, diet, mode and time of administration, rate
of excretion, drug
combination, the severity of the particular condition, and the host undergoing
therapy.
The utility of the compounds in accordance with the present invention as
inhibitors of (3-
3ecretase enzyme activity may be demonstrated by methodology known in the art.
Enzyme inhibition
nay be determined as follows.
ECL Assay: A homogeneous end point electrochemiluminescence (ECL) assay is
performed
ising a biotinylated BACE substrate. The Km of the substrate is greater than
100 gM and can not be
letermined due to the limit of solubility of the substrate. A typical reaction
contains approximately 0.1
iM enzyme, 0.25 gM of the substrate, and buffer (50 mM NaOAc, pH 4.5, 0.1
mg/ml BSA, 0.2%
MAPS, 15 mM EDTA and 1 mM deferoxamine) in a total reaction volume of 100 l.
The reaction
)roceeds for 30 min and is then stopped by the addition of 25 gL of 1 M Tris-
HC1, pH 8Ø The resulting
,nzymatic product is assayed by adding a ruthenylated antibody which
specifically recognizes the C-
erminal residue of the product. Streptavidin coated magnetic beads are added
into the solution and the
amples are subjected to M-384 (Igen Inc., Gaithersburg, MD) analysis. Under
these conditions, less
han 10% of substrate is processed by BACE 1. The enzyme used in these studies
is soluble
transmembrane domain and cytoplasmic extension excluded) human protein
produced in a baculovirus
xpression system. To measure the inhibitory potency for compounds, 12
concentrations of inhibitors
re prepared starting from 100 gM with three fold series dilution. Solutions of
the inhibitor in DMSO
re included in the reaction mixture (final DMSO concentration is 10 %). All
experiments are conducted
t rt using the standard reaction conditions described above. To determine the
IC50 of the compound, a
-44-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
four parameter equation is used for curve fitting. The errors in reproducing
the dissociation constants are
typically less than two-fold.
In particular, the compounds of the invention have activity in inhibiting the
beta-secretase
enzyme in the aforementioned assay, generally with an IC50 from about 1 nM
(.001 gM) to 200 M.
Preferred coinpounds have an IC50 from about .001 .M to 1 .M. Such results
are indicative of the
intrinsic activity of the compounds as inhibitors of beta-secretase enzyme
activity.
sAPP,6 Assay: sAPP# is the soluble N-terminal product of APP after processing
by BACE 1.
Biochemical assays for BACE-1 inhibitions have been developed for evauating
the BACE inhibition
properties of drug candidates. Suitable BACE1 assays use purified, soluble
recombinant BACE 1 with a
-oumarin labeled petide containing an optimized cleavage sequence NFEV at the
P2-P2' position. An
xemplary cell-based assay is described at Pietrak et al, Analytical
Bioclaenaistry 342 (2005), 144-15 1.
Preferred compounds of the invention have an IC50 value in a standard sAPP(3
assay of less than
l0 M, more preferably less than 1 M.
Additional assays used to evaluate the compounds of the invention for use as
pharmaceuticals
nclude Pgp transport assays and PXR assays.
Pgp Transport Assay: The compounds of the invention also demonstrate favorable
properties in
P-glycoprotein (Pgp) efflux human assay. Pgp is a xenobiotic transport
protein, which is expressed in
,arious human tissues, including the intestine, liver and kidney. Pgp acts to
transport xenobiotic
iaterials out of cells. Many therapeutically effective compounds have been
found to be Pgp substrates.
s a result, the interaction of a drug candidate with Pgp is an important
concern in pharmaceutical
-search.
Various Pgp human assays have been developed and commercialized for use in
evaluating drug
indidates. Typically, the Pgp human assay is designed to determine in vitro
inhibitory properties of
)mpounds for human PGP-mediated transport. An exemplary Pgp human assay is
described in Keogh
al, Eur JPharna Sci 27 (2006) 543-554.
PXR Assay: The pregnane X receptor (PXR) assay was designed to identify
compounds which
duce cyctochrome P450 3A4 (CYP3A4). CYP3A4 is a drug metabolizing enzyme which
is present in
rge amounts human liver microsomes. An exemplary PXR assay is described in Luo
et al, Drug
etabol and Disp (2002) 30(7):795-804. See also Iyer et al, "Functional
Evolution of the Pregmane X
,ceptor," Expert Opin Dizsg Metab Toxicol (2006) 2(3):381-397.
Several methods for preparing the compounds of this invention are illustrated
in the Schemes and
:amples herein. Starting materials are made according to procedures known in
the art or as illustrated
rein. The following examples are provided so that the invention might be more
fully understood.
iese examples are illustrative only and should not be construed as limiting
the invention in any way.
termediate I: 1-benzyl-2-methylpiperidin-4-one
- 45 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
O
N
~ \
/
1
2-Methyl piperidinone hydrochloride (Atlantic Scientific Co. Inc. 0.852 g,
5.08 mmol), powdered
sodium carbonate (2.15g 20.3 mmol) and benzyl chloride (0.585 mL, 5.08 mmol)
were
dissolved/suspended in CH3CN (8 mL) under nitrogen and heated at 70 C
overnight. An additiona10.5
mmole benzyl chloride was added, the reaction refluxed for 4 hr, then filtered
and evaporated. The
residue was chromatographed on silica eluting with a gradient of 0-20%
EtOAc/Hex to give the product.
'H NMR (400 MHz, CDC13) 6 7.4-7.24 (m, 5H), 3.97 (d, J= 13.4 Hz, 1H), 3.45 (d,
J= 13.4 Hz, 1H), 3.0
;m, 2H), 2.54, (m, 2H), 2.37 (t, J= 6.1 Hz, 2H), 2.28 (dd, J= 7.4, 14.3 Hz,
1H), 1.18 (d, J= 6.4 Hz, 3H)
)pm.
klternative synthesis of Intermediate I: 1 -benzyl-2-methylpiperidin-4-one
ntermediate I was also prepared using a method shown in Scheme 2 and similar
to that described by M.-
.. Blanco-Pilado et al, in W02004/094380 and to the experimental below for
Intermediate II, using
)enzylamine as the amine.
H NMR (400 MHz, CDC13) 8 7.38-7.28 (m, 4H), 7.25 (m, 1H), 3.96 (d, J = 13.6
Hz, 1H), 3.45 (d, J
3.4 Hz, 1H), 3.0 (m, 2H), 2.54 (m, 2H), 2.37 (t, J = 6.3 Hz, 2H), 2.28 (dd, J
= 7.5, 14.1 Hz, 1H), 1.18 (d,
= 6.6 Hz, 3H) ppm.
ntermediate II: 1-(3-isopropoxybenzyl)-2-methylpiperidin-4-one
O
eN Y
O
( /
itermediate II was prepared using a method similar to that described by M.-J.
Blanco-Pilado et al in
702004/094380, using 1-(3-isopropoxyphenyl)methanamine as the amine.
.ep 1: 3-isopropoxybenzonitrile:
-46-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
0 N
~ I \
A combination of 32g(268mmo1, Aldrich) 3-cyanophenol, 26.9mL(268mmol) 2-
iodopropane, and
88g(269mmo1) cesium carbonate in 1:1 CH2CI2:CH3CN was heated to reflux and
allowed to stir
overnight. HPLC/MS showed pure product so the suspension was filtered, washed
with CH3CN and
ooncentrated. The remaining oil was dissolved in CH2C12and filtered thru a
short pad of silica with
CH2C12. The filtrate was concentrated to dryness to give the product.
A.n alternative preparation uses the conditions similar to the above except
that postassium carbonate is
ised as the base.
H NMR (400 MHz, CDC13) S 7.35 (m, 1H), 7.21 (m, 1H), 7.12 (m, 2H), 4.58 (m,
1H), 1.35 (d, 6H)ppm.
>tep 2: (3-Isopropoxybenzyl)amine:
~O NH2
L 500niL Parr bottle was flushed with argon, then 3-isopropoxybenzonitrile
(32g, 198 mmol) was added
rid diluted with 150mL EtOH. The reaction was charged with -2mL of an aq.
slurry of Raney Nickel,
ien affixed to a Parr hydrogenation apparatus. The flask was evacuated and
flushed with N2 three times
~fore being charged with 40 psi H2. The flask was allowed to shake for 3 hr
over which time the flask
-as recharged to 40 psi and consumption of gas ceased. HPLC/MS showed no
starting material so the
italyst was carefully filtered without drying and washed with EtOH. The
filtrate was concentrated and
xrified on an Isco automated system affixed with a Biotage Flash 40(M)
cartridge eluted with 0-5%
4eOH + 0.5M NH3) in CH2C1z over 30 min at 40mL/min to give the product.
[ NMR (400 MHz, CDC13) 8 7.24 (m, 1H), 6.85 (m, 2H), 6.76 (m, 1H), 4.56 (m,
1H), 3.83 (s, 2H), 1.4
s, -2H), 1.33 (d, J= 6.0 Hz, 6H) ppm.
ep 3: 1-(3 -isopropoxybenzyl)-2-methylpiperidin-4-one:
0
-TO
-47-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
A neat solution of 1 lmL(115mmol) crotonoyl chloride (>95% pure, TCI America)
was added dropwise
to 8.7g (120mmol, Aldrich, anhydrous powder in ampules ) A1C13 in 200mL
anhydrous CHaCIZ under
argon on an ice bath keeping the temperature around 15 C then allowed to stir
10 min. The flask was
cooled to -20 C on a ethylene glycol /dry ice bath and 18.4 mL(126mmol)
vinyltrimethylsilane (Aldrich)
in 10mL DCM was added dropwise from a jacketed addition funnel cooled with ice
water maintaining
the temp below -15 C. Stirring continued at -20 C for 30 min then the reaction
was poured into 300mL
of a saturated aq solution of sodium-potassium tartrate containing 150g K2CO3
and -200mL ice. The
slurry was allowed to stir vigorously for 30 min then filtered thru celite and
washed with CH2ClZ, The
organic layer was separated, dried over Na2SO4, filtered and carefully
concentrated to give about 14g of
crude (4E)-hexa-1,4-dien-3-one which was immediately talcen up in 20mL CH3CN
and added to
17g(103mmol) (3-isopropoxybenzyl)amine (Step 2) in a slurry of 50mL CH3CN,
60mL water, 9.6g
sodium bicarbonate and stirred at rt for 16 hr. The mixture was partitioned
between EtOAc and water.
The organic layer was separated and dried over Na2S04, filtered and
concentrated. The remaining oil
was purified on an Isco automated system affixed with Biotage Flash 40(L)
cartridge eluted with 0-2.5%
(MeOH + 0.5M NH3) in CH2C12 over 30 min at 50mL/min to give the product.
1H NMR (400 MHz, CDC13) S 7.22 (t, J = 7.7 Hz, 1H), 6.92 (m, 2H), 6.79 (dd, J
= 2.4, 8.2 Hz, 1H),
4.55 (septet, J=-6 Hz, 1H), 3.92 (d, J = 13.6 Hz, 1H), 3.40 (d, J = 13.6 Hz,
1H), 3.0 (m, 2H), 2.55 (m,
2H), 2.36 (t, J = 6.3 Hz, 2H), 2.27 (dd, J = 7.5, 14.1 Hz, 1H), 1,34 (d, J=
6.2 Hz, 6H), 1.16 (d, J = 6.4 Hz,
3H) ppm.
In an alternative preparation, A1C13 (15g, 0.11 mole ) was added to a 3-necked
flask
equipped with a jacketed addition funnel, flushed with argon and cooled in an
ice bath. Crotonyl chloride
(21 g, 200 mmol) was added dropwise while keeping the temperature of the
reaction below 15 C. The
resulting light yellow solution was stirred for 15 min before the ice bath was
replaced with an
ethyleneglycol/dry ice bath and the solution cooled to -20 C. Vinylsilane
(21.1 ml, 220 mmol) was
added dropwise from the ice-cooled jacketed addition funnel keeping the
temperature of the reaction
below -20 C. The reaction was stirred for 3 hr and then added quickly to a
slurry of 200 mL saturated
aqueous sodium/potassium tartrate solution, 200g K2C03, 300mL ice and 500 mL
ether. The slurry was
stirred vigorously for 30 min then filtered through celite. The organic layer
was separated, dried over
NazSO4, filtered and carefully concentrated. The oil was dissolved in 20 mL
CH3CN and added dropwise
to a cooled (0 C) suspension of 3-(isopropoxy)benzylamine (30g, 180 mmol) in
a mixture of 2M aq
NaHCO3 (100mL) and CH3CN (30 mL). The reaction was stirred at rt overnight and
partitioned between
water and EtOAc. The organic layer was dried over Na2SO4, filtered and
concentrated. The resulting oil
was chromatographed on silica eluting with 0-50% EtOAc/Hexanes.
1H NMR (400 MHz, CDC13) 6 7.25 (m, 1H), 6.95 (m, 2H), 6.9 (m, 1H), 4.55 (m,
1H), 3.92 (d, 1H), 3.4
(d, 1H), 3.0 (m, 2H), 2.55 (m, 2H), 2.4 (m, 2H), 2.25 (m, 1H), 1.35 (d, 6H),
1.2 (d, 3H) ppm.
- 48 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Intermediate III: 1-(chloromethyl)-3-{[(1R)-1-methylpropyl]oxy}benzene
O 1. sec-BuOH
TPP / DIAD O
HO OMe CI
2. LiBH4
3. TPP I CCI4
Step 1: methyl3-{[(1R)-1-methylpropyl]oxy}benzoate
To a 0 C solution of methyl 3-hydroxybenzoate (5.00 g, 32.9 mmol) in toluene
(32.9 ml) was added (8)-
(+)-sec-butanol (3.34 ml, 36.1 mmol), triphenylphosphine (9.48 g, 36.1 mmol),
and DIAD (7.03 ml, 36.1
xnmol). After warming to rt overnight, the reaction mixture was filtered
through a fritted funnel and
washed with toluene. The filtrate was concentrated. The residue was purified
on a silica gel cartridge
(0% EtOAc / hexanes to 10% EtOAc / hexanes) to give the desired product.
Step 2: (3-{[(1R)-1-methylpropyl]oxy}phenyl)methanol
To a solution of methyl 3-{[(1R)-1-methylpropyl]oxy}benzoate (3.50 g, 16.8
mmol) in THF (67 mL) was
added 2M lithium borohydride solution in THF (25.2 ml, 50.4 mmol). The
reaction was heated to 50 C
overnight. The reaction was quenched with MeOH and the solvents were
concentrated. The residue was
dissolved in EtOAc and washed with saturated NaHCO3. The aqueous phase was
extracted with
dichloromethane and the organics were combined, washed with H20 (2 times)
dried with MgSO4,
filtered, and concentrated. The residue was purified on a silica gel cartridge
(10% EtOAc /hexanes to
20% EtOAc/hexanes) to give the desired product.
Step 3: 1-(chloromethyl)-3-{[(1R)-1-methylpropyl]oxy}benzene
To a solution of (3-{[(1R)-1-methylpropyl]oxy}phenyl)methanol (1.01 g, 5.60
mmol) in carbon
tetrachloride (18.7 ml) was added triphenylphosphine (1.40 g, 5.32 mmol). The
reaction was heated to
reflux overnight. The reaction was filtered through a fritted funnel and
washed with carbon tetrachloride.
The filtrate was concentrated. The residue was purified on a silica gel
cartridge (0% EtOAc / hexanes to
10% EtOAc / hexanes) to give the desired product.
1H NMR (CDC13): Q7.26 - 7.22 (m, 1H); 6.92 - 6.91 (m, 2H); 6.85 - 6.82 (m,
1H); 4.55 (s, 2H); 4.33 -
4.29 (m, 1H); 1.69 - 1.58 (m, 2H); 1.29 (d, J = 6.05 Hz, 3H); 0.979 (t, J =
7.42 Hz, 3H).
Intermediate IV: 2-(chloromethyl)-1-fluoro-4-{[(1R)-1-methylpropyl]oxy}benzene
-49-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
1. sec-BuOH TPP / DIAD
HO .~ CI CI
M 2. allylSnBu3 / Pd(0)
/ F 3. 03 / NaBH4 F
4. TPP / CCI4
Step1: 2-chloro-l-fluoro-4-{ [(1R)-1-methylpropyl]oxy}benzene
To a 0 C solution of 3-chloro-4-fluorophenol (2.10 g, 14.3 nimol) in toluene
(14.3 ml) was added (S)-
(+)-sec-butanol (1.39 ml, 15.0 mmol), triphenylphosphine (3.76 g, 14.3 mmol),
and DIAD (3.06 ml,
15.76 mmol). The reaction warmed to rt overnight. The reaction mixture was
filtered through a fritted
funnel and washed with toluene. The filtrate was concentrated. The residue was
diluted with EtOAc and
washed with iN NaOH. The aqueous phase was extracted with EtOAc (2 times). The
combined
organics were dried with MgSO4i filtered, and concentrated. The residue was
purified on a silica gel
cartridge (0% EtOAc I hexanes to 4% EtOAc / hexanes) to give the desired
product.
Step 2: 1-fluoro-4-{[(1R)-1-methylpropyl]oxy}-2-vinylbenzene
To a solution of 2-chloro-1-fluoro-4-{[(1R)-1-methylpropyl]oxy}benzene (1.75
g, 8.64 nunol) in dioxane
(28.8 ml) under argon were added bis(tri-t-butylphosphine) palladium(0) (0.221
g, 0.432 mmol) and
cesium fluoride (2.89 g, 19.0 mmol). Argon was bubbled through the reaction
for 2 min. To the reaction
was added tributyl (vinyl) tin (3.03 ml, 10.4 mmol) and the argon bubbled for
another 5 min. The
reaction was sealed and heated to 100 C overnight. The reaction was
partitioned between H20 and
EtOAc. The aqueous phase was extracted with EtOAc (3 times). The combined
organics were dried
with MgSO4i filtered, and concentrated. The residue was purified by column
chromatography on a silica
gel cartridge (0% EtOAc / hexanes to 4% EtOAc / hexanes) to give the desired
product.
Step 3: (2-fluoro-5-{[(1R)-1-methylpropyl]oxy}phenyl)methanol
Ozone was bubbled through a -78 C solution of 1-fluoro-4-{[(1R)-1-
methylpropyl]oxy}-2-vinylbenzene
(0.81 g, 4.17 rnmol) in dichloromethane (27.8 ml) and MeOH (13.90 ml) until
the reaction color
remained blue. The reaction stirred 10 min, and then was purged with N2 for 10
min. MeOH (25 niL)
was added, followed by sodium borohydride (0.237 g, 6.25 mmol). The reaction
warmed to rt. After 1
h, the reaction mixture was concentrated in vacuo. The residue was purified by
column chromatography
on a silica gel cartridge (12% EtOAc / hexanes) to give the desired product.
Step 4: 2-(chloromethyl)-1-fluoro-4-{[(1R)-1-methylpropyl]oxy}benzene
-50-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
To a solution of (2-fluoro-5-{[(1R)-1-methylpropyl]oxy}phenyl)methanol (0.091
g, 0.459 mmol) in
carbon tetrachloride (4.59 ml) was added triphenylphosphine resin (0.241 g,
0.918 mmol). The reaction
was heated to 78 C overnight in a pressure tube with minimal stirring. The
reaction mixture was
filtered through a fritted funnel and washed with carbon tetrachloride. The
filtrate was concentrated to
give the desired product.
'H NMR (CDC13): 8 6.96 (t, J= 9.16 Hz, 1H); 6.93 - 6.90 (m, 1H); 6.82 - 6.78
(m, 1H); 4.59 (s, 2H); 4.26
- 4.18 (m, 1H); 1.78 - 1.57 (m, 2H); 1.27 (d, J= 6.04 Hz, 3H); 0.975 (t, J=
7.33 Hz, 3H).
Intermediate V: 1-(chloromethyl)-3-(cyclopropylmethyl)benzene
0
Br 1. aIIyISnBu3 / Pd
OMe 2. Et2Zn / CICH2I CI
I 3. LiBH4
4. TPP / CCI4
Step 1: methyl3 -allylbenzoate
To a solution of inethyl3-bromobenzoate (10.0 g, 46.5 mmol) in DMF (50 niL)
was added ally tributyltin
(23.1 g, 69.8 mmol) followed by tetrakis(triphenylphoshine) palladium(0) (1.08
g, 0.93 mmol). After
stirring 80 C overnight the reaction mixture was poured into H20 (500 mL),
extracted with ethyl acetate
(three times), dried over MgSO4 and concentrated under vacuum to afford the
desired product.
LRMS (M+1) = 177.0
Step 2: methyl3-(cy.clopropylmethyl)benzoate
To a solution of inethyl3-allylbenzoate (8.39 g, 47.6 nunol) in dichloroethane
(100 mL) was added
iodochloromethane (26.9 mL, 152 mmol). The solution was cooled to 0 C and
diethyl zinc (1.0 M in
heptanes, 76.2 mL, 76.2 mmol) was added. The cooling bath was removed and the
reaction was stirred at
rt for 30 min. The reaction mixture was quenched with 1N HCI, extracted with
methylene chloride (three
times), dried with MgSO4 and concentrate under vacuum to afford the desired
product.
LRMS (M+1) =191.1
itep 3: [3-(cyclopropylmethyl)phenyl]methanol
Co a solution of inethyl3-(cyclopropylmethyl)benzoate (9.06 g, 47.6 mmol) in
THF (100 mL) was added
ithium borohydride (2.0 M in THF, 71.4 mL, 142.9 mmol). After stirring at 50 C
for 1 h the reaction
vas cooled, quenched with excess methanol and concentrated under vacuum.
Purification by silica gel
hromatography (30% EtOAc/hexanes) afforded the desired product.
-51-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Step 4: 1 -(chloromethyl)-3 -(cyclopropylmethyl)benzene
To a solution of [3-(cyclopropylmethyl)phenyl]methanol (1.67 g, 10.3 mmol) in
carbon tetrachloride
(100 mL) was added polystyrene bound triphenyl phosphine (2.15 mmol/g, 9.57 g,
20.6 mmol). After
stirring at 100 C overnight the resin was filtered of and the solvent was
removed under vacuum to afford
the desired product.
'H NMR (CDC13): 8 7.31-7.21 (m, 4H), 4.58 (s, 2H), 2.55 (d, J= 7.0 Hz, 2H),
0.98 (m, 1H), 0.55 (m,
2H), 0.20 (m, 2H).
Intermediate VI: 1-bromo-3-methylpent-2-ene
1. Horner-Emmons
2. NaOH
/Y CBr
O3.LAH 4. PBr3
Step 1: methyl-3-methylpent-2-enoate
To a 0 C mixture of methyl diethylphosphonoacetate (12.7 ml, 69.3 mmol) and
sodium methoxide (13.0
ml, 69.3 mmol) was added dropwise 2-butanone (5.81 ml, 69.3 mmol) over 30 min.
After the addition,
the mixture warmed to rt and stirred overnight. To the reaction was added 20
mL of H20. The mixture
was extracted with EtOAc (3 times). The combined organics were dried with
MgSO4, filtered, and
concentrated. The crude oil was distilled at 110 C at 35 nvnHg to give the
desired product.
Step 2: 3-methylpent-2-enoic acid
To a solution of methyl-3-methylpent-2-enoate (3.27 g, 25.5 mmol) in MeOH
(8.50 ml) was added 1N
sodium hydroxide solution (30.6 ml, 30.6 nunol). The reaction was heated to 70
C for 4 h. The reaction
was washed with EtOAc. The aqueous phase was acidified with 1N HCl and
extracted with EtOAc (3
times). The combined organics were dried with MgSO4, filtered, and
concentrated to give the desired
product.
Step 3: 3-methylpent-2-en-l-ol
Vlethanol (0.71 ml, 17.5 mmol) in ether (5.48 ml) was added to 2M lithium
aluminum hydride solution
17.5 ml, 17.5 mmol) at 0 C. To the reaction was added dropwise 3-methylpent-2-
enoic acid (2.00 g,
7.5 mmol) in ether (5.48 ml). The solution warmed to rt overnight. The
reaction was slowly quenched
-52-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
with 0.316 mL H20, 0.316 mL 1N NaOH and 0.950 mL of water. The mixture was
filtered, and the
layers were separated. The aqueous phase was extracted with EtOAc (2 times).
The combined organics
were dried with MgSO4, filtered, and concentrated to give the desired product.
Step 4: 1 -bromo-3-methylpent-2-ene
To a-15 C solution of phosphorous tribromide (0.235 ml, 2.50 mmol) and
pyridine (0.162 ml, 2.00
mmol) in hexanes (4.99 ml) was added 3-methylpent-2-en-l-ol (0.500 g, 4.99
mmol) in ether (4.99 ml)
via cannula. The reaction warmed to 0 C for 2 h. The bath was removed and the
reaction stirred at rt
for 1 h. The reaction was diluted with H20 and hexanes. The layers were
separated and the organics
were washed with 0.5 M KHSO4, brine, dried with MgSO4, filtered, and
concentrated to give the desired
product.
'H NMR (CDC13): 8 5.55 - 5.48 (m, 1H); 4.03 (d, J= 8.24 Hz, 2H); 2.18 - 2.05
(m, 2H); 1.73 (s, 3H);
1.01 (t, J= 7.50 Hz, 3H).
Intermediate VII: 1-(chloromethyl)-3-(1-cyclopropylethyl)benzene
O
Br 1. butenylSnBu3 / Pd
OMe 2. Et2Zn / CICH21 CI
3. LiAIH4
4. TPP / CCI4
Step 1: methyl 3-(1-methylprop-2-en-1-yl)benzoate
To a solution of inethyl3 bromobenzoate (1.81 g, 8.42 mmol) in DMF (50 mL) was
added (E)-4-
(tributylstannyl)but-2-ene (Weigand, S.; Bruckner, R. synthesis, 1995, 475)
(3.48 g, 10.1 nunol)
followed by tetrakis(triphenylphoshine) palladium(0) (0.49 g, 0.42 mmol).
After stirring 80 C overnight
the reaction mixture was poured into H20 (500 mL), extracted with ethyl
acetate (three times), dried over
MgSO4 and concentrated under vacuum to afford the desired product.
Purification by silica gel
chromatography (5% EtOAc/hexanes) afforded the desired product.
LRMS (M+1) = 191.1
Step 2: methyl3-(1-cyclopropylethyl)benzoate
To a solution of inethyl3-(1-methylprop-2-en-1-yl)benzoate (0.85 g, 4.49 mmol)
in dichloroethane (20
mL) was added iodochloromethane (2.54 mL, 14.4 rnmol). The solution was cooled
to 0 C and diethyl
zinc (1.0 M in heptanes, 7.13 mL, 7.13 mmol) was added. The cooling bath was
removed and the
-eaction was stirred at rt for 30 min. The reaction mixture was quenched with
1N HCI, extracted with
-53-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
methylene chloride (three times), dried with MgSO~ and concentrate under
vacuum to afford the desired
product.
LRMS (M+l) =205.1
Step 3: [3 -(1-cyclopropylethyl)phenyl]methanol
To a solution of methyl 3-(1-cyclopropylethyl)benzoate (0.917 g, 4.48 mmol) in
THF (50 mL) was added
lithium aluminum hydride (1.0 M in THF, 13.5 mL, 13.5 mmol). After stirring at
rt for 15 min the
reaction was cooled and quenched with water, extracted into ethyl acetate
(three times) and concentrated
under vacuum. Purification by silica gel chromatography (30% EtOAc/hexanes)
afforded the desired
product.
Step 4: 1-(chloromethyl)-3-(1-cyclopropylethyl)benzene
To a solution of [3-(1-cyclopropylethyl)phenyl]methanol (0.128 g, 0.73 mmol)
in carbon tetrachloride
(20 mL) was added polystyrene bound triphenyl phosphine (2.15 mmol/g, 0.68 g,
1.5 mmol). After
stirring at 100 C overnight the resin was filtered of and the solvent was
removed under vacuum to afford
the desired product.
'H NMR (CDC13) S 7.32-7.16 (m, 4H), 4.60 (s, 2H), 2.00 (m, 1H), 1.34 (d, J =
7.1 Hz, 3H, 0.94 (m, 1H),
0.56 (m, 1H), 0.44 (m, 1H), 0.19 (m, 2H).
Intermediate VIII: 1-(bromomethyl)cyclohexene
1. DIBAL I
O "0 2. PPh3, CBr4 Br
0
Step 1: cyclohex-l-en-l-ylmethanol
To a 0 C solution of inethyl-l-cyclohexene-l-carboxylate (1.46 mL, 10.7 mmol)
in THF(10 niL) was
idded 20 wt 1o DIBAL in toluene (18.2 rnL, 32.1 mmol). After stirring at 0 C
for 2h, 1N HCl was added
:o quench the solution. The resulting mixture was extracted with ether (three
times), washed with H20
~id brine, dried with NaZSO4 and concentrated. The crude compound was
chromatographed to give the
lesired product.
;tep 2: 1 -(bromomethyl)cyclohexene
- 54 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
l'o a 0"C solution of cyclohex-l-en-l-ylmethanol (0.20 g, 2.04 mmol) and
triphenylphosphine (0.59 g,
2.24 mmol) was added carbon tetrabromide (0.74 g, 2.24 mmol). After stirring
at rt for 72h, the reaction
mixture was concentrated and chromatographed to give the desired product.
Intermediate IX: 1-(bromomethyl)cyclopentene
1. DIBAL I
,O 2. PPh3, CBr4 Br -Iro O
1 -(bromomethyl)cyclopentene was prepared using the same procedures as
Intermediate K but starting
from methyl 1 -cyclopentencarboxylate.
Intermediate X: 1-isopropyl-lH-indole-6-carbaldehyde
1.
2-lodopropane, Cs2C03 ~ 2. LiBH4 ,O IN 3. Mn02 H N O O
Y:)~H
Step 1: methyl 1-isopropyl-lH-indole-6-carboxylate
To a solution of methyl 1H-indole-6-carboxylate (5.00 g, 28.5 mmol) and cesium
carbonate (18.6 g, 57.1
mmol) in DMPU (50 mL) was added 2-iodopropane (3.71 mL, 37.1 mmol). After
stirring at 80 C for 4h,
the solution was cooled to rt, poured onto ether, washed with H20 (three
times) and brine, dried with
Na2SO4, and concentrated. The crude compound was chromatographed to give the
desired product.
LCMS (M+l) =218.1
Step 2: (1-isopropyl-lH-indol-6-yl)methanol
To a 0 C solution of methyl 1-isopropyl-lH-indole-6-carboxylate (0.50 g, 2.30
mmol) in THF (5 mL) was
added 1M lithium borohydride in THF ( 6.90 mL, 6.90 nunol). After stirring at
room temperature for
96h, quenched with MeOH and let stir for lh. The reaction mixture was
concentrated, partitioned
between saturated sodium bicarbonate and EtOAc, washed with H20 and brine,
dried with Na2SO4, and
-oncentrated. The crude compound was chromatographed to give the desired
product.
' CMS (M+1) =190.2
itep 3: 1-isopropyl-lH-indole-6-carbaldehyde
- 55 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
'1'o a solution of (1-isopropyl-lH-indol-6-yl)methanol (0.18 g, 0.97 mmol) in
CC14 (5 mL) was added
manganese dioxide (0.13 g, 1.45 mmol). After stirring at 60 C for lh, then 77
C for 2h, filtered reaction
mixture through celite and concentrated. Partitioned crude compound between
saturated sodium
bicarbonate and EtOAc, washed with H20 and brine, dried witli NaaSO4, and
concentrated. The crude
compound was chromatographed to give the desired product.
LCMS (M+1) =188.1
Intermediate XI: 1-(bromomethyl)-2-methylcyclopentene
O
'. DIBAL Br
O ~ 2. 48% HBr
Step 1: (2-methylcyclopent-l-en-1-yl)methanol
To a 0 C solution (0.24 g, 1.73 mmol) methyl 2-methylcyclopent-l-ene-l-
carboxylate (Can. J. Cheni.,
1979, 57, 1431) in THF (5 mL) was added 1M DIBAL in THF (5.18 mL, 5.18 mmol).
After stirring at
0 C for 2h, 1N HC1 was added to quench the solution. The resulting mixture was
extracted with ether
(three times), washed with H20 and brine, dried with Na2SO4, and concentrated.
The crude compound
was chromatographed to give the desired product.
Step 2: 1-(bromomethyl)-2-methylcyclopentene
To a 0 C solution of (2-methylcyclopent-l-en-1-yl)methanol (0.07 g, 0.62 mmol)
in pentane (1.5 mL) was added 48% HBr (0.14 mL, 1.24 mmol). After stirring at
0 C for 30 min, the
solution was washed with brine, saturated sodium bicarbonate, and brine again.
The organic layer was
concentrated to give the desired product, which was used without further
purification.
[ntermediate XII: 3: 1-(chloromethyl)-3-(1-cyclopropylethoxy)benzene
HO 1. TPP / 1-c-Pr-ethanol O CI
OMe 2. LiBH4 I
3. TPP / CCI4
itep 1: methyl 3-(1-cyclopropylethoxy)benzoate
-56-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Methyl 3-hydroxybenzoate (10.0 g, 65.7 mmol) in toluene (65.7 ml) was cooled
to 0 C and added 1-
cyclopropylethanol (6.43 ml, 65.7 mmol), triphenylphosphine (18.9 g, 72.3
mmol), and DIAD (14.1 ml,
72.3 mmol). The reaction warmed to rt for sixteen hours. The reaction mixture
was filtered through a
fritted funnel to remove preciptated triphenylphosphine oxide and washed with
toluene. The filtrate was
concentrated. The residue was purified by column chromatography on silica gel
Biotage 65i, eluting
with 10% ethyl aceate/hexanes to give a colorless oil.
Step 2: [3-(1-cyclopropylethoxy)phenyl]methanol
Methyl 3 -(1 -cyclopropylethoxy)benzoate (11.7 g, 53.1 mmol) in
tetrahydrofuran (212 mL) was added
lithium borohydride (80.0 ml, 159 rnmol). The reaction was heated at 50 C for
twelve hours. The
reaction was quenched with methanol. The solvents were concentrated. The
residue was dissolved in
ethyl acetate and washed with saturated NaHCO3. The aqueous layer was
extracted three times with
dichloromethane and the organics were combined, washed twice with water, dried
with MgSO4, filtered,
and concentrated. The enantiomers were resolved on the chiral OD column (10cm)
with a flow rate of
300 ml/mn wavelength 275nm running 97/3 hexanes/ethanol as the solvent system.
Step 3: 1-(chloromethy,l)-3-(1-cyclopropylethoxy)benzene
[3-(1-cyclopropylethoxy)phenyl]methanol (0.418 g, 2.17 mmol) in carbon
tetrachloride (8.70 ml) was
added triphenylphosphine resin (1.14 g, 4.35 mmol). The reaction was refluxed
overnight with minimal
stirring at 78 C. The next day the mixture was filtered through a fritted
funnel and washed with
dichloromethane. The filtrate was concentrated and no purification was
necessary.
1H NMR (CDC13): 87.23 - 7.21 (m, 1H), 6.94 - 6.92 (m, 2H), 6.85 - 6.83 (m,
1H), 4.54 (s, 2H), 3.86 -
3.82 (m, 1H), 1.36 (d, J= 6.1 Hz, 3H), 1.16 - 1.09 (m, 1H), 0.58 - 0.52 (m,
2H), 0.41 - 0.36 (m, 1H),
0.30 - 0.24 (m, 1H).
Intermediate XIII: 1-(chloromethyl)-3-(cyclopropyloxy)benzene
O 1. Kcarb / CIEtOTs
HO 2= KOtBu O
OMe CI
3. Et2Zn / CICH2I
4. LiBH4
5. TPP / CCI4
,tep 1: methyl 3-(2-chloroethoxy)benzoate
-57-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
'1'o a solution of inethyl3-hydroxybenzoate (10.0 g, 65.7 mmol) in DMF (100
mL) was added potassium
carbonate (18.17 g, 131.4 mmol) and 2-chloroethyl-p-toluenesulfonate (15.7 g,
67.0 mmol). After
stirring at 60 C overnight the reaction mixture was poured
into H20, extracted with ethyl acetate (three times), dried over MgSO4 and
concentrated under vacuum.
Purification by silica gel chromatography (10% EtOAc/hexanes) afforded the
desired product.
LRMS (M+1) = 215.0
Step 2: methyl 3-(vinyloxy)benzoate
To a 0 C solution of inethyl3-(2-chloroethoxy)benzoate (5.61 g, 26.1 mmol) in
THF (50 mL) was added
potassium tei=t-butoxide (3.67 g, 32.7 mmol). When the addition was complete
the reaction was allowed
to warm to rt. After stirring at rt overnight the reaction was quenched with
water. The solution was
extracted with diethyl ether (three times), dried over MgSO4, and concentrated
under vacuum.
Purification by silica gel chromatography afforded the desired product.
LRMS (M+1) = 179.1
Step 3: methyl 3-(cyclopropyloxy)benzoate
To a solution of inethyl3-(vinyloxy)benzoate (0.83 g, 3.99 mmol) in
dichloroethane (20 mL) was added
iodochloromethane (1.09 mL, 14.9 mmol). The solution was cooled to 0 C and
diethyl zinc (1.0 M in
hexanes, 7.48 mL, 7.48 mmol) was added. The cooling bath was removed and the
reaction was stirred at
rt for 30 min. The reaction mixture was quenched with 1N HCI, extracted with
methylene chloride (three
times), dried with MgSO4 and concentrate under vacuum to afford the desired
product.
LRMS (M+1) =193.1
Step 4: 3-(cyclopropyloxy)phenyl]methanol
To a solution of inethyl3-(cyclopropyloxy)benzoate (2.83 g, 14.7 mmol) in THF
(50 niL) was added
lithium borohydride (2.0 M in THF, 22.1 mL, 44.2 mmol). The reaction mixture
was heated to 50 C for
30 min after which methanol (0.60 mL, 14.73 mL) was added and stirred for 15
min. The reaction was
,ooled and quenched with excess methanol and concentrated under vacuum.
Purification by silica gel
.hromatography (30% EtOAc/hexanes) afforded the desired product.
3tep 5: 1-(chloromethyl)-3-(cyclopropyloxy)benzene
o a solution of 3-(cyclopropyloxy)phenyl]methanol (1.77 g, 10.8 mmol) in
carbon tetrachloride (30 mL)
vas added triphenylphosphine (2.54 g, 9.70 mmol). After heating to 100 C for
12 hr the solution was
- 58 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
concentrated under vacuum. Purification by silica gel chromatography (5%
EtOAc/hexanes) afforded
desired product.
'H NIVIR. (CDCl3): 8 7.26 (m, 1H), 7.07 (m, IH), 7.01-6.97 (m, 2H), 4.56 (s,
2H), 3.73 (m, 1H), 0.80-0.77
(m, 4H).
Intermediate XIV: 2,2-dimethyl-1,2,3,4-tetrahydroquin.oline-8-carboxylic acid
0 0
OMe 1. H2 / Pd(C) OH
NH
NH 2. NaOH
Step 1: methyl 2,2-dimethyl-1,2,3,4-tetrahydroquinoline-8-carboxylate
0 A solution of methyl 2,2-dimethyl-l,2-dihydroquinoline-8-carboxylate
(Example 47, step 3) (1.00 g, 4.63
mmol) in methanol (20 mL) containing a catalytic amount of 10% palladium on
carbon was placed under
an atmosphere of hydrogen at ambient pressure and temperature. After stirring
at room temperature for 2
h the reaction mixture was filtered through a pad of celite and concentrated
under vacuum. Purification
by silica gel chromatography (2.5% EtOAc/hexanes) afforded the desired
compound.
.5
Step 2: 2,2-dimethyl-1,2,3,4-tetrahydroquinoline-8-carboxylic acid
To a solution of inethy12,2-dimethyl-1,2,3,4-tetrahydroquinoline-8-carboxylate
(0.138 g, 0.629 mmol) in
THF (5mL) and HZO (5mL) was added a 1N aqueous solution of sodium hydroxide
(1.88 mL, 1.88
20 mmol). After stirring at 50 C overnight the reaction mixture was acidified
to pH 2 using 1N aqueous
HCI, extracted with ethyl acetate (three times), dried over MgSO4 and
concentrated under vacuum to
afford the desired compound that was used without further purification.
LRMS (M+1) = 206.0
25 Intermediate XV: (5R,7S)-(5S,7R)-8-benzyl-l-(3-fluorophenyl)-7-methyl-4-
thioxo-1,3,8-
triazaspiro [4.5 ] decan-2-one
-59-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
O
HN--A ~ F
N
S
N
Step 1: 8-benzyl-l-(3-fluorophenyl)-7-methyl-4-thioxo-1,3,8-
triazaspiro[4.5]decan-2-one
The thiohydantoin was prepared from 1-benzyl-2-methylpiperidin-4-one
(Intermediate I) using a
procedure similar to that described for (5R,7S)-(5S,7R)-1-(3-fluorophenyl)-8-
(3-isopropoxybenzyl)-7-
methyl-4-thioxo-1,3,8-triazaspiro[4.5]decan-2-one (Intermediate XXXIII)
Intermediate XVI: cis 2-(3-methoxyphenyl)cyclopentanamine
0 1. PPh3, DIAD, phthalimide O
OH 2. Hydrazine NH2
Step 1: cis 2-(3-methoxyphenyl)cyclopentyl]-1H-isoindole-1,3(2H)-dione
To a 0 C solution of trans-2-(3-methoxyphenyl)cyclopentanol (Platte Valley
Scientific, 0.35 g, 1.82
mmol), triphenylphosphine (0.62 g, 2.37 mmol), and phthalimide (0.27 g, 1.82
nunol) in CH2C12 (10 mL)
was added DIA.D (0.47 mL, 2.37 mmol). After stirring at room temperature
overnight, the solution was
poured onto saturated sodium bicarbonate, extracted with EtOAc (three times),
washed with H20 and
brine, dried with Na2SO4, and concentrated. The crude compound was
chromatographed to give the
desired product.
LCMS (M+1) = 321.9
Step 2: cis 2-(3-methoxyphenyl)cyclopentanamine
To a solution of cis 2-[2-(3-methoxyphenyl)cyclopenty.l]-1H-isoindole-1,3(2H)-
dione (0.23 g, 0.72
mmol) in toluene (3 mL) was added hydrazine ( 0.23 mL, 7.23 nunol). After
stirring at room temperature
for lh, then 95 C for 4h, a precipitate formed. The mixture was cooled to rt,
filtered, and washed with
toluene. The filtrate was concentrated to give the desired product, which was
used without further
purification.
-60-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
LUMS (M+1) =192.0
Intermediate XVII: 1-(chloromethyl)-3-{cis-2-methylcyclopropyl]oxy}benzene
O 1. allyl-I / NaH
HO 2. Ru(II) ~~O CI
OMe ~j ~
3. Et2Zn / CICH2I 1 v
4. LiBH4
5. TPP / CCI4
Step 1: methyl 3-(allyloxy)benzoate
To a solution of methyl 3-hydroxybenzoate (5.0 g, 32.9 nnnol) in DMF (20 mL)
was added allyl iodide
(6.62 g, 39.4 mmol) followed by sodium hydride (60% oil dispersion, 0.95 g,
39.4 nunol). After stirring
at rt for 5 h, the reaction mixture was quenched with H20, extracted with
ethyl acetate (three times),
dried over MgSO4 and concentrated under vacuum. Purification by silica gel
chromatography (10%
EtOAc/hexanes) afforded the desired product.
LRMS (M+1) = 193.1
Step 2: methyl 3-[(1E)-prop-l-en-1-yloxy]benzoate and methyl 3-[(1Z)-prop-l-en-
1-yloxy]benzoate
To a solution of inethyl3-(allyloxy)benzoate (2.20 g, 11.4 mmol) in THF (20
mL) was added
chlorohydridotris(triphenylphosphine) ruthenium (11) toluene adduct (0.23 g,
0.23 mmol). After stirring
at 80 C for 24 h the reaction mixture was concentrated under vacuum.
Purification by silica gel
chromatography (10% EtOAc/hexanes) afforded a mixture of E and Z olefin
isomers that were separated
on a ChiralPak AD column.
LRMS (M+1) = 193.1
Step 3: methyl3-{cis-2-methylcyclopropyl]oxy}benzoate
To a solution of inethyl3-[(LE)-prop-l-en-l-yloxy]benzoate (1.0 g, 5.2 nunol)
in dichloroethane (10 mL)
was added iodochloromethane (2.93 mL, 16.6 mmol). The solution was cooled to 0
C and diethyl zinc
;1.0 M in heptanes, 5.20 mL, 5.20 mmol) was added. The cooling bath was
removed and the reaction
vas stirred at rt for 30 min. The reaction mixture was quenched with 1N HCI,
extracted with methylene
:hloride (three times), dried with MgSO4 and concentrate under vacuum to
afford the desired product.
.RMS (M+1) =207.3
ltep 4: (3-{cis-2-methylcyclopropyl]oxy}phenyl)methanol
-61-
CA 02615656 2008-01-16
WO 2007/011833
PCT/US2006/027594
To a solution of methyl 3-{cis-2-methylcyclopropyl]oxy}benzoate (0.925 g, 4.49
mmol) in THF (10 mL)
was added lithium borohydride (2.0 M in THF, 6.72 mL, 13.5 mmol). After
stirring at 50 C overnight
the reaction was cooled and quenched with excess methanol and concentrated
under vacuum.
Purification by silica gel chromatography (30% EtOAc/hexanes) afforded the
desired product.
Step 5: 1-(chloromethyl)-3- {cis-2-methylcyclopropyl] oxy} benzene
To a solution of (3-{cis-2-methylcyclopropyl]oxy)phenyl)methanol (0.275 g,
1.54 mmol) in carbon
tetrachloride (40 mL) was added polystyrene bound triphenyl phosphine (2.15
mmol/g, 1.44 g, 3.08
mmol). After stirring at 100 C overnight the resin was filtered of and the
solvent was removed under
vacuum to afford the desired product.
1H NMR (CDC13) S 7.27 (m, 1H), 7.04 (d, J= 1.6 Hz, 1H), 6.71 (m, 2H), 4.57 (s,
2H), 3.40 (m, 1H),
1.15 (d, J= 5.5 Hz, 3H), 1.12 (m, 1H), 0.94 (m, 1H), 0.58 (m, 1H).
Intermediate XVIII: spiro[2.5]octan-6-amine
1. Ph3P=CH2
p 2. Et2Zn / CICH21
3. H C I
4. NH2OH / NaOAc NH2
5. LiAIH4
Step 1: 8-methylene-1,4-dioxaspiro[4.5]decane
To a slurry of 8.46 g (23.7 mmol) triphenylphosphonium bromide in 60 mL of
ether was added 9.4 mL
20 (23.7 mmol) of n-BuLi at rt. The ylide was allowed to form over 4h before a
solution containing 3.7 g
(23.7 mmol) of 1,4 cyclohexanedione ethylene ketal in 5: etherlTHF was added.
The resulting mixture
was refluxed gently overnight, cooled, and filtered. The filtrate was washed
with water (two times),
brine, and dried over MgSO4. Evaporation of the solvent and column
chromatography (9:1 Hexanes /
EtOAc) afforded the desired olefin.
25 1H NMR 8 4.64 (s, 2H), 3.95 (s, 4H), 2.31 (t, J=7 Hz, 2H), 1.71 (t, J=7 Hz,
2H).
Step 2: 7,10-dioxaspiro[2.2.4.2]dodecane
Chloroiodomethane (4.8 mL, 61.6 mmol) was added to a OC mixture containing
2.97 g (19.3 mmol) of
30 the olefin from step 1 in 50 rnL of DCE followed by the addition of 30.8 mL
(30.8 mmol) of Et2Zn (1M
in hexanes). The reaction was stirred at 0 C for lh before it was quenched
with 1N HC1. The mixture
was extracted with DCM (three times) and the combined extracts were dried over
MgSO4 and
-62-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
concentrated. Column chromatography (9:1 Hexanes / EtOAc) afforded the desired
compound as a
colorless liquid.
Step 3: spiro[2.5]octan-6-one
A solution containing 3.0 g (17.8 mmol) of the ketal from step 2 in 100 mL of
THF was treated
with 100 mL (100 mmoL) of 1N HCI. The reaction was allowed to stir for 16h
then extracted
with ether (3 times). The combined extracts were washed with brine and dried
over MgSO4.
Evaporation of the solvent afforded the desired ketone as an oil.
'H NMR (CDCl3) S 2.4 (t, J=7Hz, 2H), 1.65 (t, J=7Hz, 2H), 0.45 (s, 4H).
Step 4: spiro[2.5]octan-6-one oxime
To a solution containing 2.1 g (16.9 mmol) of the ketone from step 3 in 10 mL
of ethanol was added 2.0
g (28.7 mmol) of hydroxylamine hydrochloride followed by 4.0 g (29 nunol) of
NaOAc in 20 mL of
water. The resulting mixture was refluxed for 3h, cooled and concentrated to
one-half volume and the
precipitate was collected.
'H NMR (CDC13) S 8.38 (bs, 1H), 2.61 (t, J=7Hz, 2H), 2.3 (t, J=7Hz, 2H), 1.65
(m, 4H), 0.41 (s, 4H).
Step 5: spiro[2.5]octan-6-amine
A solution containing 1.0 g(7.2 nunol) of the oxime from step 4 in 30 mL of
THF was treated with 21
mL (21 mmol) of LAH (1M in ether). The reaction mixture was refluxed for 3h,
cooled and quenched
with 4 mL of water and 8 mL of 1N NaOH. The solids were filtered and the
filtrate was extracted with
ether (three times). The combined extracts were dried and evaporated to give
the desired amine.
'H NMR (CDC13) 5 2.61 (m, 1H), 2.0-1.6 (m, 4H), 1.25 (m, 2H), 0.9 (d, 2H),
0.41-0.18 (s, 4H).
[ntermediate XIX: trans 6-phenylspiro[2.4]heptan-5-amine
O
o0f~ OMe 1. Et2Zn / CICH2I 1111NH2 2 NaOH
3. DPPA / BnOH
4. H2 / Pd(C) '
tep 1: methyl trans-6-phenylspiro[2.4]heptane-5-carboxylate
-63-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Chloroiodomethane (6.3 g, 35.5 mmol) was added to a 0 C mixture containing 2.4
g(11.1 mmol) of
methyl trans-4-methylene-2-phenylcyclopentanecarboxylate (J. Arn. Claefn. Soc.
1983, 105, 2315) in 25
mL of DCE followed by the addition of 17.8 mL (17.8 mmol) of Et2Zn (1M in
hexanes). The reaction
was stirred at 0 C for lh before it was quenched with 1N HCI. The mixture was
extracted with DCM
(three times) and the combined extracts were dried over MgSO4 and
concentrated. Column
chromatography (9:1 Hexanes / EtOAc) afforded the desired compound as a
colorless liquid.
LRMS (M+H) = 231.0
Step 2: trans-6-phenylspiro[2.4]heptane-5-carboxylic acid
To a solution containing 1.0 g (4.3 mmol) of the ester from step 2 dissolved
in 25 mL of a 1/1
methanol / THF mixture was added 13 mL (13 mmol) of NaOH. The reaction was
stirred for 3h
before it was concentrated and treated with 20 mL of 1N HCI. The precipitate
was dissolved in
50 mL of DCM and separated from the aqueous phase. The organic extract was
dried over
MgSO4 and concentrated to give the desired carboxylic acid.
LRMS =171.02.
Step 3: benzyl [trans-6-phenylspiro[2.4]hept-5-yl]carbamate
To a solution containing 750 mg (3.47 mmol) of the acid from step 3 in 25 mL
of benzene was added
0.53 mL (3.8 mmol) of TEA, 413 mg (3.8 mmol) of benzyl alcohol and 0.75 mL
(3.5 mmol) of DPPA
and the solution was refluxed under nitrogen for 17h. The reaction mixture was
cooled and diluted with
100 mL of EtOAc and washed with saturated NaHCO3 (three times), water (two
times) and brine. The
organic extracts were dried over MgSO4i concentrated and chromatographed (3:2
Hexanes / EtOAc) to
afford the desired carbamate.
LRMS (M+H) = 322.01.
3tep 4: trans 6-phenylspiro[2.4]heptan-5-amine
k solution containing 1.0 g (3.1 mmol) of the carbamate from step 4 and 131 mg
of 10% Pd(OH)2 in 20
nL of methanol was stirred under a balloon of hydrogen for 2h. The reaction
mixture was filtered
hrough Celite and evaporated to leave the desired anline as an oil.
,CMS (M-NH3) = 171.0
E1 NMR (CDC13) b 7.41-7.13 (m, 5H), 3.41 (q, J=7Hz, 1H), 2.82 (q, J=7Hz, 1H),
2.21 (bs, 2H), 1.93 (m,
H), 1.65 (m, 1H), 0.55 (m, 4H).
~.itermediate XX: 1, 1 -dimethylsilolan-3-amine
-64-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
1. vinylMgBr / CpZTiC12 ~
CI2SiMe2 NH
2. Sharpless aziridination 2
3. LiAIH4
4. sodium naphthalenide
Step 1: 1,1-dimethyl-2,5-dihydro-lH-silole
To a-40 solution of dichlorodiniethylsilane (6.0 g, 46.5 mmol) in THF (100mL)
was added
bis(cyclopentadienyl)titanium dichloride (0.58 g, 2.3 mmol) followed by vinyl
magnesium bromide
(1.OM in THF, 98 ml, 98 mmol). After stirring for 4 h at -40 C the reaction
was quenched with water,
extracted using diethyl ether (three times) and dried using MgSO4. The
solution was filtered through a
pad of silica gel and concentrated under vacuum
Step 2: 3,3-dimethyl-6-[(4-methylphenyl)sulfonyl]-6-aza-3-
silabicyclo[3.1.0]hexane
To a solution of l,1-dimethyl-2,5-dihydro-lH-silole (3.0 g, 26.7 mmol) in
acetonitrile (50 mL) was added
phenyltrimethylammonium tribromide (1.0 g, 2.67 mmol) and chloramine-T (6.69g,
29.4 mmol). After
stirring at rt overnight the reaction mixture was filtered though a pad of
Celite and concentrated under
vacuum. Purification by silica gel chromatography (20% EtOAc/hexanes) afforded
the desired product.
LRMS (M+1) = 281.9
Step 3: N-(1,1-dimethylsilolan-3-yl)-4-methylbenzenesulfonamide
To a 0 C solution of 3,3-dimethyl-6-[(4-methylphenyl)sulfonyl]-6-aza-3-
silabicyclo[3.1.0]hexane (0.5 g,
1.8 mmol) in THF (10 ml) was added lithium aluminum hydride (1.OM THF, 5.33
mL, 5.33 mol). After
stirring at rt overnight, the reaction was quenched by the sequential addition
of H20 (0.2 niL), 1N NaOH
(0.2mL), and H20 (0.6 mL). The mixture was filtered through a pad of celite
and concentrated under
vacuum. Purification by silica gel chromatography (20% EtOAc/hexanes) afforded
the desired product.
Step 4: 1,1-dimethylsilolan-3-amine
To a solution of naphthalene (0.764 g, 5.96 mmol) in DME (6 mL) was added
sodium metal (0.137 g,
5.96 mmol). After stirring the reaction mixture for 30 min a solution ofN-(1,1-
dimethylsilolan-3-yl)-4-
methylbenzenesulfonamide (0.338 g, 1.19 mmol) in DME (5 mL) was added. The
reaction mixture was
stirred at rt for 2 h the quenched using ethereal HCl to pH = 2 and
concentrated under vacuum. The
residue was dissolved in diethyl ether and water extracted with diethyl ether
(three times). The aqueous
layer was treated w/ NaOH until pH = 10 and extracted with diethyl ether
(three times), dried over
MgSOA and concentrated under vacuum.
- 65 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
'H NMR (CDC13) S 3.13 (m, 1H), 1.88 (m, 1H), 1.49 (br, s,2 H), 1.30 (m, 1H),
1.00 (m, 1H), 0.77 (m,
1H), 0.50 (m, 1H), 0.34 (dd. J= 9.5, 14 Hz, IH), 0.15 (s, 3H), 0.11 (s, 3H).
Intermediate XXI:
0 CI CI F F F F
DAST 4M HCI/Dioxane
HN, Boc HN, Boc NH3+CI
XXIA XXIB XXI
To a stirred solution of XXIA (0.85 g, 0.004 mol) in 8.0 mL dichloroethane,
was added
diethylaminosulfur trifluoride (0.79 mL, 0.006 mol). The mixture was stirred
at 60 C overnight, then
quenched with saturated NaHCO3, extracted with EtOAc (3x). The combine
extracts were washed with
brine, dried over anhydrous MgSO4, filtered, concentrated and purified by
silica gel column
chromatography (ETOAc-Hex 0.5:9.5) to yield XXIB as a white solid. Compound
XXIB was treated
with 4M HCl/dioxane at room temperature for 1 h. The solvent was removed under
reduced pressure to
afford XXI as an amine-HCl salt.
El-MS na/z: 136.20 (M + H)+.
Intermediate XXII: (3S)-1-(methylsulfonyl)pyrrolidin-3-aminium chloride
O 1. MsCI, DIEA, CH2CI2, 0 C O~S
HN
2. 4N HCI, dioxane, rt N
N )~Ok
H NH3CI
The BOC-protected aminopyrrolidine (enantiomerically pure, TCI, 1.0097 g, 5.42
mmol, 1.0 eq) was
dissolved in CH2CI2 (11 mL). DIEA (1.10 mL, 6.33 mmol, 1.17 eq) was added, and
the reaction was
3tirred and cooled to 0 C. Methanesulfonyl chloride (0.50 mL, 6.46 mmol, 1.2
eq.) was added, and the
-eaction was stirred and allowed to warm to rt over 2 h. The reaction was
diluted with CH2C12, and
vashed with 1N hydrochloric acid, then with saturated sodium bicarbonate
solution. The organic
;olution was dried over magnesium sulfate, filtered, and concentrated. The
crude product was dissolved
n dioxane (10 mL), and 4N hydrochloric acid in dioxane (3 mL) was added. After
lh, LCMS revealed
hat there was still a reasonable amount of starting material remaining,
additional 3 mL of hydrochloric
cid in dioxane was added, and the reaction was allowed to sit at rt for 18h.
The reaction mixture was
oncentrated to afford the desired aniine hydrochloride.
iI-MS na/z: 165 (M + H)+.
-66-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Intermediate XXIII: Tr=ans- 2-fluorocyclohexanaminium bromide
Ts
DIEA, TsCI, CH2CI2 THF, TBAF NH HBr/AcOH, PhOH NH2 HBr
ONH 64% aN-Ts 69% C~,88% 0~"" 'F F
XXIIIA XXIIIB XXIIIC XXIII
The cyclohexene imine XXXiIIA was prepared according to the procedure of
Watson and Yudin (J.
Org. Claenz. 2003, 68, 5160-5167, supp. material pg. S3). A solution of
XXXIIIA (5.2 g, 0.053 mol) and
DIEA (9.2 mL, 0.053 mol) in CH2CI2 (266.0 niL) was stirred at 0 C, and p-
methyl-benzenesulfonyl
chloride (10.0 g, 0.053 mol) was added slowly. The resulting mixture was
stirred at rt for 2 h, quenched
with water, and extracted with CHzCl2 three times. The combine extracts were
washed with water,
saturated NaHCO3, brine, and dried over anhydrous MgSO4, filtered,
concentrated and purified by silica
gel column chromatography (EtOAc-Hexanes 1:9) to afford XXIIIB as a white
solid.
El-MS rn/z: 252.15 (M + H)+.
To a stirred solution of X.XIIIB (8.6 g, 0.034 mol) in 68.0 mL THF, was added
37.5 mL of 1M Bu4NF in
THF. The resulting mixture was stirred at 45 C until completion (monitored by
TLC). The solvent was
evaporated, and the crude was purified by silica gel column chromatography
(EtOAc- Hexanes 2:8) to
afford .XXIIIC as white solid.
EI-MS nz/z: 272.10 (M + H)+.
A thick-walled pressure bottle was charged with XXIIIC (6.4 g, 0.024 mol),
phenol (2.2 g, 0.024 mol),
and 118.0 niL of 33% w/w HBr in acetic acid. The bottle was firmly stoppered,
and the mixture was
heated at 70 C for 8 h. The bottle was chilled on ice. The mixture was poured
into 500.0 mL of cold dry
ether, and chilled using ice bath for several hours. The precipitated solid
were collected and washed
thoroughly with additional ether to afford XXIII as amine-HBr salt. EI-MS
ni/z: 118.20 (M + H)+. 'H
NMR (CD3OD): 8 ppm 1.3-1.6 (m, 4H), 1.7-1.9 (br m, 2H), 2.08 (m, 1H), 2.19 (m,
1H), 3.23 (m, 1H),
4.4-4.6 (2 x td, J=10.27, 4.89 Hz, 1 H),
[ntermediate XXIV: 3,3 -difluorocyclohexanaminium chloride
O O CI'-'_"CI F F F F
PdC12(MeCN)z, CHZCIZ
1 I DAST 4.4% HCOOH/MeOH, Pd/C, HCI
O
6'N 36% NCbz 79% 6,NH2 HCI
(XIVA Ph~1 O~NH2 XXIVB H 36/ ~IVC H XXIVD
74%
-67-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
To a solution of XXIVA (1.4 mL, 0.015 mol) in 15.0 mL CH2Cla, was added
PdC12(MeCN)2 (0.259 g,
0.001 mol) and carbamic acid benzyl ester (1.5 g, 0.010 mol). The resulting
mixture was stirred at rt24 h,
filtered through a short bed of silica gel, washed with EtOAc three times,
concentrated and purified by
silica gel column chromatography (EtOAc- Hexanes 3:7) to yield YXIVB as a
white solid.
'H NMR (CD3OD): & 1.67 (m, 2 H), 1.97 (m, 1 H), 2.10 (m, 1 H), 2.24 (m, 2 H),
2.37 (m, 1 H), 2.70 (dd,
1=14.18, 4.40 Hz, 1 H), 3.99 (br. s., 1 H), 4.77 (br. s., 1 H), 5.08 (s, 2 H),
7.34 (m, 5 H).
EI-MS ria/z: 248.10 (M + H)+.
To a stirred solution of XXIVB (0.988 g, 0.004 mol) in dichloroethane, was
added diethylaminosulfur
trifluoride (0.79 mL, 0.006 mol). The mixture was stirred at 60 C overnight,
then quenched with
saturated NaHCO3i and extracted with EtOAc three times. The combine extracts
were washed with
brine, dried over anhydrous MgSOd, filtered, and concentrated. Crude XXIVC was
purified by silica gel
column chromatography (EtOAc- Hexanes 2:8) to yield a white solid.
EI-MS na/z: 270.10 (M + H)+.
A round-bottomed flask was charged with XXIVC (0.300 g, 0.001 mol) and 23.0 mL
of 4.4% formic
acid/MeOH, purged with nitrogen gas, then added - 0.300 g of 10% Pd/C. The
resulting mixture was
stirred under nitrogen at rt until completion (monitored by LCMS). The mixture
was filtered over celite
followed by a MeOH rinse. The solvent was removed under reduced pressure to
yield XXIV as an amine-
HCOOH salt. The crude product was treated with 4N HCI/dioxane and the
volatiles removed under
reduced pressure. This treatment was repeated three times. The white
precipitate was obtained to afford
XXIV as an amine-HCl salt.
El-MS m/z: 136.20 (M + H)+.
Intermediate XXV: 1-fluoropropan-2-aminium chloride
F'y MeOH, BnNH2, AcOH, NaBH3CN F-"Y 4.4% HCOOH/MeOH, Pd/C, HCI F'y
0 30% HN -, Ph 50% NH2 HCI
XXVA XXVB XXV
To a stirred solution of XXVA (1.4 mL, 0.020 mol), benzyl amine (2.2 mL, 0.020
mol), acetic acid (1.7
mL, 0.030 mol) in 100.0 niL MeOH, was added sodium cyanoborohydride (1.9 g,
0.030 mol) in small
portions. The mixture was stirred at 60 C overnight. After solvent removal,
water was added. The
product was extracted with EtOAc (three times). The conibine extracts were
washed with water (twice),
brine, and dried over anhydrous MgS04, filtered, and concentrated to afford
crude XXVB which was
purified by silica gel column chromatography (EtOAc- Hexanes 3:7 - 4:6) to
yield a yellow oil.
EI-MS m/z: 168.15 (M + H)+.
- 68 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
x.as.v was synthesized in a similar manner described for XXTV above.
Compound XXVB (0.9 g, 0.005 mol) afforded XXV as an amine-HCI salt.
'H NMR (CD3OD): 8 ppm 1.32 (dd, J=6.85, 0.98 Hz, 3 H), 3.63 (br, 1 H), 4.40
(dd, J=10.27, 6.36 Hz,
0.5 H), 4.52 (dd, J=10.52, 6.60 Hz, 0.5 H), 4.58 (dd, J=10.52, 3.18 Hz, 0.5
H), 4.70 (dd, J=10.52, 3.18
Hz, 0.5 H).
Intermediate XXVI: 2-isopropylcyclopropanaminium chloride
0 o 'N=N+=CH2 O O O OH Boc
CH2CI2/Et2O, Pd(OAc)2 MeOH, LiOH t-BuOH, (PhO)2PON3, TEA HN~ 4N HCI/ Dioxane
NH~ HCI
96% 81% 14%
XXVIA XXVIB xNIC 7 XXVID XXVI
To an ice cold solution of XXVIA (1.28 g, 0.010 mol) and Palladium(II) acetate
(0.017 g, 0.074 mmol) in
50.0 mL of 2:5 w/w CH2C12/Et20, was added slowly -50.0 mL of ethereal solution
of diazomethane
(Caution: Diazoinethane is explosive and toxic. For handling procedures, see
Moore and Reed, Org.
Synth. Coll. TPol. 5, Pg. 351, see also procedure or preparation of
Interinediate UVIII) which was
prepared from N-methyl-N'-nitroso-N-nitrosoguanidine (5.9 g, 0.040 mol) right
before being used. The
reaction mixture was stirred at 0 C for 1 h, allowed to warm to rt for 3 h,
and quenched with few drops
AcOH, extracted with Et20 (twice). The combine extracts were washed twice with
saturated NaHCO3,
once with brine, and dried over anhydrous MgSO4, filtered, and concentrated to
afford crude XXVIB as
colorless oil. 'H NMR (CD3OD): b ppm 0.72 (m, 1 H), 0.96 (m, 6 H), 1.05 (d,
J=6.85 Hz, 1 H), 1.12 (m,
1 H), 1.21 (m, 1 H), 1.38 (m, 1 H), 3.65 (s, 3 H).
To a solution of crude XXVIB (1.37 g, 0.0096 mol) in 48.0 mL MeOH, was added
10.0 mL of 1M LiOH.
The reaction mixture was stirred at 60 C overnight. MeOH was removed under
reduced pressure. The
reaction mixture was quenched with 2N HCI, extracted with EtOAc (three times),
washed with brine, and
dried over anhydrous MgSO4, filtered, and concentrated to afford crude XXVIC
as colorless oil.
EI-MS in/z: 129.15 (M + H)+.
I'o a solution of crude XYVIC (1.0 g, 0.0078 mol) and triethylamine (1.2 mL,
0.0086 mol) in 15.6 mL t-
)utyl alcohol, was added diphenyl phosphoryl azide (1.26 mL, 0.0086 mol). The
reaction mixture was
tirred at 90 C overnight. t-Butyl alcohol was removed under reduced pressure.
The reaction mixture was
[uenched with 50.0 mL of 10% Na2CO3, extracted three tinies with EtaO, washed
with 10% Na2CO3,
,rine, and dried over anhydrous MgSO4i filtered, concentrated and purified by
silica gel column
hromatography (EtOAc- Hexanes 1:9) to yield XXVID as colorless oil. Compound
XXVID was treated
rith 4N HCI/dioxane at room temperature for 1 h. The solvent was removed under
reduced pressure to
fford XXVI as an amine-HCI salt.
-69-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
'H NMR (CD3OD): & ppm 0.72 (m, 1 H), 0.87 (m, 1 H), 0.9-1.1 (br m, 8 H), 2.40
(ddd, J=7.58, 3.67, 3.42
Hz, 1 H).
Intermediate XXVII: trans-2-fluorocyclopentanaminium chloride
~NH2 TsCI TEA TBAF THF K..NHTs PhOH 60 C ~N-Ts v~ K...NH2HBr
+
'OH CHZC12 50 C 'F HBr/HOAc ,F
XXVIIA XXVIIB XXVIIC XXVII
TsC1(10.1g, 2.Oeq) was added to a stirred solution of crude racemic compound
XXVIIA. (2.69g,
0.0266mo1), triethylamine (14.8 mL, 4.Oeq) in CH2C12 (60 mL). The reaction
mixture was stirred
overnight. The reaction mixture was extracted with saturated aqueous NaHCO3 /
CH2C12 twice, aqueous
NaH2PO4 (pH=4) solution / CH2CI2 twice, washed with brine twice, dried with
Na2SO4 and concentrated
to afford crude compound XXVIIB Purification by Combiflash chromatography
(120g silica gel, 10%
EtOAc/Hexane) gave compound XXVIIB.
El-MS na/z: 238(M + H)+.
1.OM TBAF in THF (7.0 mL, 1.3eq) was added dropwise to a stirred solution of
compound XXVIIB
(1.27g, 0.00536mo1) in THF (8 mL). The reaction mixture was stirred at 45 C
overnight. Concentration
and purification by Combiflash chromatography (120g silica gel, 10%
EtOAc/Hexane) afforded
compound XXVIIC.
El-MS m/z: 258(M + H)+.
Compound XXVIIC (0.712g, 0.00277mol) and Phenol (0.521g, 2.Oeq) were dissolved
in 33% HBr in
HOAc (10 mL) under N2 protection. The reaction mixture was stirred at 60 C
overnight, concentrated
and dissolved in EtOAc (10-15 mL). Hexane (10-20 mL) was added until most of
product precipitated.
The solvent was decanted, and the precipitate was washed with EtZO once.
Drying in vacuo at 60 C for 2
hours afforded compound .XXVII.
EI-MS rn/z: 104 (M + H)}.
Intermediate XXVIII: 2-propylcyclopropanaminium
-70-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
NH 0
H
OZN, )~ N
N 0 H N KOH, Pd(OAc)2, 0
Et0 / 1' Me CH2Cl2, Et20 HO
2. NaOH(aq.), MeOH, D
O
O Ph0-P' Et3N, t-BUOH,
HO 1. PhO~ N3 D CIH3N
2. HCI(dioxane)
Caution: Diazomethane is explosive and toxic. For handling procedures, see
Moore and
Reed, Org. Synth. Coll. Vol. 5, Pg.351). A solution of diazomethane was
prepared as follows. A
biphasic mixture of 60 mL diethyl ether and potassium hydroxide (7.0 g, 175
rnmol) dissolved to a
volume of 21 mL with water, were placed into a smooth 125 mL Erlenmeyer flask.
The mixture was
cooled to 0 C and a blast shield placed in front of the reaction. The N-methyl-
N'-nitro-N-
nitrosoguanidine (8.94 g, 60.8 mmol) was added in portions over 5 minutes,
with some visible gas
evolution occurring with each addition. The mixture was left to sit at 0 C for
10 min.
The ethyl trans-2-hexenoic acid (2.1441 g, 15.1 mmol) was dissolved into
dichloromethane (15
mL) containing palladium diacetate (22.3 mg, 0.10 mmol, 0.007 eq.). This
mixture was stirred and
cooled to 0 C.
The ethereal diazomethane solution was then decanted from the Erlenmeyer flask
and added to
the olefin solution, in portions, using a smooth plastic pipette. The stirred
reaction was then allowed to
warm to rt over 1.5h. The reaction was then cooled to 0 C, and the excess
diazomethane was quenched
by addition of acetic acid until gas evolution stopped. The reaction mixture
was then diluted with diethyl
ether, washed with saturated sodium bicarbonate solution, dried over magnesium
sulfate, filtered and
then concentrated to an oil. 1H NMR revealed the crude product to consist of a
3:1 mixture of
cyclopropane:olefin. This mixture was carried on directly to the next
reaction.
A portion of the crude cyclopropane ester (573.3mg, 3.67 mmol) was dissolved
into methanol (6
0 mL), and 4 mL of 1N NaOH(aq) solution (aq.) was added. The mixture was
stirred hard and heated in an
aluminum block at 70 C for lh, then cooled to rt. The reaction mixture was
then diluted with ether,
acidified with 1H hydrochloric acid, and extracted twice with ether to provide
the crude acid.
The acid (390.4 mg, 3.04 mmol, 1.0 eq.) was placed in a scintillation vial.
tert-Butyl alcohol (5
mL) was added, followed by triethylamine (0.49 mL, 3.52 mmol, 1.16 eq.) and
diphenylphosphoryl azide
!5 (942.2 mg, 3.42 mmol, 1.13eq.). The reaction was stirred and heated to 90
C in an aluminum block for
18 h, then cooled to rt. The reaction mixture was diluted with diethyl ether,
washed with IN
hydrochloric acid, then with 10% potassium carbonate solution. The organic
solution was dried over
magnesium sulfate, filtered and concentrated to oil. The oil was purified by
flash chromatography over
-71-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
silica gel (10% ethyl acetate in hexanes, using TLC and ninhydrin stain for
product detection) to provide
the N-Boc-amine.
The crude N-Boc-amine was dissolved into dioxane (1 mL), and treated with 4N
hydrochloric
acid (anhydr.) in dioxane (2 mL) for 4 h. The reaction mixture was then
concentrated to a solid and
placed under high vacuum for 3 days, providing the desired cyclopropylamine as
the hydrochloride salt
as a white solid.
'H NMR (CD3OD, 400 MHz) S: 2.35 (ddd, J=7.4, 4.0, 3.4Hz, 1H), 1.46 (ddd,
J=7.3, 7.3, 7.3Hz, 2H),
1.38-1.20 (m, 2H), 1.18-1.07 (m, 1H), 0.96 (t, J=7.4Hz, 3H), 0.92-0.84 (m,
1H), 0.67 (ddd, J=6.8, 6.8,
6.4Hz, 1H).
Intermediate XXIX: 2,2-difluorocyclohexanaminium chloride
0 0
NHBoc CI~CI NHBoc Et2NSF3 NHBoc HCI NH2HCI
OH DMSO/TEA O
CI~/CI F F
XXIXA CH2CI2 XXIXB 60 C XXIXC F XXIX F
DMSO (2.51 mL, 6eq) in CH2C12 (2 mL) was added dropwise at -78 C to a stirred
solution of oxalyl
chloride (1.52 mL, 3 eq) in CH2C12 (11 mL) under N2 atmosphere. After stirring
for 10 min, compound
XXIXA (1.27g, 0.00590mol) in CH2C12 (3 mL) was added dropwise. The reaction
mixture was stirred at
-78 C for 6 h. TEA (4.93 mL, 6eq) was added dropwise at -78 C. The reaction
mixture was extracted
with saturated aqueous NaHCO3 /EtOAc twice, aqueous NaH2PO4 (PH=4) solution /
EtOAc twice,
washed with brine twice, dried with MgSO4 and concentrated to afford crude
compound XXIXB.
Purification by Combiflash chromatography (120g silica gel, 10% EtOAc/Hexanes)
gave compound
XXIXB.
El-MS m/z: 214 (M + H)+.
DAST reagent (Et2NSF3) was added dropwise to a stirred solution of compound
XXIXB (0.972 g,
0.00456 mol) in 1,2-dichloroethane (9 mL) under N2 atmosphere. The reaction
mixture was stirred at
60 C overnight. Extraction with saturated aqueous NaHCO3 /EtOAc twice,
washing with brine twice,
dried with MgSO4 and concentration afforded crude compound XXIXC (1.20g). El-
MS rn/z: 136
(M -C5H802 +H)+. Crude compound XXIXC was dissolved in 4N HCUdioxane (5 mL),
stirred for 1
hour, concentrated and purified by reverse phase C-18 column to afford
compound XXIX.
El-MS m/z: 136 (M + H)+.
Intermediate XXX: 2,2-difluorocyclopentanaminium chloride
-72-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
O O
NHBoc CICI NHBoc Et2NSF3 NHBoc HCI NH2 HCI
~ ---- _
OH DMSO/TEA O Ci/\,Cl F F
XXXA CH2CI2 F F
XXXB 60 C xxxc xxx
DMSO (1.92 mL, 6eq) in CH2CI2 (2 mL) was added dropwise at -78 C to a stirred
solution of oxalyl
chloride (1.16 mL, 3 eq) in CHX1Z (11 mL) under N2 protection. After stirring
for 10 min, compound
XXXA (0.905 g, 0.00450 mol) in CH2ClZ (3 mL) was added dropwise. The reaction
mixture was stirred
at -78 C for 6 hours. TEA (3.76 mL, 6 eq) was added dropwise at -78 C. The
reaction mixture was
extracted with saturated aqueous NaHCO3 /EtOAc twice, aqueous NaH2PO4 (pH=4)
solution / EtOAc
twice, washed with brine twice, dried with MgSO~ and concentrated to afford
crude compound XXXB
(1.25 g). Purification by Combiflash chromatography (80 g silica gel, 8%
EtOAc/Hexanes) afforded
compound XXXXB.
EI-MS na/z: 100 (M -C5H802 + H)+.
DAST reagent (Et2NSF3) was added dropwise to a stirred solution of compound
X.XXB (0.303 g,
0.00152 mol) in 1,2-dichloroethane (3 mL) under N2 atmosphere. The reaction
mixture was stirred at 60
C overnight. The reaction was extracted with saturated aqueous NaHCO3 /EtOAc
twice, washed with
brine twice, dried with MgSO4, concentrated and purified by Combiflash
chromatography (40 g silica
gel, 5% EtOAc/Hexanes) to afford compound XXXC.
EI-MS rn/z: 122 (M + H)+.
Compound XXXC (0.098 g, 0.443 mmol) was dissolved in 4N HCI/dioxane (3 mL),
stirred for several
hours, and then concentrated to afford crude compound XXX.
El-MS na/z: 122 (M + H)+.
Intermediate XXXI: cis-2-fluorocyclohexanaminium chloride
~
~ o~ o Ph~
OTMS N OTf 0 Ph
F HN NH~HCI
XXXIB F NH2CHPh2 Pd/C H2
CH2CI2 DCE NaBH(OAc)3 MeOH HCI
XXXIA xxxic XXXID
xxxi
-73-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Compound XXXIA (1.70 g, 0.00998 mol), compound XXXIB (2.10 g, 0.00850 mol)
were dissolved in
CH2Cla (10 mL), stirred overnight. The reaction mixture was purified directly
by chromatography (20%
EtOAc/Hexanes) to afford compound XXXIC.
'H NMR (CDC13). 6 4.78-4.98 (ddd, JEF = 48 Hz, JHH = 8 Hz, J'HH = 4 Hz, 1H), S
2.50-2.60 (m, 1H), 8
2.36-2.46 (m, 1H), 6 2.25-2.36 (m, 1H), S 1.93-2.07 (m, 2H), b 1.78-1.93 (m,
1H), 8 1.59-1.76 (m, 2H).
NaBH(OAc)3 (1.718 g, 2.0 eq) was added to a stirred solution of compound XXXIC
(0.471 g,
0.00405mo1), aminodiphenylmethane (0.769 mL, 1.1 eq) in 1,2-dichloroethane (10
mL). The mixture was
stirred overnight. The reaction mixture was quenched with saturated aqueous
NH4C1 solution, extracted
with CH2ClZ twice, washed with brine twice, dried with Na2SO4 and concentrated
to afford crude
compound XXXID.
EI-MS rra/z: 284 (M + H)+.
Crude compound XXXID (0.909 g), MeOH (35 mL), 1M HCl aqueous solution (8.11
mL, 2.0 eq), and
10% Pd/C (0.458 g) were placed in a Parr flask. The mixture was hydrogenated
on a Parr shaker at 40 psi
for 1.5 hours. Filtration through celite, concentration and purification by
reverse phase C- 18 column
afforded compound XXXI.
Intermediate XXXII: (5R,7S)-(5S,7R)-1-(3-fluorophenyl)-4-imino-8-(3-
isopropoxybenzyl)-7-methyl-
1,3,8-triazaspiro[4.5]decan-2-one
0
O O O
Zn (dust), HOAc
61, BnO CI 60 C
Et3N, THF (N)"
MeMgBr, -78 C
Bn0 O Bn0__~0
O H2N F N H N~ H
20% Pd(OH)Z/C \ N F
N F ~
MeOH, Hz(g)
~ . '=-.
N TiCla, Zn(CN)2 N N
~ HOAc, 45 C ~ H
BnO O O OBn (+l-)-trans
(+/-)-trans
O O
~ N F O HN F
N F CI ~\
~ CIsCN HN N I\
~., H3CCN, K3P04 CH2C12; H20
N H D N N
\
(+/-)-trans O ~O \
~ / (+/-)-trans I (+l-)-trans
/
-74-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
4-methoxypyridine (5.36 g, 49.1 mmol, 1.0 eq) was weighed into a 500 mL flask
with a
stir bar and septum. The flask was flushed with nitrogen, and THF (80 mL) was
added, followed by
triethylamine (0.70 mL, 5.0 mmol, 0.10 eq). The solution was stirred and
cooled to -78 C, at which
point benzyl chloroformate (7.0 inL, 49.7 mmol, 1.01 eq) was added over 1 min,
giving a large amount of
white precipitate. An additional portion of THF (50 mL) was added to assist
stirring. After stirring at -
78 C for 10min, a 1.4M solution of methyl magnesium bromide in toluene:THF
(3:1) (50 mL, 70mmo1,
1.4equiv) was added over 1.5 min, causing most of the precipitate to go into
solution. The cold bath was
removed and the reaction was allowed to stir and warm to rt over 2h. The
reaction was then cooled to -
C in an ice salt bath, then quenched by addition of 1H hydrochloric acid. The
reaction was diluted
with ether, and the aqueous layer removed. The organic layer was washed with
brine, dried over
magnesium sulfate, filtered and concentrated to provide the desired enone,
which was carried on directly
to the next reaction.
'H NMR (CDC13-d, 400 MHz) S: 7.74(br s, 1H), 7.38 (m, 5H), 5.31 (m, 1H), 5.26
(s, 2H), 4.72 (br s, 1H),
2.84 (dd, J=15.6, 7.3Hz, IH), 2.30 (d, J=15.6Hz, 1H), 1.25 (br s, 3H).
EI-MS m/z: 246 (M + H)+.
The enone (11.7 g, 47.7 mmol, 1 eq) was dissolved into acetic acid (70 mL),
heated to 60
C, and zinc dust (12.9 g, 197 mmol, 4.14 eq) was added in 4 portions over
2.5h. The reaction was then
filtered through celite using ethyl acetate, then concentrated to an oil. The
oil was dissolved into diethyl
ether and water, and the aqueous layer was removed. The organic layer was
washed three times with
saturated sodium bicarbonate solution, then dried over magnesium sulfate,
filtered and concentrated. The
crude product was purified by filtration over silica gel in a Buchner funnel,
using 25% ethyl acetate in
hexanes to remove less polar impurities, followed by 50% ethyl acetate in
hexanes to elute the desired
product, which was obtained as a yellow oil after concentration.
A portion of the ketone (5.36 g, 21.7 mmol, 1.0 eq), 3-fluoroaniline (6.0 mL,
62.4 mmol,
2.88 eq) and acetic acid (70 mL) were placed in a 200 mL flask. The solution
was stirred and cooled to
slightly below rt in an ice bath, then a 1M solution of titanium tetrachloride
in dichloromethane (28 mL,
28 mmol, 1.29 eq) was added over 2 min. The reaction was then stirred and
warmed to 50 C in an oil
bath, and zinc cyanide (10.0 g, 85.2 mmol, 3.93 eq) was added. The reaction
was stirred at 50 C for
15.5h, at which point LCMS indicated that a small amount of ketone remained.
Another portion of
aniline (1.3 mL, 13.5 mmol, 0.62 eq) was added, followed by zinc cyanide (1.97
g, 16.8 mmol, 0.77 eq).
LCMS after 30min indicated that all of the ketone had been consumed. The
reaction was diluted with
dichloromethane and washed twice with 1N hydrochloric acid, then three times
with saturated sodium
bicarbonate solution. The organic solution was then dried over magnesium
sulfate, filtered and
concentrated to provide the aminonitrile. If desired, the mixture of trans and
cis products can be
separated at this stage, using silica gel chromatography, at 1.2-1.3% EtaO in
CH2C12, giving the desired
anti isomer as the faster eluting fraction.
-75-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
A portion of trarns aminonitrile (1.859 g, 5.06 mmol) was dissolved into
methanol (40
mL) in a Parr flask. A slurry of 20% Pd(OH)2/C (247.8 mg) in ethyl acetate (2
mL) was added, and the
flask was attached to a Parr shalcer, and hydrogenated under 40psi hydrogen
pressure for 3.5h. The
reaction was then filtered through celite, and concentrated to an oil. If not
previously separated, the cis
and trans isomers are separable at this stage by silica gel chromatography
(95% dichloromethane: 5% of
2N anunonia (MeOH)), with the undesired cis isomer (Rf-0.20) eluting slightly
faster than the desired
trans isomer (Rf 0.16).
El-MS m/z: 234 (M + H)}.
A portion of the above trans piperidine (211 mg, 0.91 mmol, 1.0 eq.) and 3-
(isopropoxy)benzyl
chloride (250 mg, 1.35 nunol, 1.48 eq.)) were dissolved into 5 mL of
acetonitrile containing potassium
carbonate (540 mg, 3.9 mmol, 4.2 eq.). The reaction mixture was stirred at 60
C for 16 hrs and was then
poured into saturated sodium bicarbonate solution. After extraction with 30 mL
of dichloromethane three
times, the combined organic layer was dried over sodium sulfate. The desired
product was obtained by
column chromatography (3% ether, 97% dichloromethane).
A portion of benzyl piperdine prepared as described above (1.7563 g, 4.60
mmol, 1.0 eq.) was
placed in a flask and dichloromethane (20 mL) was added. The mixture was
stirred and cooled to 0 C,
and trichloroacetyl isocyanate (0.60 mL, 5.05 mmol, 1.10 eq.) was added. After
stirring for 5 min,
LCMS revealed that some of the starting material remained. Another portion of
trichloroacetyl
isocyanate (0.20 mL, 1.69 mmol, 0.37 eq.) was added. The reaction mixture was
then stirred for 10 min
and then water (415 L, 23.1 mmol, 5.0 eq.) was added. The reaction mixture
was then capped and
placed in a -20 C freezer overnight. The reaction was then warmed to rt and
stirred hard for 2.5h with a
magnetic stirrer. The reaction was then concentrated to a white foam. Flash
chromatography over silica
gel (95:6.5:1 dichloromethane:methanol:saturated anunonium hydroxide (aq.)
provided the desired
iminohydantoin as a white solid.
'H NMR (CD3OD, 400 MHz) 8: 7.34 (q, J=7.7Hz, 1H), 7.15-7.00 (m, 4H), 6.77 (d,
J=8.3Hz, 1H), 6.70-
6.60 (m, 211), 4.54 (septet, J=5.9Hz, 1H), 3.85 (d, J=13.7Hz, 111), 3.14 (d,
J=13.2Hz, 1H), 2.65-2.55 (m,
1H), 2.35-2.25 (m, 111), 2.20-2.05 (m, 311), 2.00-1.85 (m, 2H), 1.29 (dd,
J=6.1, 1.2Hz, 6H), 1.18 (d,
J=5.9Hz, 3H).
EI-MS rn/z: 425 (M + H)+.
Intermediate XXXIH: (5R,7S)-(5S,7R)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-
7-methyl-4-thioxo-
1, 3, 8-triazaspiro [4.5] decan-2-one
-76-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
O
N N F 0 0 p HN
CiN S N I\ F
N CH2CI2; H20
p 2. Na2S, HOAc, H20 Y I \ O \
/ (+I-)-trans . ~ I / (+/-)_trans
A portion of the racemic, trans aminonitrile (2.4716 g, 6.48 mmol, 1.0 eq.)
was dissolved
into dichloromethane (32 mL). The reaction was stirred and cooled to 0 C, at
which point
chlorosulfonyl isocyanate (0.76 mL, 7.77 mmol, 1.20 eq.). After 45min, LCMS
indicated that some
starting material remained. Another portion of chlorosulfonyl isocyanate
(0.060 mL, 0.61 min.ol, 0.09
eq.) was added. After 5min, water (10 nnL) was added, and the biphasic mixture
was stirred hard.
In a 1L glass bottle with a plastic cap, a solution of anhydrous sodium
sulfide (9.79 g,
125 mmol, 19.4 eq.) in water (150 mL) was prepared and cooled to an internal
temperature of less than 5
C. Acetic acid (10.3 mL, 180 mmol, 27.8 eq.) was added dropwise over 10min,
keeping the internal
temperature below 8 C, causing moderate gas evolution. The dichloromethane
solution of the
iminohydantoin was then added to the thiol solution, using a total of 20 mL
additional dichloromethane
for the transfer. The bottle was then capped, stirred hard and allowed to warm
to rt. After two days of
stirring, the reaction was diluted with ethyl acetate, and the organic layer
was removed. The organic
layer was washed with saturated sodium bicarbonate solution, then with brine.
The organic solution was
then dried over magnesium sulfate, filtered and concentrated. Flash
chromatography over silica gel (25%
ethyl acetate in hexanes) provided the desired thiohydantoin.
'H NMR (CD3OD, 400 MHz) 6: 7.40-7.30 (m, 1H), 7.15-7.05 (m, 2H), 7.01 (d,
J=7.4Hz, 1H), 6.94 (d,
J=8.8Hz, 1H), 6.80-6.60 (m, 3H), 4.52 (septet, J=5.9Hz, 1H), 3.86 (d,
J=13.7Hz, 1H), 3.15-2.85 (m, 1H),
2.85-2.40 (m, 2H), 2.40-2.15 (m, 1H), 2.05-1.70 (m, 4H), 1.32 (d, J=6.3Hz,
6H), 1.25-1.05 (m, 2H).
EI-MS tn/z: 442 (M + H)+.
EXAMPLE 1
Racemic 5(R,S)7(R,S)-8-benzyl-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-
1,3,8-
triazaspiro[4.5]dec-3-en-2-one diastereomer A
O
N~ F
H / N
' /
N
d
-77-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
In a flask 1-benzyl-2-methylpiperidin-4-one (Intermediate I, 163 mg, 0.8 mmol)
was dissolved in MeOH
(0.275mL) and a solution of KOCN (0.11 mL of an approximately 9 Molar solution
made from
dissolving 0.81mg KOCN in 1.1 mL water ) was added in one portion with
vigorous stirring.
Cyclohexyl isocyanide (0.096 mL, 0.76 mmol) was added, followed by powdered
aniline hydrochloride
(0.118g, 0.802 mmol, added in small portions over 5 minutes). The reaction was
stirred overnight, then
evaporated and the residue portioned between CHC13 and saturated bicarbonate
solution, the organic was
dried with NazSO4i filtered and evaporated. The residue was chromatographed on
a reverse phase column
eluting with a gradient of 5-95% CH3CN/water 0.1% TFA. The earlier eluting of
two diastereomers was
isolated after lyophilization of the fractions and its free base obtained by
partitioning between CHC13 and
saturated bicarbonate. The organic layer was dried (Na2SO2) filtered and
evaporated to give the product
as a foam.
'H NMR (400 MHz, CDC13) S 7.7 (d, J= 7.8 Hz, 1H), 7.4-7.28 (m, 6H), 7.0 (m,
3H), 3.99 (m, 1H), 3.70
(d, J= 13.5 Hz, 1H), 3.62 (d, J= 13.5 Hz, 1H), 3.1 (m, 1H), 2.73 (m, 1H), 2.55
(m, 1H), 2.03 (m, 3H),
1.90 (m, 1H), 1.8-1.6 (m, 4H), 1.38 (m, 2H), 1.2-1.0 (m, 3H), 1.15 (d, J= 6.2
Hz, 3H) ppm.
EXAMPLE 2
Racemic 5(R,S)7(S,R)-8-benzyl-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-
1,3,8-
triazaspiro[4.5]dec-3-en-2-one Diastereomer B
N~O
F
N ~ N
H
N
In a pear-shaped flask Intermediate I(0.800 mg, 3.93 mmol) was dissolved in
MeOH (1.3 mL) and a
solution of KOCN (0.547 mL of an approximately 9 Molar solution made from
dissolving 0.81mg KOCN
in 1.1 mL water) was added in one portion with vigorous stirring. Cyclohexyl
isocyanide (0.473 mL,
3.74 nunol) was added, followed by powdered 3-fluoroaniline hydrochloride
(prepared by treating an ice-
cooled solution of 3-fluoroanaline in ether with a 1 Molar solution of HCl in
ether and isolated either by
evaporating to give the solid or by filtering off and collecting the solid
precipitate) 0.581g, 3.93 nunole,
added in small portions over 5 min). The reaction was stirred 48 hr, then
partioned between CHC13 and
saturated bicarbonate solution, the organic was dried with Na2SO4, filtered
and evaporated. The residue
was chromatographed on silica eluting with a gradient of 0-5% MeOH/CHC13 and
the earlier and later
-78-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
diastereomeric products were isolated. The later eluting diastereomer was
further purified by reverse
phase column eluting with a gradient of 10-95% CH3CN/water 0.1% TFA. The pure
fractions were
evaporated and the free base obtained by partitioning between CHC13 and
saturated bicarb. The organic
layer was dried (Na2SO4) filtered and evaporated to give the product as a
foam.
'H NMR (400 MHz, CDCI3) S 8.24 (d, J= 7.7 Hz, 1H), 7.4-7.3 (m, 4H), 7.2
(buried), 7.0 (m, 3H), 4.15 (
d, J= 12.8 Hz, 1H), 3.94 (m, 1H), 3.0 (d, J= 12.8 Hz, 1H), 2.78 (m, 1H), 2.58
(m, 1H), 2.24 (dd, J= 7.0,
14.5 Hz, 1H), 2.1 (m, 3H), 1.95-1.8 (m, 4H), 1.75-1.5 (m, 3H), 1.35 (m, 2H),
1.28 (d, J= 6.4 Hz, 3H), 1.2
(m, 1H), 1.0 (m, 1H).
Example 2 was separated into its enantiomers 2a and 2b by reverse phase chiral
chromatography on a
ChiralPak AD 5 cm x 50 cm 20 prep column eluting with a gradient of 90/10 to
40/60 hexanes/EtOH
containing 0.1% dietllylamine monitored at 265 nM.
The first eluting enantiomer 2a was further purified by nonchiral reverse
phase HPLC and the free base
isolated from partition between saturated bicarbonate and CHC13.
5(R),7(S)-8-benzyl-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-1,3,8-
triazaspiro[4.5] dec-3-en-2-
one
'H NMR (400 MHz, CDC13) 8 8.24 (d, J= 7.7 Hz, 1H), 7.4-7.3 (m, 4H), 7.25
(buried), 7.0 (m, 3H), 4.14
(d, J= 12.6 Hz, 1H), 3.95 (m, 1H), 3.0 (d, J= 12.8 Hz, 1H), 2.79 (m, 1H), 2.58
(m, 1H), 2.24 (dd, J=
7.0, 14.8 Hz, 1H), 2.2-2.0 (m, 3H), 1.9-1.75 (m, 3H), 1.75-1.6 (m, 3H), 1.45-
1.3 (m, 2H), 1.25 (d, J= 6.2
Hz, 3H), 1.2 (m, 1H), 1.0 (dq, J= 3.6, -12 (x3)Hz) ppm.
Second eluting enantiomer 2b. The material obtained from the chiral column
were partitioned between
saturated bicarbonate and CHC13, dried with Na2SO4, filtered and evaporated to
give the product.
(S),7(R)-8-benzyl-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-
one
'H NMR (400 MHz, CDC13) 6 8.27 (d, J= 8.2 Hz, 1H), 7.4-7.3 (m, 4H), 7.25
(buried), 7.0 (m, 3H), 4.14
(d, J= 12.8 Hz, 1H), 3.95 (m, 1H), 3.0 (d, J= 12.8 Hz, 1H), 2.79 (m, 1H), 2.58
(m, 1H), 2.24 (dd, J=
7.1, 14.4 Hz, 1H), 2.2-2.0 (m, 3H), 1.9-1.75 (m, 3H), 1.75-1.6 (m, 3H), 1.45-
1.3 (m, 2H), 1.28 (d, J= 6.2
Hz, 3H), 1.2 (m, 1H), 1.0(dq, J= 3.1, -12 (x3)Hz) ppm.
In a manner similar to that described for Examples 1 and 2, using the
appropriate intermediates
outlined above and the appropriate aniine and isocyanide, the following
compounds of Table 1 were
prepared:
-79-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Table 1
Ex. No. Interm,ediate Structure IUPAC Name Mass Spec
M+1 Data
3 O, Racemic 5(R,S)7(R,S) 507.5
II N N~ F -4-(cyclohexylamino)-1-(3-fluorophenyl)-
H ~ ~ 8-(3-isopropoxybenzyl)-7-methyl-1,3,8-
Y N triazaspiro[4.5]dec-3-en-2-one
"- Diastereomer A
4 ON Racemic 5(R,S)7(S,R) 507.5
N N F -4-(cyclohexylamino)-1-(3-fluorophenyl)-
U/ 8-(3-isopropoxybenzyl)-7-methyl-1,3,8-
Y N triazaspiro[4.5]dec-3-en-2-one
-, Diastereomer B
Racemic 5(R,S)7(R,S)-8-benzyl-4- 431.4
I a N~
(cYclohexYlamino)-7-methy1-1-pheny1-
N i N '
H ~ ~ 1,3,8-triazaspiro[4.5]dec-3-en-2-one
N Diastereomer A
i
6 a Racemic 5(R,S)7(S,R) 431.4
N NN ' -8 benzyl-4-(cyclohexylarnino)-7-methyl-
H ~ ~ 1-phenyl-1,3,8-triazaspiro[4.5]dec-3-en-2-
N one Diastereomer B
7 Racemic 5(R,S)7(R,S)-8-(3- 467.5
II N~ ' F isopropoxybenzyl)-4-(isopropylamino)-7-
H Ij/ rnethyl-l-(3-methylphenyl)-1,3,8-
y N triazaspiro[4.5]dec-3-en-2-one
Diastereomer A
-80-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Ex. No. Interniediate Structure NPAC Name Mass Spec
M+l Data
8 o Racemic 5(R,S)7(S,R) 467.5
II ~N N~ \ F -8-(3-isopropoxybenzyl)-4-
H (isopropylamino)-7-methyl-l-(3-
N rnethylphenyl)-1,3,8-triazaspiro[4.5]dec-3-
0 en-2-one Diastereomer B
9 O,N- 0 5(R,S)7(R,S)-8-benzyl-4- 369.1
'' (cyclohexylamino)-1,7-dimethyl-1,3,8-
H triazaspiro[4.5]dec-3-en-2-one
N Diastereomer A
OIN- 0 5(R,S)7(S,R)-8-benzyl-4- 369.1
'' (cyclohexylamino)-1,7-dimethyl-1,3,8-
H triazaspiro[4.5]dec-3-en-2-one
N Diastereomer B
Examples 1 to 10 are depicted above in enamine fonn, but may also exist in
tautomeric imine
fom1, as described above.
EXAMPLE 11
5 (5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-7-
methy1-1,3,8-
triazaspiro[4.5]dec-3-en-2-one (R,S enantiomer of Example 4)
0 F
CL NJil,~N
N "CH
3
H3CITIO
CH3 &
-81-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Scheme for Example 11
(Adapted from General Scheme 7)
CondiOons A.
Zn(CN)2
~ 0 HOAc
H3CI0 1.CBZCI rt
MeMgBr ovemlght
/ -. -- ~
~ I 2 Zn / ~ CH3 resolution /CH3
HOAC O O uAD 0, O or
I/ Condlions B.
N column
11-1 11-2 11-3S 1. TMSCN
HOAc RT
2. Eplmerization
F F
0 F 0 F
N, HN ~~ N~ HN ~~ HN N HN~
N
HNJ ~ HN
C.,, 'N/ '"aCH
N CH3 =O N '=.iCH3 N CH3
~ ~
I~ O~O O O 1. 2. MeOH/ CI3CCON=HZOCI TF~. I~ O O I/ ~O
11-4 115 11-6 11-7
neat
cyclohexylamine
0 F
_ O F
N~A N ~ ~ H2/Pd/C
~ I/'CH
3 HCI / MeOH H
H 3
I \ O O
/
11-8 11-9
G DMF
O ~ O OH KzC03
HO \ ~ HaC~O \ HsC \ H3C I I 18hr (+l- Naq
I/ KzC~ CH3 I/ NaBH4 H3 I/ Ph3P CH3
CCIq 11-10c
11-10a 11-106
-\ N
N
N~l,,.. ~ ~
H 'CH
3
H3Cy0
CH3 I/ 11-10 (F_xam Ip e 111
Step 1: Raceinic Benzyl2-methyl-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate 11-
2
4-methoxypyridine (796g, 7.29 mole) was stirred in 8 L of anhydrous THF in a
20 L reactor. The reactor
was cooled to -30 C, then methylmagnesium bromide (5.1 L, 7.29 mole) was
added as a 1.4M solution in
-82-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
3:1 toluene/THF was added via cannula one 800mI. bottle at a time with 800m1s
added over a 5 min time
period. After the addition was complete and the reaction temperature was -30
C, benzyl chloroformate
(1244g, 7.29 mole) was added dropwise over a 60 min period via addition
funnel. The warmest
temperature reached was 16 C. After addition was complete the reaction was
warmed to 25 C and
stirred for 1.5 hrs. The reaction was cooled to 0 C and quenched with 4.OL of
2 N HCI. 4L of MTBE
and brine was added and the layers separated. The temperature was now 25 C.
The aqueous phase was
extracted with 2 x 2L of MTBE. The combined organics were washed with brine
and dried over
Na2SO4, filtered and concentrated to give the crude oil. Chromatography using
a Varian Metaflash 150
long (15 em x 60 cm long 5 kilo silica) and eluting with 10-35% EtOAc/Heptanes
gave the product as an
oil.
1H NMR (400 MHz, CDC13) S 7.85 (dd, J= 1.5, 8.2 Hz, 1H), 7.38 (in, 6H), 5.31
(d, J= 12 Hz, 1H),
5.27 (d, J = 12 Hz, 1H), 4.74 (m, 1H), 2.92(dd, J = 7, 17 Hz, 1H), 2.26 (d, J
= 17 Hz, 1H), 1.21 (d, J= 7
Hz, 3H).
LCMS observed mass = 202
Step 2: Reduction to Racemic benzyl 2-methyl-4-oxopiperidine-l-carboxylate 11-
3
Benzyl 2-methyl-4-oxo-3,4-dihydropyridine-1(2H)-carboxylate (823g, 3.35 mole)
was stirred in 5L of
glacial acetic acid and heated to 90 C under argon in a 20 L reactor. Zinc
dust (218g, 3.35 mole) was
added and the reaction heated to 100 C for 1 h. Several more 0.25-0.5 eq
portions of zinc dust were
added over the next few hrs, the reaction was allowed to cool to ambient
temperature overnight, then re-
heated and treated with further portions of zinc dust (total 10 hr 100 C,
548g, 8.43 mole, 2.5 eq zinc).
The reaction was filtered through a pressed pad of Celite, rinsing with 4.0 L
of HOAc. The zinc pad was
never allowed to dry and the temperature of the zinc pad was monitored by
thermocouple. The pad was
washed with copious amounts of H20 and stored under water until disposal. The
filtrate was
concentrated and co-evaporated with toluene to give crude product that was
diluted with 700 mL 10%
EtOAc/Heptane and -200m1 CH2C12 was added to form a single phase. This
material was loaded onto a
Varian 150 M (2.5Kg ) silica gel column and eluted with a gradient of 10%
EtOAc to 40% EtOAc in
Heptane. The fractions were concentrated to give the crude product as an oil.
The crude material may be
treated with a workup from aqueous bicarbonate.
1H NMR (400 MHz, CDC13) S 7.37 (m, 5H), 5.18 (s, 2H), 4.80 (m, 1H), 4.34 (m,
1H), 3.38 (m, 1H),
2.7(dd, J = 6.7, 18 Hz, 1H), 2.5 (m, 1H), 2.2-2.4 (m, 2H), 1.2 (d, J = 7 Hz,
1H).
LCMS observed mass = 248.2 (m+l)
Step 3: Resolution to benzyl (2S)-2-methyl-4-oxopiperidine-l-carboxylate 11-3S
-83-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
The crude Racemic benzyl 2-methyl-4-oxopiperidine-l-carboxylate was dissolved
in MeOH and
chromatographed on a 10cm Chiralpak AD column eluting with 100% MeOH in 2.5g
injections to give
the two separated enantiomers. The desired enantiomer eluted first, 95%ee.
Step 4: Benzyl (2S,4R)-4-cyano-4-[(3-fluorophenyl)amino]-2-methylpiperidine-l-
carboxylate 11-4 and
benzyl (2R,4R)-4-cyano-4-[(3-fluorophenyl)amino]-2-methylpiperidine-l-
carboxylate
11-5
Conditions A: Zn(CN)2
CBZ piperidinone 7-3S (30.2g, 0.122 mole) was dissolved in 240 mL of glacial
acetic acid and 3-
fluoroaniline (13.55g, 0.122 mole) was added followed by zinc cyanide (71.6g,
0.61 mole). In an
alternative method, 2.5 equivalents of Zinc Cyanide may be used. The reaction
was stirred at room
temperature overnight then poured into an equal volume of ice/ ammonium
hydroxide solution (260mL)
and the pH adjusted until it was basic. The basic solution was extracted three
times with chloroform and
the organics were dried over MgSO4, filtered and evaporated. The crude
material loaded directly onto a
silica gel column and chromatographed with 30% Ethyl acetate/Hexanes to give
the products as a viscous
yellow oil. The diastereomers were not separated at this point.
1H NMR (400 MHz, CDC13 mixture of diastereomers) S 7.36 (m, -12H), 7.21 (m, -
2H), 6.63 (m, -6H),
6.42 (m, -1H), 5.18 (s, -1H), 5.15 (s, -4H), 4.9 (bs, -1H), 4.8 (m, -1H), 4.6
(m, -1H), 4.28-4.2 (m,
-2H), 4.0 (m, -1H), 3.84 (s, -1H), 3.76 (s, -1H), 3.4-3.2 (m, -3H), 2.7 (m, -
1H), 2.6 -2.2 (m, -9H), 1.95
(m, -1H), 1.85 (m, -1H), 1.45 (d, J = 7 Hz, -3H), 1.2 (d, J = 7Hz, -2H).
LC/MS ion fragment mass of 251
Step 4: Benzyl (2S,4R)-4-cyano-4-[(3-fluorophenyl)amino]-2-methylpiperidine-l-
carboxylate 11-4 and
benzyl (2R,4R)-4-cyano-4-[(3-fluorophenyl)amino]-2-methylpiperidine-l-
carboxylate
11-5
Conditions B: TMSCN/AcOH and epimerization
CBZ piperidinone 7-3S (13.91g, 0.056 moles) was dissolved in 56 mL of Glacial
acetic acid and cooled
to zerodegrees C. 3-fluoroaniline (6.5g, 0.059 moles) was added followed by
dropwise addition of
TMSCN (6.7g, 9 mL, 0.067 moles). The reaction was stirred at rt for a few
hours, an additiona10.5 ml of
aniline and 1 mL of TMSCN was added and the reaction stirred until starting
material was consumed
(overnight). Some crystalline product was filtered off and washed with
hexanes. The volume of the
mother liquor was reduced in vacuo and then poured into an ice/ammonium
hydroxide solution. The
solution was extracted two times with dichloromethane and the organics were
dried over Na2SO4,
filtered and evaporated. The crude material was loaded directly onto a silica
gel column and eluted with
40% diethyl ether/hexanes and 30% ethylacetate/hexanes, to give the product as
an amber oil. The
combined products were dissolved in EtOH (150 mL). To this TMSCN was added (15
mL, 0.110 Mol)
and the mixture sealed and heated in an 85 C oil bath for 6 h. The mixture
was concentrated to dryness
-84-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
to yield the crude product as an oil. The crude material was loaded directly
onto a silica gel column and
then eluted with 40% diethyl ether/hexanes and 30% ethylacetate/hexanes to
give the products as an
amber oil.
1H NMR (400 MHz, CD3OD, mixture of diastereomers) 5 7.35 (m, -5H), 7.3(m, -
2H), 7.2-7.1 (m,
-1.5H), 6.68 (m, -1.5H), 6.6 (m, -1.5 H), 6.5 (m, -1.5 H), 5.13 (ABq, -3H),
4.55 (m, -1H), 4.38 (m,
-0.5H), 4.2 (m, -1H), 4.0 (m, -0.5 H), 3.4-3.3 (m, -3H), 2.5 (m, -2.5 H), 2.25
(m, -1H), 2.15 (m, -1H),
1.9 (m, -1H), 1.7 (m, -1H) ppm.
LCMS (m+l) = 251.2
Step 5: Cyclization to benzyl (5R,7S)-1-(3-fluorophenyl)-4-imino-7-methyl-2-
oxo-1,3,8-
triazaspiro[4.5]decane-8-carboxylate 11-6 and benzyl (5R,7R)-1-(3-
fluorophenyl)-4-imino-7-methyl-2-
oxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate 11-7
The mixture of benzyl (2S,4R) and (2R,4R) -4-cyano-4-[(3-fluorophenyl)amino]-2-
methylpiperidine-l-
carboxylate and benzyl (2R,4R)-4-cyano-4-[(3-fluorophenyl)amino]-2-
methylpiperidine-l-carboxylate
(43.7g, 0.119 moles) was dissolved in 400mL CH2C12 and
trichloroacetylisocyanate (29.2g, 0.155 moles)
was added via pipette. The reaction turned red instantly and faded over 15
min, the reaction was
monitored by LCMS and the reaction to form the acylated intermediate was done
in 10 min. The
reaction was stirred at rt for another 45 min and again showed no starting
material by LCMS. 50 mL of
MeOH was added followed by 20 mL of water and 27 mL (0.155 moles) of Hunig's
base. The reaction
was heated at 50 C for 4 hrs, when LCMS showed the cyclization was done. The
reaction was diluted
with CHzClzi washed with brine and dried over MgSO4, filtered and evaporated
to give the crude product,
which was chromatographed on silica with 10% MeOH/CHC13/1% Triethylamine. The
desired isomer
eluted after the undesired isomer to give the desired product as a white
solid.
11I NMR (400 MHz, CD3OD) 6 7.3 (m, 4H), 7.23 (bd, J= 7 Hz, 2H), 7.12 (m, 2H),
7.04 (dt, J = 2, 8 Hz,
1H), 4.92 (d, J = 12.3 Hz, 1H), 4.67 (bd, J = 11 Hz, 1H), 3.95 (dd, J = 7, 14
Hz, 1H), 3.46 (m, 1H), 3.12
(m, 1H), 2.56 (m, 1H), 2.19 (m, 2H), 1.94 (dd, J = 11.5, 14.7 Hz, 1H), 1.01
(d, J = 6.2 Hz, 3H) ppm.
acylated intermediate LCMS ion fragment detected = 207.1
desired iminohydantoin product LCMS ion fragment detected = 410.9
Step 6: Benzyl (5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-2-oxo-
1,3,8-
triazaspiro[4.5]dec-3-ene-8-carboxylate 11-8
Benzyl (5R,7S)-1-(3-fluorophenyl)-4-imino-7-rnethyl-2-oxo-1,3,8-
triazaspiro[4.5]decane-8-carboxylate
(27.2g, 0.066 moles) was dissolved in 100mL toluene, cyclohexylamine (60 mL,
0.523 moles) was added
and the mixture was heated to 110 deg C over the weekend in a 1 L roundbottom
flask fitted with a
condenser. The reaction was diluted with CHC13 and MeOH until soluble and
washed with 1 Normal
HCl three times to remove excess cyclohexylamine. The organic was dried with
MgSO4, filtered and
concentrated to give the product which was used in the next step without
further purification.
-85-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
1H NMR (400 MHz, CDC13) S 7.42-7.10 (m, 9H), 4.88-4.81 (m, 2H), 4.66 (d, J=
11.6 Hz), 3.98 (dd, J
= 7.3, 14.1 Hz, 1H), 3.66 (m, 1H), 3.55 (m, 1H), 3.24 (ddd, J= 5.6, 12.4, 14.2
Hz, 1H), 2.78 (m, 1H),
2.54 (dd, J= 7.0, 14.6 Hz, 1H), 2.24 (dd, J= 5.1, 16.0 Hz, 1H), 2.03 (m, 2H),
1.84 (m, 2H), 1.69 (m, 1H),
1.73-1.23 (m 3H), 1.05 (d, J= 6.1 Hz, 3H).
LCMS ion fragment = 493.01
Step 7: (5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one
(11-9)
Benzyl (5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-2-oxo-1,3,8-
triazaspiro[4.5]dec-3-ene-
8-carboxylate (27.9g, 0.057 moles) was suspended in MeOH (-200 mL) and
methanolic HCl was added
until the solids all went into solution. Pd(OH)2 (4g, moisture content 60%)
was added and the reaction
was flushed with hydrogen and lcept under a hydrogen balloon. The reaction was
stirred at room
temperature for 30 min. The reaction was evacuated and recharged with H2 once
to remove CO2. The
reaction was filtered through celite and concentrated, then the free base was
obtained by portioning
between CHCL3 and 1 N NaOH. The organic was dried over MgSO4, filtered and
evaporated to give the
product.
1H NMR (400 MHz, CD3OD) 8 7.45 (m, 1H), 7.18 (m, 3H), 3.74 (m, 2H), 2.85 (m,
1H), 2.50 (m, 2H),
2.1 (m, 2H), 1.96 (m, 3H), 1.81 (m, 4H), 1.6 (m, 2H), 1.5-1.05 (m, 6H), 0.98
(d, J = 6Hz, 3H) ppm.
LCMS ion mass fragment = 359.0
Step 8: (5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-
7-methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one (11-10
(5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one (17g,
0.0475 moles) was dissolved in DMF (200 mL) and powdered K2C03 (26.2g, 0. 190
moles), 3-
isopropoxybenzylchloride (7-10c 8.77g, 0.0475 moles) and NaI (0.36g, 0.0024
moles) was added. The
solution was heated to 65 C overnight. The reaction was diluted with water
(500 mL) and extracted three
times with CHC13. The combined organics were dried over MgSO4, filtered and
concentrated then
chromatographed using a series of solvents: 50% Ethyl acetate/Hexanes, then
100% Ethyl acetate, then
10% MeOH/CHC13 containing 1% TEA to give the product, which was further
purified on a Waters
automated system affixed with a Chiralpak AD 10cm x 50 cm cartridge eluting at
150 mL/min with
isocratic 20% isopropyl alcohol in hexanes with no modifier.
An alternative workup consisted of filtering the cooled reaction through
celite and diluting with EtOAc,
then washing with aqueous LiCl solution and brine. The organic layers were
dried over Na2SO4, then
concentrated and pumped on with heat to remove residual DMF. Chromatography on
silica eluting with
0-100% EtOAc/Hexanes gave the product, which was purified further as described
above.
-86-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
1H NMR (400 MHz, CDC13) S 8.34 (d, J = 8.4 Hz, 1H), 7.32 (dd, J= 8, 14.6 Hz,
1H), 7.24 (m, 1H), 7.0
(m, 3H), 6.8 (m, 3H), 4.55 (pentet, J = 6 Hz, 1H), 4.10 (d, J = 12.8 Hz, 1H),
3.95 (m, 1H), 2.92 (d, J =
12.8 Hz, 1H), 2.8 (m, 1H), 2.54 (m, 1H), 2.23 (dd, J = 7, 14 Hz, 1H), 2.1 (m,
3H), 1.9-1.6 (m, 7H), 1.4
(m, 1H), 1.33 (d, J = 6 Hz, 6H), 1.26 (d, J= 6.3 Hz, 3H), 1.35-1.2 (m, 2H),
1.1 (m, 1H).
LCMS ion fragment = 507.11
Step 9: (5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-
7-methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one dihydrochloride (Example 11 HCI salt)
(5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-7-methyl-
1,3,8-
triazaspiro[4.5]dec-3-en-2-one was dissolved in high quality acetonitrile,
cooled to 0 C and 2.5
equivalents of HCl in diethyl ether were added. The solution was allowed to
warm to rt. The solution was
then reduced to a powdery solid on the rotovap. The residue was suspended in
acetonitrile and
evaporated two times to give the desired bis-salt.
1H NMR (400 MHz, CDC13) 8 11.1 (bs, 1H), 10.23 (bs, 1H), 7.5-7.1 (m, 5H), 6.9
(m, 3H), 4.59 (pentet,
J= 6 Hz, 1H), 4.53 (bd, J = 11 Hz, 1H), 4.32 (bs, 1H), 3.66 (bs, 1H), 3.5-3.2
(m, 3H), 2.97 (bs, 1H), 2.85
(bd, J = 15 Hz, 1H), 2.63 (bd, J = 15 Hz, 1H), 2.21 (m, 1H), 2.0 (m, 2H), 1.7-
1.4 (m, 10H), 1.34 (d, J = 6
Hz, 3H), 1.31 (d, J= 6 Hz, 3H), 1.28 (m, 1H), 1.19 (m, 1H).
Step 10a: 3-isopropoxybenzaldehyde
0
H3CYC \ H
CH3\ I /~
To a 1 molar solution of 3-hydroxybenzaldehyde (100g, 0.819 moles) in
isopropyl alcohol (820 mL) was
added 2-iodopropane (146.2g, 0.860 moles) followed by powdered potassium
carbonate (339.5g, 0.457
moles) and the mixture was heated to reflux under nitrogen for a minimum of 8
hrs. The reaction was
complete by TLC. Water was added to the cooled reaction until all salts were
dissolved. The mixture was
extracted with ether three times. The combined ether extracts were washed with
water, 2 M NaOH and
again with water until clear (three times) then brine. The organic layer was
dried over magnesium sulfate
and filtered and evaporated to give the desired product as a pale oil.
1H NMR (400 MHz, CDC13) 6 9.95 (s, 1H), 7.2 (m, 3H), 7.12 (m, 1H), 4.6 (m,
1H), 1.32 (bs, 6H) ppm.
LCMS ion fragment = 164.1
Step lOb: Prep of 3-isopropoxybenzylalcohol
-87-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
OH
H3C'T'0
CH3
To a 1 molar solution of 3-isopropoxy benzaldehyde (102g, 0.621 moles) in
methanol (620 mL) cooled to
zero degrees was added (slowly) sodium borohydride powder (25.8g, 0.683 moles)-
dissolved in a
minimum of methylene chloride and passed through a plug of silica gel washing
with more methylene
chloride until the silica gel was free of the product. The eluent was stripped
to an oil and pumped on high
vacuum overnight.
1H NMR (400 MHz, CDC13) 8 7.25 (m, 1H), 6.9 (bs, 2H), 6.8 (db, J= 8 Hz, 1H),
4.65 (d, J 8Hz, 2H),
4.55 (pentet, J= 6 Hz, 1H), 1.7 (m, 1H), 1.34 (d, J = 6 Hz, 6H).
LCMS ion fragment = appears as 367.2
Step l Oc: Prep of 3-isopropoxybenzylchloride with triphenylphosphine
OH Ph3P CI
H3C O H3CYo
CH I CCI4 ICH3
3
To a stirred solution of the 3-isopropoxybenzylalcohol (19.5g, 116 mmole) in
carbon tetrachloride was
added triphenylphosphine (32g, 122 mmoles) and the mixture was refluxed. The
crude reaction was pre-
loaded onto silica gel and chromatographed eluting with 10% EtOAc/ hexanes to
give the product.
1H NMR (400 MHz, CDC13) 8 7.25 (m, 1H), 6.95 (m, 2H), 6.82 (m, 1H), 4.57 (m,
1H), 4.54 (s, 2H),
1.33 (d, J= 6 Hz, 6H).
(LCMS ion fragment = appears as 190.1).
EXAMPLE 12
(5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-2-oxo-8-(3-
thienylmethyl)-1,3-diaza-8-
azoniaspiro[4.5]dec-3-ene trifluoroacetate and (5S,7R)-4-(cyclohexylamino)-1-
(3-fluorophenyl)-7-
-88-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
methyl-2-oxo-8-(3-thienylmethyl)-1,3-diaza-8-azoniaspiro[4.5]dec-3-ene
trifluoroacetate
0
N
NN
H
N+
O
F
O'
F
S
F
N
O O
-~
N H
N ~/ N F
j~ F 3-ThiophenecarboxYaldehYde
H (CH3COO)3BHNa, AcOH
N+
N O
H ~ I F
11-9 0_
racemic S F
Step 1: (5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-2-oxo-8-(3-
thienylmethyl)-1,3-diaza-
8-azoniaspiro[4.5]dec-3-ene trifluoroacetate and (5S,7R)-4-(cyclohexylamino)-1-
(3-fluorophenyl)-7-
methyl-2-oxo-8-(3-thienylmethyl)-1,3-diaza-8-azoniaspiro[4.5]dec-3-ene
trifluoroacetate
To a stirred solution of (5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-
methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one and (5S,7R)-4-(cyclohexylamino)-1-(3-
fluorophenyl)-7-methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one (prepared as described for Intermediate 11-9
starting with racemic
piperidinone 11-3, 50.0 mg, 0.134 mmol), 3-thiophene-carboxaldehyde (0.05 g,
0.42 mmol), and acetic
acid (0.01 mL, 0.17 nunol) in 1 niL DCE was added sodium triacetoxyborohydride
(90.0 mg, 0.42
mmol). The reaction mixture was stirred at ambient temperature for 16 h,
washed with saturated sodium
bicarbonate, water, and brine. The reaction solution was dried with Na2SO4i
and concentrated in vaccuo.
The crude compound was purified on a Gilson reverse phase preparatory column,
to give the desired
product.
LRMS (M+1) = 455.16
-89-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
'H NMR (CD3OD) S 7.50-7.48 (m, 2H), 7.36-7.34 (m, 1H), 7.19-7.13 (m, 3H), 6.96-
6.94 (d, 1H), 4.45-
4.41 (d, 1H), 4.29-4.25 (d, 1H), 3.74-3.72 (m, 1H), 3.44-3.41 (m, 1H), 2.85-
2.51 (m, 6H), 2.03-2.00 (d,
2H), 1.89-1.85 (d, 2H), 1.72-1.68 (d, 1H), 1.59-1.26 (m, 8H).
The compounds in Table 2 were prepared by alkylated intermediate 11-9 or
racemic 11-9
(prepared as described for Intermediate 11-9 starting with racemic
piperidinone 11-3), with the
appropriate commercially available halide in a manner similar to that
described for Example 11, or, they
were prepared when intermediate 11-9 was reductively alkylated with the
appropriate commercially
available aldehyde as described for Example 12. The products were purified by
normal or reverse phase
chromatography to give the free bases or salts. In some cases the salts
isolated from chromatography
were converted to the free bases with an aqueous worlcup. They could then be
converted to different salts
by mixing the free base in an appropriate organic HCl solution, like ethereal
HCl, and evaporating to give
the product as the solid salt.
Table 2
1 ?~~ Structttre ChernicalriarrleIVIa -q s
Spec (M+H)
13 (5R,7S)-4-(cyclohexylamino)-8-(2- 467.2
0 fluorobenzyl)-1-(3-fluorophenyl)-7-methyl-
N
H ~ N ~ 1,3,8-triazaspiro[4.5]dec-3-en-2-one and
~ / (5S,7R)-4-(cyclohexylamino)-8-(2-
N F fluorobenzyl)-1-(3-fluorophenyl)-7-methyl-
1,3,8-triazaspiro[4.5]dec-3-en-2-one
F
14 (5R,7S)-4-(cyclohexylamino)-1-(3- 514.3
N--f 0 fluorophenyl)-7-methyl-2-oxo-8-[3-(1H-
H b'-:-_, ~ pyrrol-1-yl)benzyl]-1,3-diaza-8-
~ / azoniaspiro[4.5]dec-3-ene trifluoro acetate
O\N N F and (5S,7R)-4-(cyclohexyl amino)-1-(3-fluorophenyl)-7-methyl-2-oxo-8-
[3-(1H-
ol-1-Y1)benzY1]-1,3-diaza-8-
pYrr
azonias iro[4.5]dec-3-ene trifluoroacetate
-90-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Ex Structure Chemical name Mass
Spec
(M+H)
15 (5R,7S)-4-(cyclohexylamino)-1-(3- 517.2
~ fluorophenyl)-7-methyl-2-oxo-8-[3-
H ~ N ~ (trifluoromethyl)benzyl]-1,3-diaza-8-
~ / azoniaspiro[4.5]dec-3-ene trifluoro acetate
F F N F and (5S,7R)-4-(cyclohexyl amino)-1-(3-
F fluorophenyl)-7-methyl-2-oxo-8-[3-
~ (trifluoromethyl)benzyl]-1,3-diaza-8-
azonias iro 4.5 dec-3-ene trifluoroacetate
16 (5R,7S)-8-(3-tert-butoxybenzyl)-4- 521.3
(cyclohexylamino)-1-(3-fluorophenyl)-7-
H N ~ methyl-1,3,8-triazaspiro[4.5]dec-3-en-2-one
and (5S,7R)-8-(3-tert-butoxybenzyl)-4-
N F (cyclohexylamino)-1-(3-fluorophenyl)-7-
0 methyl-1,3,8-triazaspiro[4.5]dec-3-en-2-one
17 0 (5R,7S)-4-(cyclohexylamino)-8-[(2E)-3,7- 495.1
F dimethylocta-2,6-dien-1-yl]-1-(3-
J~ N
=.
H
fluorophenyl)-7-methyl-1,3,8-
N triazaspiro[4.5]dec-3-en-2-one
18 (5R,7S)- 4-(cyclohexylamino)-1-(3- 427.6
fluorophenyl)-7-methyl-8-(3 -methylbut-2-
en-l-yl)-2-oxo-1,3-diaza-8-
HN azoniaspiro[4.5]dec-3-ene trifluoroacetate
>= p and (5S,7R)- 4-(cyclohexylamino)-1-(3-
N fluorophenyl)-7-methyl-8-(3-methylbut-2-
N en-1-yl)-2-oxo-1,3-diaza-8-
~ azoniaspiro[4.5]dec-3-ene trifluoroacetate
F
-91-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Ex Structure Chemical nanle Mass
Spec
(M+H)
19 (5R,7,S)-4-(cyclohexylamino)-1-(3- 455.1
N o fluorophenyl)-7-methyl-2-oxo-8-(3-
N ~ ~ thienylmethyl)-1,3-diaza-8-
H
1 ~ azoniaspiro[4.5]dec-3-ene trifluoroacetate
N and (5S,7R)-4-(cyclohexylamino)-1-(3-
~ fluorophenyl)-7-methyl-2-oxo-8-(3-
S thienylmethyl)-1,3-diaza-8-
azonias iro[4.5 dec-3-ene trifluoroacetate
20 0 (5R,7S)-4-(cyclohexylammonio)-1-(3- 445.0
N--~ F fluorophenyl)-7-methyl-2-oxo-8-
NN [(trimethylsilyl)methyl]-1,3-diaza-8-
H 1 ~
azoniaspiro[4.5]dec-3-ene dichloride
N
jSiJ
21 0 (5R,7S)-4-(cyclohexylammonio)-1-(3- 459.0
Q N~ F fluorophenyl)-7-methyl-2-oxo-8-[2-
Nn N (trimethylsilyl)ethyl]-1,3-diaza-8-
azoniaspiro[4.5]dec-3-ene dichloride
H 1 ~
N
~
The compounds in Table 3 were prepared by alkylating intermediate 11-9 or
racemic 11-
9 (prepared as described for Intermediate 11-9 starting with racemic
piperidinone 11-3), with the
appropriate custom-made halide in a manner similar to that described for
Example 11, or, they were
prepared when intermediate 11-9 or racemic 11-9 was reductively alkylated with
the appropriate custom-
made aldehyde as described for Example 12. The products were purified by
normal or reverse phase
chromatography to give the free bases or salts. In some cases the salts
isolated from chromatography
were converted to the free bases with an aqueous workup. They could then be
converted to different salts
-92-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
by mixing the free base in an appropriate organic acid solution, lilce
ethereal HCI, and evaporating to give
the product as the solid salt.
Table 3
Ex Tntermediate Stnicture Chemical name Mass Spec
(M+H)
22 XII (5R,7S')-4-(cyclohexylamino)-8- 533.7
F [3 -(1-cyclopropylethoxy)benzyl]-
H N 1-(3-fluorophenyl)-7-methyl-
'NJ =,, 1,3,8-triazaspiro[4.5]dec-3-en-2-
I~Iy
~ one
Ie
23 III 0 (5R,7S)-4-(cyclohexylamino)- 1 - 521.2
F (3-fluorophenyl)-7-methyl-8-(3-
N" N ~ / fL(1R -1-
H
< methylpropyl]oxy}benzyl)-1,3,8-
N ='' ,
0 triazaspiro[4.5]dec-3-en-2-one
\
/
24 IV 0 (5R,7S)-4-(cyclohexylamino)-8- 539.3
N4 _ F (2-fluoro-5-{[(1R)-1-
~NJ' ~/ methY1propY1]oxY}benzY1)-1-(3-
fluorophenyl)-7-methyl-1,3,8-
N
o triazaspiro[4.5]dec-3-en-2-one
F
25 V 0 (5R,7S)-4-(cyclohexylamino)-8- 503.3
~4 _ F [3-(cyclopropylmethyl)benzyl]-1-
N" ~\
H (3-fluorophenY1)-7-methY1-1>3>8-
N triazaspiro[4.5]dec-3-en-2-one
-93-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Ex Intermediate Structure Chemical name Mass Spec
(M+H)
26 VI O (5R,7S)-4-(cyclohexylamino)-1- 441.0
(3-fluorophenyl)-7-methyl-8-
H N~ [(2E)-3-methylpent-2-en-l-yl]-
, 1,3,8-triazaspiro[4.5]dec-3-en-2-
N one
i27 XIII (5R,7S)-4-(cyclohexylamino)-8- 505.2
N- f 0 [3-(cyclopropyloxy)benzyl]-1-(3-
N N F fluorophenyl)-7-methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one
N and (5,S,7R)-4-(cyclohexylamino)-
O
~ 8-[3-(cyclopropyloxy)benzyl]-1-
(3-fluorophenyl)-7-methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one
28 VII (5R,7S)-4-(cyclohexylamino)-8- 517.1
Qo {3-[(1S)-1-
HJ., N I~ F cyclopropylethyl]benzyl}-1-(3-
fluorophenyl)-7-methyl-2-oxo-
C.
N ~~.
1,3-diaza-8-azoniaspiro[4.5]dec-
( 3-ene chloride and
(5R,7S)-4-(cyclohexylamino)-8-
Q /O {3-[(1R)-1-
NN N F cyclopropylethyl]benzyl}-1-(3-
H fluorophenyl)-7-methyl-2-oxo-
~
N 1,3-diaza-8-azoniaspiro[4.5]dec-
I 3-ene chloride
-94-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Ex Intermediate Strticture Chemical name Mass Spec
M.+1=I)
29 VIII (5R,7S)-8-(cyclohex-l-en-1- 453.3
N 0 ylmethyl)-4-(cyclohexylamino)-1-
H -fluorophenyl)-7-methyl-1,3,8-
N ~ N .~ F (3
~ / triazaspiro[4.5]dec-3-en-2-one
N and (5S,7R)-8-(cyclohex-l-en-1-
ylmethyl)-4- (cyc lohexylamino)-1-
(3-fluorophenyl)-7-methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one
30 IX (5R,78)-4-(cyclohexylamino)-8- 439.1
N (cYclopent-l-en-1-YlmethY1)-1-(3
~ -
H fluorophenyl)-7-methyl-2-oxo-
~ / 1,3-diaza-8-azoniaspiro[4.5]dec-
N 3-ene trifluoroacetate and
~ (5 S,7R)-4-(cyclohexylamino)-8-
(cyclopent-l-en-1-ylmethyl)-1-(3-
fluorophenyl)-7-methyl-2-oxo-
1,3-diaza-8-azoniaspiro[4.5]dec-
3-ene trifluoroacetate
31 X (5R,7S)-4-(cyclohexylamino)-1- 530.10
N 3-fluorophenY1)-8-[(1-sopropY1-
~ (i
H J N ~ F 1H-indol-6-yl)methyl]-7methyl-
~ / 1,3,8-triazaspiro[4.5]dec-3-en-2-
N one and (5S,7R)-4-
N (cyclohexylamino)-1-(3-
~ / fluorophenyl)-8-[(1-isopropyl-
1FI-indol-6-yl)methyl]-7-methyl-
1,3,8-triazaspiro[4.5]dec-3-en-2-
one
- 95 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Ex Intermediate Structure Chemical name Mass Spec
(M+H)
32 XI (5R,7S)-4-(cyclohexylamino)-1- 453.24
(3-fluorophenY1)-7-methY1-8-[(2-
~
HJ' N methylcyclopent-l-en-l-
I ~ yl)methyl]-1,3,8-
~=,
triazaspiro[4.5]dec-3-en-2-one
The compounds in Table 4 were prepared in a manner similar to that described
for
Example 11. Intermediate 11-6 or racemic 11-6 (prepared as described for
Intermediate 11-6 starting
with racemic piperidinone 11-3), was treated with the appropriate amine in a
manner similar to that
described for Intermediate 11-8. The amine or amine salt was heated with the
resulting iminohydantoin
neat or with an appropriate base like N-methylmorpholine as the base/cosolvent
and in some instances an
additional appropriate solvent like toluene was used. The protecting group was
then removed as
described for Intermediate 11-9 and the piperidine nitrogen was treated in one
of several ways. The
piperidine nitrogen was alkylated with the appropriate alkylating agent,
either commericially available or
prepared as described herein, or acylated with an appropriate acid to form the
amide, then reduced as
described for Example 47, or reductively aminated as described for Example 12
to give material that was
purified either by normal or reverse phase chromatography to give the free
bases or salts. In some cases
the compounds were further purified using chiral HPLC to give the final
compounds. In some cases the
salts isolated from chromatography were converted to the free bases with an
aqueous workup. They could
then be converted to different salts by mixing the free base in an appropriate
organic acid solution, like
ethereal HCl, and evaporating to give the product as the solid salt.
-96-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Table 4
Ex # Inteimediate Structure Chemical name Mass
Spec
(M+H)
33 III (5R,7S)-4-[(1R,4R)- 533.1
0 bicyclo[2.2.1]hept-2-ylamino]-
H NJN ' I~F 1-(3-fluorophenyl)-7-methyl-8- H (3-{[(1R)-1-
N methylpropyl]oxy}benzyl)-
O 1,3,8-triazaspiro[4.5]dec-3-en-
~ ( , 2-one and (5R,7S)-4-[(1S,4S')-
H bicyclo[2.2.1]hept-2-ylamino]-
0 1-(3-fluorophenyl)-7-methyl-8-
H, N N F (3-{[(1R)-1-
H methylpropyl]oxy}benzyl)-
N 1,3,8-triazaspiro[4.5]dec-3-en-
40 2-one
34 XVII 0 (5R,7S)-4-(cyclobutylamino)- 491.1
qN N F 1-(3-fluorophenyl)-7-methyl-8-
H (3-{[(1S,2R)-2-
N ~-, methYlcYclopropY1]oxY}benzY1
)-2-oxo-1,3-diaza-8-
azoniaspiro[4.5]dec-3-ene
o chloride and
'kNJNN F (5R,7S)-4-(cyclobutylamino)-1-
H n 141-1 (3-fluorophenyl)-7-methyl-8-
N (3-{[(1R,28)-2-
~,,= ,o
methylcyclopropyl]oxy}benzyl
)-2-oxo-1,3-diaza-8-
azoniaspiro[4.5]dec-3-ene
chloride
-97-
CA 02615656 2008-01-16
WO 2007/011833
PCT/US2006/027594
Ex # Intermediate Structure Chemical name Mass
Spec
(M+14)
35 XXIII 0 (5R,7S)-8- 459.0
PN- F (cyclopentylmethyl)-1V-
r
F N N [(1S,2S)-2-fluorocyclohexyl]-l-
~ (3 fluorophenyl) 7-methyl-2-
N oxo-1,3,8-triazaspiro[4.5]dec-
3-en-4-aminium chloride and
C (5R,7S)-8-(cyclopentylmethyl)-
Q N-~/ F N-[(1R,2R)-2-
1
F N N fluorocyclohexyl]-1-(3- H fluorophenyl)-7-methyl-2-oxo-
N ==''s
1,3,8-triazaspiro[4.5]dec-3-en-
4-aminium chloride
36 Commercially (5R,7S)-4-(cyclopentylamino)- 530.1
available 1-(3-fluorophenyl)-8-(3-
HN ,,~_N isopropoxybenzyl)-7-methyl-2-
i No oxo-1,3-diaza-8-
N azoniaspiro[4.5]dec-3-ene
1 \
chloride
F
37 XVIl7 0 (5R,7S)-8-benzyl-l-(3- 475.6
N--~ F fluorophenyl)-7-methyl-4-
N~' N ~.
(spiro[2.5]oct-6-ylamino)-
1,3,8-triazaspiro[4.5]dec-3-en-
N ==,
2-one
-98-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Ex # Intermediate Structure Chem.ical name Mass
Spec
+H
38 YIX (5R,7S)-1-(3-fluorophenyl)-8- 596.8
N 0 F (3-isopropoxybenzyl)-7-
H methyl-2-oxo-N-[(5S,6R)-6-
~ phenylspiro[2.4]hept-5-yl]-
\ 1,3,8-triazaspiro[4.5]dec-3-en-
~ 4-aminium chloride and
(5R,7S')-1-(3-fluorophenyl)-8-
(3-isopropoxybenzyl)-7-
! methyl-2-oxo-N-[(5R,6S)-6-
N ~F phenylspiro[2.4]hept-5-yl]-
H 1,3,8-triazaspiro[4.5]dec-3-en-
N 4-aminium chloride
o\
39 XXI F F (5R,7S)-4-[(4,4- 544.6
difluoro cyclohexyl) amino] -1-
(3-fluorophenyl)-8-(3-
HN,rNX= isopropoxybenzyl)-7-methyl-2-
~ oxo-1,3-diaza-8-
N
azoniaspiro[4.5]dec-3-ene
chloride
F
40 XXI F F (5R,7S)-8-benzyl-4-[(4,4- 486.6
difluorocyclohexyl)amino]-1-
( 3 -fluorophenyl)-7 -methyl-2-
oxo-1,3-diaza-8-
HN~,N>=o azoniaspiro[4.5]dec-3-ene
chloride and (5S,7R)-8-benzyl-
'D--N
4-[(4,4-
~ ~1
~ difluorocyclohexyl)arnino]-1-
F (3-fluorophenyl)-7-methyl-2-
-99-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Ex # In.termediate Structure Chemical name Mass
Spec
(M+H)
oxo-1,3-diaza-8-
azoniaspiro[4.5]dec-3-ene
chloride
41 XX O (5R,7S)-8-(cyclobutylmethyl)- 457.1
"Sa N--~ F 4-{[(3R)-1,1-dimethylsilolan-3-
~jN yl]anunonio}-1-(3-
H
fluorophenyl)-7-methyl-2-oxo-
N 1,3-diaza-8-
azoniaspiro[4.5]dec-3-ene
dichloride and
N~0 F (5R,7S)-8-(cyclobutylmethyl)-
~
N ! nJ 4-{[(3S)-1,1-dimethylsilolan-3-
H 1 / yl]ammonio}-1-(3-
N fluorophenyl)-7-methyl-2-oxo-
1,3-diaza-8-
azoniaspiro[4.5]dec-3-ene
dichloride
42 Commercially Me Me 0 (5R,7S)-N-[(1R)-1,2- 415
available N- F dimethylpropyl]-1-(3-
Me 'HJ'/.. N 1 ~ fluorophenyl)-7-methyl-8-(3-
methylbut-2-en-l-yl)-2-oxo-
M "'Me 1,3,8-triazaspiro[4.5]dec-3-en-
Me zz~ 4-aminium trifluoroacetate and
Me Me 0 (5R,7~S)-N-[(1S)-1,2-
x ~ ~ F dimethylpropyl]-1-(3-
Me H
Me N ~'Me fluorophenyl)-7-methyl-8-(3-
methylbut-2-en-1-yl)-2-oxo-
~ 1,3,8-triazaspiro[4.5]dec-3-en-
Me 4-aminium trifluoroacetate
EXAMPLE 43
-100-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
(5R,7S)-8-(cyclobutylmethyl)-4- {[(1R,2R)-2-fluorocyclohexyl]ammonio} -1 -(3-
fluorophenyl)-7-methyl-2-
oxo-1,3-diaza-8-azoniaspiro[4.5]dec-3-ene dichloride and (5R,7S)-8-
(cyclobutylmethyl)-4-{[(1S,2S')-2-
fluorocyclohexyl]ammonio}-1-(3-fluorophenyl)-7-methyl-2-oxo-1,3-diaza-8-
azoniaspiro[4.5]dec-3-ene
dichloride
4 F ~ F
NHJ'I' 2NHJN/
F
N N
I? /:?
Step 1: Benzyl (5R,7S)-4-{[(1R,2R)-2-fluorocyclohexyl]amino}-1-(3-
fluorophenyl)-7-methyl-2-oxo-
1,3,8-triazaspiro[4.5]dec-3-en-8-carboxylate and benzyl (5R,7S)-4-{[(1S,2S)-2-
fluorocyclohexyl]amino} - 1 -(3 -fluorophenyl)-7-methyl-2-oxo- 1,3,8-
triazaspiro[4.5] dec-3-
en-8-carboxylate
N--~O F N-/O F
N
HJ N and F H
N N
O-~-O
~
A solution containing 1.60 g (3.90 mmol) of benzyl (5R,7S)-1-(3-fluorophenyl)-
4-imino-7-methyl-2-oxo-
1,3,8-triazaspiro[4.5]decane-8-carboxylate (Intermediate 11-6) in 6 mL of N-
methylmorpholine was
treated with 3.09 g (15.6 mmol) of trans-2-fluorocyclohexanaminium bromide
(Intermediate XXIII) and
the resulting mixture was heated to 120 deg C for 48 h in a sealed tube. The
reaction was cooled,
quenched with 25 mL of 1N HCl and extracted three times with 100 mL of a 9:1
mixture of DCM and
MeOH. The combined organic extracts were washed with 50 niL of 1N HC1 and 50
mL of brine. The
organic phase was dried over MgSO4, filtered and concentrated. Column
chromatography (90:10:1)
DCM / MeOH / TEA afforded the desired compound as a sticky tan solid.
LCMS (M+H) = 511.4
Step 2: (5R,7S)-4-{[(1R,2R)-2-fluorocyclohexyl]amino}-1-(3-fluorophenyl)-7-
methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one and (5R,7S)-4-{[(1 S,2S)-2-
fluorocyclohexyl]amino}-1-
(3-fluorophenyl)-7-methyl-1,3,8-triazaspiro [4.5]dec-3-en-2-one
-101-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
N ~ J,e N ~
QNJF
H ~/ and F H ~/
N N
H H
Benzyl (5R,7S)-4-{[(1R,2R)-2-fluorocyclohexyl]amino}-1-(3-fluorophenyl)-7-
methyl-2-oxo-1,3,8-
triazaspiro[4.5]dec-3-en-8-carboxylate and benzyl (5R,7S)-4-{[(1S,2S)-2-
fluorocyclohexyl]amino}-1-(3-
fluorophenyl)-7-methyl-2-oxo-1,3,8-triazaspiro[4.5]dec-3-en-8-carboxylate (450
mg, 0.88 mmol) was
dissolved in 250 mL of MeOH. The solution was degassed and 619 mg of 20%
Pd(OH)2 was added.
The reaction was flushed with hydrogen and kept under a hydrogen balloon at
room temperature for 2 h.
The flask was evacuated of hydrogen and filtered through Celite. Evaporation
of the solvent afforded the
desired product as a white solid.
LCMS (M+H) = 377.3
Step 3: (5R,7S)-8-(cyclobutylmethyl)-4-{[(1R,2R)-2-fluorocyclohexyl]amino}-1-
(3-fluorophenyl)-7-
methyl-1, 3, 8-tri azaspiro [4.5 ] dec-3 -en-2-one
F
N~ Qo
N ~
H
To a solution containing 55 mg (0.15 mmol) of (5R,7S)-4-{[(1R,2R)-2-
fluorocyclohexyl]amino}-1-(3-
fluorophenyl)-7-methyl-1,3,8-triazaspiro[4.5]dec-3-en-2-one and (5R,7S)-4-
{[(1S,2S)-2-
fluorocyclohexyl]amino}-1-(3-fluorophenyl)-7-methyl-1,3,8-triazaspiro[4.5]dec-
3-en-2-one in DMF (1.5
mL) was added powdered K2C03 (81 mg, 0.58 mmol) and bromomethylcyclobutane (22
mg (0.15 mmol).
The solution was heated to 60 C overnight. The reaction was diluted with
water (1.5 mL) and extracted
three times with EtOAc. The combined organics were dried over MgSO4, filtered
and concentrated then
chromatographed using 100% EtOAc to give the desired product which was further
purified on a Waters
automated system affixed with a Chiralpak AD 5 cm x 50 cm cartridge eluting at
80 mL/min with
isocratic 20% ethyl alcohol in hexanes with no modifier. The second peak was
the product.. The salt
could be formed as described for the examples in table 5.
-102-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
1H NMR (400 MHz, CDC13) S 9.34 (d, J = 7.2 Hz, 1H), 7.35 (m, 1H), 7.04 (m,
3H), 4.42 (ddd, J = 4.8,
10.4, 50 Hz, 1H), 4.03 (m, 1H), 2.99 (m, 1H), 2.84 (dd, J=7.5, 12.6 Hz, 1H),
2.54 (m, 2H), 2.23 (m, 4H),
2.1 (m, 4H), 1.9-1.6 (m, 8H), 1.4-1.2 (m, 4H), 1.11 (d, J= 6.3 Hz, 3H).
LCMS (M+H) = 445.4
Step 4: (5R,7S)-8-(cyclobutylmethyl)-4-{[(1S,2S)-2-fluorocyclohexyl]amino}-1-
(3-fluorophenyl)-7-
methyl-1, 3, 8-tri aza spiro [4.5 ] dec-3 -en-2-one
Q
N--~ F
N-J,l N ~
~-,
F H ~ o
N (5R,7S)-8-(cyclobutylmethyl)-4-{[(1S,2S)-2-fluorocyclohexyl]amino} - 1 -(3 -
fluorophenyl)-7-methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one could also be isolated as the first peak from
the above chromatography
and its salt (5R,7S)-8-(cyclobutylmethyl)-4-{[(1S,2S)-2-
fluorocyclohexyl]ammonio}-1-(3-fluorophenyl)-
7-methyl-2-oxo-1,3-diaza-8-azoniaspiro[4.5]dec-3-ene dichloride could be
prepared as described for the
examples in table 5.
LCMS (M+H) = 445.08
The compounds in Table 5 were prepared in a manner similar to that described
for
Example 11. Intermediate 11-3S underwent the Strecker reaction with the
appropriate aniline. The
resulting Strecker product was taken through the cyclization and
iminohydantoin displacement reactions
as described for Example 11. The protecting group was then removed as
described for Example 11 and
the piperidine nitrogen was treated in one of several ways. The piperidine
nitrogen was alkylated with the
appropriate alkylating agent, either commercially available or prepared as
described herein, or acylated
with an appropriate acid to form the amide, then reduced as described for
Example 47, or reductively
aminated as described for Example 12 to give material that was purified either
by normal or reverse
phase chromatography to give the free bases or salts. In some cases the
compounds were further purified
using chiral HPLC to give the final compounds. In some cases the salts
isolated from chromatography
were converted to the free bases with an aqueous workup. They could then be
converted to different salts
by mixing the free base in an appropriate organic acid solution, like ethereal
HCl, and evaporating to give
the product as the solid salt.
-103-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Table 5
Ex # Aniline Structure Chemical name Mass
Spec
(M+H)
44 3-Chloro 0 (5R,7S')-1-(3-chlorophenyl)-8- 443.2
Q N-~ CI (cyclobutylmethyl)-1V-
NJ''.
H 1 / cyclohexyl-7-methyl-2-oxo-
1,3,8-triazaspiro[4.5]dec-3-en-
N 4-aminium chloride
45 3-Bromo 0 (5R,7S)-1-(3-bromophenyl)-8- 487.1
Q N~ Br (cyclobutylmethyl) N-
N~'= N ~
H 1 ~ cyclohexyl-7-methyl-2-oxo-
1,3,8-triazaspiro[4.5]dec-3-en-
N
4-aminium chloride
EXAMPLE 46
(5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-7-methyl-
1,3, 8-
triazaspiro[4,5]dec-3-ene-2-thione and (5S,7R)-4-(cyclohexylamino)-1-(3-
fluorophenyl)-8-(3-
isopropoxybenzyl)-7-methyl-1,3, 8-triazaspiro [4,5] dec-3 -ene-2-thione
s F
a N-\
NJN
j... 6
H
Y N
O &
3-Fluoroaniline hydrochloride (4.80g, 0.033 moles) was added slowly to a
suspension of 1-(3-
isopropylbenzyl)-2- methylpiperidin-4-one (Intermediate II, 8. l Og, 0.031
moles), cyclohexyl isocyanide
(3.62 g, 4.11 mL, 0.033 moles), and potassium thiocyanate (3.16g, 0.033 moles)
in methanol (500 mL) at
0 C. The reaction was warmed to rt and additional methanol was added to
completely dissolve the
-104-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
starting materials. The reaction was heated to 70 C and monitored via LCMS for
16 hrs. The reaction
was concentrated to give the desired product as a crude oil. The material was
purified on silica with 0-
50% EtOAc (+1.5% MeOH containing 0.1% NH4OH) in hexanes. The cis isomer eluted
first, followed
by the desired trans isomer second.
1H NMR (400 MHz, CDC13) 8 8.1 (d, J = 8.1 Hz, 1H), 7.41 (dd, J = 8.1, 6.3 Hz,
1H) 7.25 (m, 1H), 7.12
(dt, J = 1.8, 8.3 Hz, 1H) 6.96 (d, J= 7.9 Hz, 1H), 6.90 (bd, 1H), 6.84 (bd,
1H), 6.77 (m, 2H), 6.56 (pentet,
J= 6.1 Hz, 1H), 4.15 (m, 1H), 4.10 (d, J= 12.8 Hz, 1H), 2.90 (d, J= 12.8 Hz,
1H), 2.83 (m, 1H), 2.53 (m,
1H), 2.18 (d, J = 7.5, 14.2 Hz, 1H), 2.10 (m, 2H), 2.0 (m, 1H), 1.9 (m, 2H),
1.8 (bd, 1H), 1.75-1.6 (m,
5H), 1.4 (m, 1H), 1.33 (d, J = 6 Hz, 6H), 1.27 (d, J = 6.3 Hz, 3H), 1.20 (m,
1H), 1.05 (m, 1H) ppm.
LCMS = 523.5 (m+l)
In an alternative preparation the piperidinone is dissolved in 10 volumes of
10% water/methanol and
treated with the isonitrile, thiocyanate and aniline. The solution is heated
to 60 C and a solution of 1
equivalent benzenesulfonic acid in methanol is added via syringe pump over 2-3
hrs.
EXAMPLE 47
Alternative synthesis of (5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3-
isopropoxybenzyl)-7-
methyl-1,3,8-triazaspiro[4.5]dec-3-en-2-one dihydrochloride (Example 11 HCl
salt)
-
~ F 1) thionyl chloride, aWjj"' ~ ~ F
termediate NN \/ methylene chloride N N
ii
NJ2) methanol 3-fluoroaniline HCI H 3) acetic acid, methanol H
cyclohexyl isocyanide 4) HCI
potassium thiocyanate ~ N ~ N =,,
methanol
.2HCI
Example 47
Example 46
(5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-7-methyl-
1,3,8-
triazaspiro[4.5]dec-3-en-2-one dihydrochloride
-105-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
O F
N--<
N J1,,,.. N b
H
Y N 111 ,
0 I ~ * 2HCI
/
Thionyl chloride (16 mL, 0.22 moles) was added to a solution of 4-
(cyclohexylamino)- 1 -(3 -
fluorophenyl)-8-(3-isopropoxybenzyl)-7-methyl-1,3,8-triazaspiro[4,5]dec-3-ene-
2-thione (Example 46)
(7.9g, 0.015 mole) in chloroform (100 mL). The reaction was heated to reflux
for lh (at which time an
aliquot quenched into MeOH showed no starting material remaining) and then
carefully evaporated. The
resulting oil was dissolved in -100mL CHC13, placed in an ice-cooled jacketed
addition funnel and added
dropwise to 250 mL of cold (0 deg C) MeOH. The temperature throughout the
addition was maintained
<10 C. The reaction was stirred for lhr at 0 C at which time LCMS showed no
sm or chloride
remaining. The reaction was then evaporated to give a brown foam. The foam was
dissolved in MeOH
(-200 mL) and treated with glacial acetic acid (50 mL), and the reaction was
heated to 40 C. Most of the
starting material was gone after a short period of time. LCMS after 1 hr of
heating showed - 5 % sm or
other impurity remaining. The reaction was evaporated. The small amount of
remaining starting material
was consumed upon evaporation. A small portion of the crude material was
extracted from
CHC13/aqueous bicarbonate, the organic was dried over Na2SO4 and evaporated to
give neutral racemic
product for characterization.
11I NMR (400 MHz, CDC13) S 8.35 (d, J = 7.5 Hz, 1H), 7.33 (dd, J= 8.1, 14.6
Hz, 1H), 7.24 (m, 1H),
7.0 (m, 3H), 6.8 (m, 3H), 4.55 ( pentet, J = 6 Hz, 1H), 4.10 (d, J = 12.8 Hz,
1H), 3.96 (m, 1H), 2.93 (d, J
= 12.5 Hz, 1H), 2.82 (m, 1H), 2.55 (m, 1H), 2.24 (dd, J = 7.1, 14.4 Hz, 1H),
2.1 (m, 3H), 1.95-1.6 (m,
7H), 1.4 (m, 1H), 1.34 (d, J= 6 Hz, 6H), 1.28 (d, J= 6.2 Hz, 3H), 1.35-1.2 (m,
1H),1.2 (m, 1H), 1.1 (m,
1H).
LCMS ion fragment = 507.11
The remaining crude was chromatographed (Biotage Flash, 0-100% EtOAc followed
by 5% (2 M
NH3/MeOH)/CHC13). Fractions containing the desired product were isolated, then
the material was
resolved using a Chiralpak AD 10x50 cm column eluted with 20/80 IPA/hexane
until the first peak
(desired) eluted, then with 50:50 IPA/Hexane to flush off the second undesired
isomer. The desired
material was dissolved in high quality acetonitrile, cooled to 0 C and 2.0
equivalents of HCl in diethyl
ether were added. The solution was then reduced to a powdery solid on the
rotovap. The residue is
suspended in acetonitrile and evaporated two times to give the desired bis-
salt.
- 106 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
1H NMR (400 MHz, CDC13) S 8.35 10.9 (bs, 1H), 10.83 (bd, J = 8.2 Hz, 1H), 7.5
(m, 1H), 7.43 (m, 1H),
7.3 (bd, J = 8.6 Hz, 1H), 7.23 (m, 1H), 7.18 (m, 1H), 6.88 (m, 3H), 4.59
(pentet, J= 6 Hz, 1H), 4.5 (bd, J
= 14.5 Hz, 1H), 4.4 (m, 1H), 3.70 (m, 1H), 3.48 (m, 1H),3.8-3.65 (m, 2H), 3.05
(m, 1H), 2.92 (bd, J= 15
Hz, 1H), 2.67 (bd, J = 14.8 Hz, 1H), 2.25 (m, 1H), 2.1-2.0 (m, 3H), 1.7 (m,
2H), 1.64 (d, J= 6 Hz, 3H),
1.6-1.4 (m, 5H), 1.33 (d, J = 6 Hz, 3H), 1.31 (d, J= 6.2 Hz, 3H), 1.29 (m,
1H), 1.18 (m, 1H) ppm.
EXAMPLE 48
8- { [(5R, 7,S)-4-(cyclohexylamino)-1-(3 -fluorophenyl)-7-methyl-2-oxo-1, 3 -
diaza-8-azoniaspiro [4.5 ] dec-3 -
en-8-yl]methyl} -2,2-dimethyl-1,2-dihydroquinolinium dichloride
Q O
N
H~N F
NH N
O
O N
N-// ' N F
N N F BOP, DIPEA, DMF H
NH N
N H NH OH
o O
vI
11-9 11-9A
LiAIH4
THF
~O
H~~N~ F
NH
Example 48
Step 1: methyl 2-[(1,1-dimethylprop-2-yn-1-yl)amino]benzoate
- 107 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
To a solution of methyl anthranilate (5.54 g, 36.6 mmol), triethylamine (3.48
g, 34.5 mmol), cuprous
chloride (0.21 g, 2.15 mmol), copper powder (0.163 g, 2.56 mmol) in HZO (4 mL)
and THF (14 mL) was
added 3-chloro-3-methyl-1-butyne (2.21 g, 21.6 mmol). After heating to 65 C
for 4 h the reaction was
cooled, diluted with water and extracted using diethyl ether (three times).
The combined organic layers
were washed with water, dried using MgSO4 and concentrated under vacuum.
Purification by silica gel
chromatography (5% EtOAc/hexanes - 10% EtOAc/hexanes) afforded the desired
product.
LRMS (M+1) = 218.2
Step 2: methy12,2-dimethyl-1,2-dihydroquinoline-8-carboxylate
To a solution of inethyl2-[(1,1-dimethylprop-2-yn-1-yl)amino]benzoate (1.5 g,
6.90 mmol) in toluene (30
mL) was added cuprous chloride (0.683 g, 6.90 mmol). After stirring at 100 C
overnight the reaction
was concentrated under vacuum. Purification by silica gel chromatography (5%
EtOAc/hexanes)
afforded the desired product.
Step 3: 2,2-dimethyl-1,2-dihydroquinoline-8-carboxylic acid
To a solution of methyl 2,2-dimethyl-1,2-dihydroquinoline-8-carboxylate (0.188
g, 0.865 mmol) in THF
(51nL) and H20 (5mL) was added a 1N aqueous solution of sodium hydroxide (3.46
mL, 3.46 mmol).
After stirring at 60 C overnight the reaction mixture was acidified to pH 2
using 1N aqueous HCI,
extracted with ethyl acetate (three times), dried over MgSO4 and concentrated
under vacuum to afford the
desired compound that was used without further purification.
'H NMR (CDC13) 8 7.73 (d, J= 8.2 Hz, 1H), 6.98 (d, J= 7.1 Hz, 1H), 6.46 (t, J=
7.6 Hz, 1H), 6.24 (d, J
= 9.7 Hz, 1H), 1.39 (s, 6H).
LRMS (M+1) = 204.0
Step 4: (5R,7S")-4-(cyclohexylamino)-8-[(2,2-dimethyl-1,2-dihydroquinolin-8-
yl)carbonyl]-1-(3-
fluorophenyl)-7-methyl-1, 3 , 8-triazaspiro [4.5 ] dec-3 -en-2-one
To a solution of 7-9 (0.309 g, 0.861 mmol) in DMF (10 mL) was added : 2,2-
dimethyl-1,2-
dihydroquinoline-8-carboxylic acid (0.175 g, 0.861 mmol), diisopropyethylamine
(0.334 g, 2.58 mmol)
and BOP reagent (0.381 g, 0.861 mmol). After stirring at 50 C overnight the
reaction mixture was
diluted with water and extracted using chloroform (three times). The combined
organic layer were dried
over MgSO4 and concentrated under vacuum. Purification by silica gel
chromatography (4%
methanol/chlorform/1% triethylamine) afforded the desired product.
LRMS (M+l) = 544.1
- 108 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Step 5: 8-{[(5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-2-oxo-1,3-
diaza-8-
azoniaspiro[4.5]dec-3-en-8-yl]methyl}-2,2-dimethyl-1,2-dihydroquinolinium
dichloride
To a solution of (5R,7S)-4-(cyclohexylamino)-8-[(2,2-dimethyl-1,2-
dihydroquinolin-8-yl)carbonyl]-1-(3-
fluorophenyl)-7-methyl-1,3,8-triazaspiro[4.5]dec-3-en-2-one (0.468 g, 0.861
mmol) in THF (20 mL) was
added lithium aluminum hydride (1.0 M in THF, 4.30 mL, 4.30 mmol). After
stirring at rt for 15 min the
reaction was quenched sequentially with H20 (2 mL), 1N NaOH (2 mL) and H20 (6
ml) and then
extracted with methylene chloride (three times). The organic layers were dried
over MgSO4 and
concentrated under vacuum. Puriflcation by reverse phase HPLC afforded the
desired compound. The
free base was obtained after aqueous worlcup with aqueous base and an organic
solvent like chloroform
and the HCl salt was prepare by mixing the free base with ethereal HCl and
evaporating to give the
product as a solid.
'H NMR (CDC13): 8 7.38 (d, J= 8.0 Hz, 1H), 7.09 (t, J= 8.3 Hz, 1H), 7.04 (d,
J= 7.9 Hz, 1H), 6.98 (d, J
= 9.5 Hz, 1H), 6.82 (d, J= 7.4 Hz, 1H), 6.73 (d, J= 7.4 Hz, 1H), 6.49 (t, J=
7.4 Hz, 1H), 6.27 (d, J= 8.0
Hz, 1H), 5.87 (d, J= 8.0 Hz, 1H), 5.21 (s, 1H), 4.05 (d, J= 12 Hz, 1H), 3.93
(m, 1H), 2.72 (m ,1H), 2.63
(d, J= 12 Hz, 1H), 2.86 (m, 1H), 2.17-1.11 (m, 15H), 1.35 (s, 3H), 1.29 (s,
3H), 1.21 (d, J= 6.0 Hz, 3H).
LRMS (M+1) = 530.1
Example 49 was prepared in a manner similar to that described for Example 48,
using
intermediate XIV(2,2-dimethyl-1,2,3,4-tetrahydroquinoline-8-carboxylic acid
described above in the
amide formation step.
L'.x In.ter.mediate St1-ucture Chetiiical n4me Mass
Spec
49 XIV 8-{[(5R,7S)-4-(cyclohexylamino)- 532.1 Qo
1 -(3-fluorophenyl)-7-methyl-2-
N ~ N ~ F oxo-1,3-diaza-8-
H ~
~ / azoniaspiro[4.5]dec-3-en-8-
NH N yl]methyl}-2,2-dimethyl-1,2,3,4-
I tetrahydroquinolinium dichloride
EXAMPLE 50
(5R,7R)-4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-7-vinyl-
1,3,8-
triazaspiro[4.5]dec-3-en-2-one
- 109 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
0
J.~ N F
H
y N Il
o ~
I~
0 0
o cl o,-,-.si. Zn
TBAF
o o o AcOH 0-1-0 N ~MgBr
-3i- -Si-
O N N_ O_ K+ F
C N "
K2CO3 N H
YC (~ CI F N
I ~ o ~ HCI ~ I ~ NH2 o
P
1'r
Step 1: 2-(trimethylsilyl)ethyl 4-oxo-2-vinyl-3,4-dihydropyridine-1 (2H)-
carboxylate
4-Methoxypyridine (17.7 ml, 174 mmol) was dissolved in tetrahydrofuran (500
ml) and cooled to -30 C.
Vinylmagnesium bromide (174 ml, 174 mmol) was added dropwise followed by the
addition of 2-
(trimethylsilyl)ethyl chloridocarbonate (31.5 g, 174 mmol). The solution was
stirred for 30 min at -30 C
and quenched with 1N HCI. The resulting solution was extracted three times
with diethyl ether. The
combined organic fractions were combined, dried with Na2-SO4, and
concentrated. The residue was
purified by column chromatography on silica gel Biotage 65i, eluting with 30%
ethyl acetate/hexanes to
give a yellow liquid.
Step 2: 2-(trimethylsilyl)ethyl4-oxo-2-vinylpiperidine-l-carboxylate
2-(trimethylsilyl)ethyl 4-oxo-2-vinyl-3,4-dihydropyridine-1(2H)-carboxylate
(29.1 g, 109 mmol) in acetic
acid (500 ml) was added zinc dust (42.7 g, 652 mmol). The solution stirred at
room temperature for 2 hrs
and was filtered through a pad of celite. The solvent was evaporated under
reduced pressure and the
product was purified by column chromatography on silica gel Biotage 65i,
eluting with 20% ethyl
acetate/hexanes.
-110-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Step 3: 2-vinylpiperidin-4-one
2-(trimethylsilyl)ethyl4-oxo-2-vinylpiperidine-l-carboxylate (24.1 g, 89.0
mmol) was dissolved in
tetrahydrofuran (90 ml) at 0 C and added TBAF (268 ml, 268 mmol) dropwise. The
solution stirred at
0 C for 30 min then at rt for an additional three hrs. The solution was
quenched with 1N HCl and
extracted five times with EtOAc. The organic fractions were combined, dried
with NazSO4, and
concentrated. The crude product was not purified.
Step 4: 1-(3-isopropoxybenzyl)-2-vinylpiperidin-4-one
2-vinylpiperidin-4-one (4.85 g, 38.7 mmol) in acetonitrile (40 ml) was added 1-
(chloromethyl)-3-
isopropoxybenzene (7.16 g, 38.7 mmol) and finely ground K2C03 (16.1 g, 116
mmol). The mixture was
stirred at 60 C for 12 hrs. The solution was filtered, and the solvent was
evaporated under reduced
pressure. The residue was purified by column chromatography on silica gel
Biotage 65i, eluting with
15% ethyl acetate/hexanes.
Step 5: (5R,7R)-4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-
7-vinyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one
1-(3-isopropoxybenzyl)-2-vinylpiperidin-4-one (7.00 g, 25.6 nnnol) in methanol
(14 ml) was added
cyclohexyl isocyanide (3.17 ml, 25.6 mmol) then potassium cyanate (2.08 g,
25.6 mmol) in water (5 ml)
was added. 3-Fluoroaniline hydrochloride (3.78 g, 25.6 mmol) was then added at
0 C. The mixture was
stirred at rt for 12 hrs. The reaction was incomplete and another half
equivalent of cyclohexyl isocyanide
(1.59 ml, 12.8 mmol), potassium cyanate (1.04 g, 12.8 mmol), and 3-
fluoroaniline hydrochloride (1.89 g,
12.8 mmol) was added. The mixture stirred for an additional twelve hours. The
solution was
concentrated and purified on silica ge17% methanol/chloroform with 0.1%
triethylamine. The impure
product was purified a second time by flash chromatography on silica gel
starting with 50% ethyl
acetate/hexanes to 100% ethyl acetate. The diastereomers were resolved on a
Chiral AD column 10%
ethanol/hexanes with 0.3% diethylamine 250ml/min at 250nm.
'H NMR (CDC13): 8 8.13 (d, J= 8.0 Hz, 1H), 7.38 - 7.32 (m, 1H), 7.26 - 7.20
(m, 1H), 7.05 - 6.96 (m,
3H), 6.81 - 6.75 (m, 3H), 5.87 - 5.78 (m, 1H), 5.23 - 5.16 (m, 2H), 4.57 -
4.51 (m, 1H), 4.06 (d, J= 13
Hz, 1H), 3.99 - 3.95 (m, 1H), 2.96 - 2.74 (m, 3H), 2.28 - 2.22 (m, 1H), 2.13 -
2.03 (m, 3H), 1.98 - 1.88
(m, 2H), 1.85 -1.79 (m, 2H), 1.76 -1.65 (m, 2H), 1.42 -1.09 (m, 11H).
LRMS=519
The compounds in table 6 were prepared in a manner similar to that described
for
Example 50 using the appropriate Grignard reagent in the piperidinone
formation and using the
- 111 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
appropriate benzyl halide in the alkylation step. The products were purified
by normal or reverse phase
chromatography to give the free bases or salts. The diastereomers were
resolved via chiral
chromatography. In some cases the salts isolated from chromatography were
converted to the free bases
with an aqueous workup. They could then be converted to different salts by
mixing the free base in an
appropriate organic acid solution, lilce ethereal HCI, and evaporating to give
the product as the solid salt.
Table 6
Ex # Structure Chemical name Mass
Spec
(M+H)
51 461
Q N--f 0 (5R,7R)-8-benzyl-4-
H'// N (cyclohexylamino)-1-(3-
fluorophenyl)-7-vinyl-1,3,8-
~===.
N I~ triazaspiro[4.5]dec-3-en-2-one
52 533
~ N--{~o (5R,7R)-4-(cyclohexylamino)-1-
H 1N F
(3-fluorophenyl)-8-(3-{[(1R)-1-
methylpropyl]oxy}benzyl)-7-
~ N
o vmyl- 1,3,8-triazaspiro[4.5]dec-3 -
en-2-one
~ \
i
53 532.7
Q O
N (5R,7R)-4-(cyclohexylamino)-1-
~
H os, N F (3-fluorophenyl)-8-(3-
isopropoxybenzyl)-7-[(1E)-prop-
I 1-en-l-yl]-1,3,8-
~~ N triazaspiro[4.5]dec-3-en-2-one
- 112 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Ex # Stnicture Chemical name Mass
Spec
(M+H)
54 532.1
N(5R,7R)-4-(cyclohexylamino)-1-
NJ~, N F (3-fluorophenyl)-8-(3-
isopropoxybenzyl)-7-[(1Z)-prop-
N ~
-TO
triazaspiro[4.5]dec-3-en-2-one
EXAMPLE 55
(5R,7S)-1-(3-fluorophenyl)-7-methyl-4-(methylammonio)-8-[(2'-methylbiphenyl-3-
yl)methyl]-2-oxo-1,3-
diaza-8-azoniaspiro[4.5]dec-3-ene dichloride
O
N-~
H
~ =,
N F
-113-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
O O O
HN~ N-~ N-~
N 'A N
HN~~~''' H H
F N ~., F N F
CBZ CBZ H
11-6A 11-6B
11-6
0
1/ 0
N-\
N~
~-,,. ~ J~ N
J~ ~1 ~ H
N ~ ,,
H
N
N ='-,, F
N ' ", F
/ I I
11-6C
Example 55
Step 1: Benzyl (5R,7,S)-1-(3-fluorophenyl)-7-methyl-4-(methylamino)-2-oxo-
1,3,8-triazaspiro[4.5]dec-3-
ene-8-carboxylate
To a flask containing benzyl (5R,7S)-4-amino-l-(3-fluorophenyl)-7-methyl-2-oxo-
1,3,8-
triazaspiro[4.5]dec-3-ene-8-carboxylate (343 mg, 0.86 mmol; Intermediate 11-6)
was added methylaniine
(2.0 M THF, 4.3 mL, 8.6 mmol). The vessel was sealed and placed in a 70 C oil
bath and stirred
overnight. The reaction was diluted with aqueous NaHCO3 and extracted with
EtOAc (three times). The
combined organic layers were washed with brine, isolated and subsequently
dried over Na2SO4.
Evaporation of solvent and further drying under vacuum gave crude product that
was used in the next
step.
LCMS [M+H] = 411.2
Step 2: (5R,7S)-1-(3-fluorophenyl)-7-methyl-4-(methylamino)-1,3,8-
triazaspiro[4.5]dec-3-en-2-one
(1 1-6A)
The product from step 1 above, benzyl (5R,7S)- 1 -(3 -fluorophenyl)-7-methyl-4-
(methylamino)-2-oxo-
1,3,8-triazaspiro[4.5]dec-3-ene-8-carboxylate (370 mg, 0.86 mmol) was
dissolved in 8 mL MeOH. The
solvent was degassed with a nitrogen flow for 10 min. and Pd(OH)2 (30 mg, 20%
wt. Pd) added. The
mixture was purged with a hydrogen balloon for 10 min. and then maintained
under atmospheric
- 114 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
hydrogen at rt overnight with stirring. The reaction was then filtered over
Celite, the cake rinsed with
EtOAc and the filtrate concentrated to dryness under reduced pressure to give
after drying under vacuum
the product as a white solid.
LCMS [M+H] = 291.2
Step 3: (5R,7S)-1-(3-fluorophenyl)-8-(3-iodobenzyl)-7-methyl-4-(methylamino)-
1,3,8-
triazaspiro[4.5]dec-3-en-2-one
(5R,7S)-1-(3-fluorophenyl)-7-methyl-4-(methylamino)-1,3,8-triazaspiro[4.5]dec-
3-en-2-one (250 mg,
0.86 mmol) from step 2 above was dissolved in DMSO (8.0 mL). The flask was
charged with K2C03
(594 mg, 4.30 mmol) and 3-iodo-benzylbromide (255 mg, 0.86 mmol). The mixture
was then sealed with
a septum and placed in 50 C oil bath and allowed to stir overnight. The
mixture was diluted with water
and extracted with EtOAc (three times). The combined organic layers were
washed with aqueous LiCI
(three times), followed by brine and then dried over Na2S04. Solvent removal
under reduced pressure
gave crude product. Purification over silica via automated flash
chromatography (0 to 20 %
MeOH/CHzCl2 over 20 min.) gave after solvent removal the product as a white
solid: LCMS [M+H] _
507.3
Step 4: (5R,7S)-1-(3-fluorophenyl)-7-methyl-4-(methylammonio)-8-[(2'-
methylbiphenyl-3-yl)methyl]-2-
oxo-1,3-diaza-8-azoniaspiro[4.5]dec-3-ene dichloride (Example 54)
A Biotage microwave vial was charged with intermediate (5R,7S)-1-(3-
fluorophenyl)-8-(3-iodobenzyl)-7-
methyl-4-(methylamino)-1,3,8-triazaspiro[4.5]dec-3-en-2-one (60 mg, 0.118
mmol) from step 3 above,
PdCl2dppf (4.3 mg, 0.01 mmol) and 2-tolylboronic acid (21 mg, 0.15 mmol). The
vial was sealed and put
under a nitrogen atrnosphere. To the solids was added aqueous 1.5M K2C03 (0.24
mL, 0.35 mmol) and
degassed THF (0.7 mL). The mixture was briefly vortexed and heated in an
Optimizer microwave for 5
min. at 120 C. The reaction enclosure was removed and the reaction diluted
with EtOAc and water.
The organic layer was washed with brine, dried over Na2S04 and the solvent
removed under reduce
pressure. Purification over silica via automated flash chromatography (0 to
10% MeOH/CH2C12)
afforded, after solvent removal under reduced pressure, the product as a white
solid. The salt was
prepared by mixing the free base with ethereal HCl and evaporating to give the
product as a solid.
LCMS [M+H] = 471.2
EXAMPLE 56
(5R,7S)-8-(cyclobutylmethyl)-N-cyclohexyl-l-[4'-(isopropylsulfonyl)biphenyl-2-
yl]-7-methyl-2-oxo-
1,3,8-triazaspiro[4.5]dec-3-en-4-aminium chloride and (5S,7R)-8-
(cyclobutylmethyl)-N-cyclohexyl-l-[4'-
(isopropylsulfonyl)biphenyl-2-yl]-7-methyl-2-oxo-1,3,8-triazaspiro[4.5]dec-3-
en-4-aminium chloride
-115-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
OO
O
/
/ N I ~
H~
/
N
Step 1: 4'-(isopropylsulfonyl)biphenyl-2-amine
To a solution of 2-bromoaniline (1.51 g, 8.78 mmol) in a mixture of benzene
(58 mL), H20 (23 mL) and
ethanol (3 mL) was added 4-(isopropylsulfonylphenyl) boronic acid (3.00 g,
13.2 nnnol) followed by
tetraltis(triphenylphoshine) palladium(0) (1.01 g, 0.88 mmol). After stirring
85 C for 48 h the reaction
mixture was poured into H20 (500 mL), extracted with chloroform (three times),
dried over MgSO4 and
concentrated under vacuum. Purification by silica gel chromatography (20%
EtOAc/hexanes - 40 10
EtOAc/hexanes) afforded the desired product.
LRMS (M+1) = 276.0
Step 2: benzyl4-cyano-4-{[4'-(isopropylsulfonyl)biphenyl-2-yl]amino}-2-
methylpiperidine-1-carboxylate
To a solution of benzyl 2-methyl-4-oxopiperidine-l-carboxylate (1.97 g, 7.95
mmol) and 4'-
(isopropylsulfonyl)biphenyl-2-amine (2.19 g, 7.95 mmol) in acetic acid (25 mL)
was added trimethylsilyl
cyanide (0.79 g, 7.95 mmol). After stirring the reaction at rt overnight the
reaction was poured into an
icy solution of ammonium hydroxide (30 mL). The solution was extracted with
chloroform (three times),
dried over MgSO4 and concentrated under vacuum. Purification by silica gel
chromatography afforded
the desired product. To enhance the cis/trans product ratio the isolated
material was dissolve in methanol
(20 mL) and trimethylsilyl cyanide (3.18 g, 23.9 mmol) was added. After
stirring the reaction at 70 C
overnight the reaction was concentrated under vacuum. Purification by silica
gel chromatography
afforded the desired product.
LRMS (M+1) = 532.1
Step 3: benzyl (5R,7S)-4-amino-l-[4'-(isopropylsulfonyl)biphenyl-2-yl]-7-
methyl-2-oxo-1,3,8-
triazaspiro[4.5]dec-3-ene-8-carboxylate and benzyl (5S,7R)-4-amino-l-[4'-
(isopropylsulfonyl)biphenyl-2-
yl]-7-methyl-2-oxo-1,3, 8-triazaspiro[4.5]dec-3-ene-8-carboxylate
- 116 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
To a solution ofbenzyl4-cyano-4-{[4'-(isopropylsulfonyl)biphenyl-2-yl]amino}-2-
methylpiperidine-l-
carboxylate (4.23 g, 7.96 nunol) in methylene chloride (75 mL) was added
trichloroacetyl isocyanate
(1.95 g, 10.34 mmol). After stirring the reaction mixture for 4 h at 65 C the
reaction was cooled and a
solution of diisopropylamine (1.34 g, 10.34 mmol) in H20 (10 mL) and methanol
(15 mL) was added.
After stirring at 65 C for 2 h the reaction mixture was cooled and washed with
brine (once), dried over
MgSO4 and concentrated under vacuum. Purification by silica gel chromatography
(5%
methanol/chloroform/1%triethylamine - 15% methanol/chloroform/1 triethylamine)
afforded the desired
product
LRMS (M+1) = 575.0
Step 4: benzyl (5R,7S)-4-[(tert-butoxycarbonyl)amino]-1-[4'-
(isopropylsulfonyl)biphenyl-2-yl]-7-methyl-
2-oxo-1,3,8-triazaspiro[4.5]dec-3-ene-8-carboxylate and benzyl (5S,7R)-4-
[(tert-butoxycarbonyl)amino]-
1-[4'-(isopropylsulfonyl)biphenyl-2-yl]-7-methyl-2-oxo-1,3,8-
triazaspiro[4.5]dec-3-ene-8-carboxylate
To a solution ofbenzyl (5R,7S)-4-amino-l-[4'-(isopropylsulfonyl)biphenyl-2-yl]-
7-methyl-2-oxo-
1,3,8-triazaspiro[4.5]dec-3-ene-8-carboxylate and benzyl.(5S,7R)-4-amino-1-[4'-
(isopropylsulfonyl)biphenyl-2-yl]-7-methyl-2-oxo-1,3,8-triazaspiro [4.5]dec-3-
ene-8-carboxylate
(2.09 g, 3.64 mmol) in THF (50 mL) was added BOC-anhydride (0.952 g, 4.36
mmol). After
stirring at 70 overnight the reaction was concentrated under vacuum.
Purification by silica gel
chromatography (4% methanol/chloroform/1 %triethylamine) afforded the desired
product.
LRMS (M+l) = 675.1
Step 5: benzyl (5R,7S)-4-(cyclohexylamino)-1-[4'-(isopropylsulfonyl)biphenyl-2-
yl]-7-methyl-2-oxo-
1,3,8-triazaspiro[4.5]dec-3-ene-8-carboxylate and benzyl (5S,7R)-4-
(cyclohexylamino)-1-[4'-
(isopropylsulfonyl)biphenyl-2-yl]-7-methyl-2-oxo-1,3,8-triazaspiro[4.5] dec-3-
ene-8-carboxylate
To a solution of benzyl (5R,7S)-4-[(tert-butoxycarbonyl)amino]-1-[4'-
(isopropylsulfonyl)biphenyl-2-yl]-
7-methyl-2-oxo-1,3,8-triazaspiro[4.5]dec-3-ene-8-carboxylate and benzyl
(5S,7R)-4-[(tert-
butoxycarbonyl)amino]-1-[4'-(isopropylsulfonyl)biphenyl-2-yl]-7-methyl-2-oxo-
1,3,8-triazaspiro[4.5]dec-
3-ene-8-carboxylate (1.97 g, 2.92 nunol) in toluene (20 ml) was added
cyclohexylamine (2.03 g, 20.4
mmol). After stirring at 110 C overnight the reaction mixture was diluted with
chloroform, washed with
1N aqueous HCI (three times), dried over MgSO4 and concentrated under vacuum
to afford the desired
product.
LRMS (M+1) = 657.4
Step 6: (5R,7S)-4-(cyclohexylamino)-1-[4'-(isopropylsulfonyl)biphenyl-2-yl]-7-
methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one and (5S,7R)-4-(cyclohexylamino)-1-[4'-
(isopropylsulfonyl)biphenyl-2-yl]-
7-methyl-1, 3, 8-triazaspiro [4.5 ] dec-3 -en-2-one
- 117 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
To a solution of benzyl (5R,7S)-4-(cyclohexylamino)-1-[4'-
(isopropylsulfonyl)biphenyl-2-yl]-7-methyl-2-
oxo-1,3,8-triazaspiro[4.5]dec-3-ene-8-carboxylate and benzyl (5S,7R)-4-
(cyclohexylamino)-l-[4'-
(isopropylsulfonyl)biphenyl-2-yl]-7-methyl-2-oxo-1,3,8-triazaspiro[4.5]dec-3-
ene-8-carboxylate (1.90g,
2.92 mmol) in methanol (50 mL) was added a catalytic amount of 10% palladium
on carbon. After
stirring for 1 h under and atmosphere of hydrogen at ambient pressure and
temperature the reaction
mixture was filtered through a pad of celite and concentrated under vacuum to
afford the desired product
that was subsequently used without further purification.
LRMS (M+1) = 523.2
Step7: (5S,7R)-8-(cyclobutylmethyl)-4-(cyclohexylamino)-1-[4'-
(isopropylsulfonyl)biphenyl-2-yl]-7-
methyl-1,3,8-triazaspiro[4.5]dec-3-en-2-one and (5S,7R)-8-(cyclobutylmethyl)-4-
(cyclohexylamino)-1-
[4'-(i sopropyl sul fonyl)biphenyl-2-yl] -7-methyl-1, 3, 8-triazaspiro [4. 5]
de c-3 -en-2 -one
To a solution of (5R,7S)-4-(cyclohexylamino)-1-[4'-(isopropylsulfonyl)biphenyl-
2-yl]-7-methyl-1,3,8-
triazaspiro[4.5]dec-3-en-2-one and (5S,7R)-4-(cyclohexylamino)-1-[4'-
(isopropylsulfonyl)biphenyl-2-yl]-
7-methyl-1, 3, 8-triaza spiro [4. 5] dec-3 -en-2-one
(0.2 g, 0.38 mmol) in DMF (1.5 mL) was added potassium carbonate (0.21 g, 1.53
nunol) followed by
(bromomethyl)cyclobutane (0.057 g, 0.38 mmol). After stirring the at 70 C
overnight the reaction
mixture was filtered and purified by reverse phase HPLC to afford the desired
product. The free base of
the product was formed by aqueous workup with aqueous base and an organic
solvent like chloroform
and the HCl salt was prepared by mixing the free base with ethereal HCl and
evaporating to give the salt.
LRMS (M+l) = 591.3
1H NMR (CDC13) 8 7.87 (t, J= 8.7 Hz, 2H), 7.74 (dd, J= 6.5, 8.2 Hz, 2H), 7.49
(m, 4H), 3.91 (m, 1H),
3.21 (m, 1H), 2.75 (m, 2H), 2.51-0.95 (m, 24H), 1.30 (d, J= 6.8 Hz, 6H), 1.05
(d, J= 6.2 Hz, 3H).
The following examples in Table 7 were prepared using a procedure similar to
that
described for Example 2, starting with the 1-benzyl-2-methylpiperidin-4-one,
(Intermediate I,), except
that tetrabutylammonium isocyanate was used in place of KOCN. In some
instances, the racemic
mixture was resolved via chiral HPLC to give the final enantiomerically pure
product.
- 118 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Table 7
Ex # Structure Chemical nanie Mass
Spec
+H)+
57 (5R,7S)- 8-benzyl-4- 409
(cyclohexylamino)-l -
N-~ 0 (cyclopropylmethyl)-7-methyl-2-
N / N oxo-1,3-diaza-$-
H azoniaspiro[4.5]dec-3-ene
N "'Me trifluoroacetate
58 (5R,7S)-(5S,7R)-8-benzyl-4- 395
(cyc lohexylamino)-1-
a N 0 cyclopropyl-7-methyl-2-oxo-1,3-
N
N- diaza-8-azoniaspiro[4.5]dec-3-ene
H trifluoroacetate
N Me
59 (5R,7S)-(5S,7R)-8-benzyl-l- 409
cyclobutyl-4-(cyclohexylamino)-
0 7-methyl-2-oxo-1,3-diaza-8-
~
~\ azoniaspiro[4.5]dec-3-ene
H trifluoroacetate
N Me
( \
60 (5R,7S')-(5S,7R)-8-benzyl-4- 423
(cyclohexylamino)-1-cyclopentyl-
7-methyl-2-oxo-l,3-diaza-8-
azoniaspiro[4.5]dec-3-ene
trifluoroacetate
- 119 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Ex # StnGcture Ghemical name Mass
Spec
M+H)-'
N~O
N
N
H
N Me
61 (5R,7S)-(5S,7R)-8-benzyl-l- 437
cyclohexyl-4-(cyclohexylamino)-
0 7-methyl-2-oxo-1,3-diaza-8-
%~N azoniaspiro[4.5]dec-3-ene
aN-
- 0 H trifluoroacetate
N Me
62 (5R,7S)-(5S,7R)-8-benzyl-4- 409
(cyclohexylamino)-7-methyl-l-(2-
/O Me methylprop-2-en-1-yl)-2-oxo-1,3-
j~\N diaza-8-azoniaspiro[4.5]dec-3-ene
H trifluoroacetate
N Me
63 (5R,7S')-(5S,7R)-8-benzyl-4- 425
(cyclohexylamino)-7-methyl-2-
oxo-1-(tetrahydrofuran-3 -yl)-1, 3 -
diaza-8-azoniaspiro[4.5]dec-3-ene
trifluoroacetate
-120-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Ex # Structure Chemical naine Mass
Spec
M+H. +
N--f 0
aN-
O
H N ~O
N Me
EXAMPLE 64
(5R,7S)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-7-methyl-4- { [(3S)-1-
(methylsulfonyl)pyrrolidin-3-
yl]amino}-2-oxo-1,3-diaza-8-azoniaspiro[4.5]dec-3-ene trifluoroacetate and
(5S,7R)-1-(3-fluorophenyl)-
8-(3-isopropoxybenzyl)-7-methyl-4-{ [(3S)-1-(methylsulfonyl)pyrrolidin-3-
yl]amino} -2-oxo-1,3-diaza-8-
azoniaspiro[4.5]dec-3-ene trifluoroacetate
O"/
O O"S O~S O
HN-/ O' ~ N N-~
N
N F F
aNN
I / NH3CI H
N DIEA, DMSO, 100 C N
\ O \ O
)00C111 Example 64
The amine salt Intermediate .XXII (167.3 mg, 0.834 nunol, 10 eq. Amine
synthesis was described above),
DMSO (0.45 mL), DIEA (150 L, 0.86 mmol, 10 eq.), and the thiohydantoin
(Intermediate XXXIII, 37.8
mg, 0.0856 nunol, 1.0 eq.) were placed into a vial with a stir bar. The
reaction was stirred and heated in
a 100 C aluminum block for 3h, and was then cooled to rt and submitted
directly for reverse phase
preparative HPLC (acetonitrile:water), to provide the desired analogue as the
trifluoroacetate salt.
'H NMR (CD3OD, 400 MHz) S: 7.35-7.21 (m, 2H), 7.20-7.05 (m, 3H), 7.00 (d,
J=6.9Hz, 1H), 6.79 (s,
1H), 6.75 (s, 1H), 6.74 (s, 1H), 4.61 (septet, J=6.1Hz, 1H), 4.28 (d,
J=13.2Hz, 1H), 4.45-4.40 (br s, 1H),
-121-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
4.18 (d, J=13.2Hz, 1H), 3.70-3.55 (m, 2H), 3.50-3.35 (m, 2H), 2.95-2.90 (m,
5H), 2.75-2.50 (m, 4H),
2.50-2.25 (m, 3H), 2.25-2.05 (m, 1H), 1.53 (br s, 3H), 1.32 (d, J=5.9Hz, 6H).
El-MS rn/z: 572 (M + H)+.
Examples 65-67 described in Table 8 are prepared in a manner similar to the
procedure
of Example 64 as shown in the scheme below. Intermediate XXXIII and the
corresponding amine / or
amine salt (commercially available or the preparation described above) are
dissolved in DMSO or DMF.
The resulting mixture is heated at 80 C -100 C until the reaction is
complete. The desired invention
compounds are purified by preparative HPLC. In some cases chiral HPLC was used
to isolate the
products.
O /O
HN~ N~
h/N-Q
S NRNH2 R,H Solvent F
N -,, F or neat N
\ I ~
XXXIII
Table 8
Ex # Intermediate Structure Chemi-cal Na7ne Mass
Spec
i42+fI' _:, .
65 XXV (5R,7S)-4-[(3,3-
p difluorocyclohexyl)amino]-1-
N-~/
N J; N F (3-fluorophenyl)-8-(3-
H isopropoxybenzyl)-7-methyl-2- 543
~
O N oxo-1,3-diaza-8-
azoniaspiro[4.5]dec-3-ene
trifluoroacetate
- 122 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Ex # Intermediate Structure Chemical Name Mass
Spec
M+H +
66 XXV 0 (5R,7S)- (5S,7R)-4-[(2-fluoro- 485
F~N JN N F 1-methylethyl)amino]-1-(3-
H fluorophenyl)-8-(3-
N isopropoxybenzyl)-7-methyl-
01,3,8-triazaspiro[4.5]dec-3-en-
2-one
67 Commercially 0 (5R,7S)- (5S,7R)-4-{[(1S)-1,2- 495
available N4 dimethylpropyl]amino}-1-(3-
NJ' N N~ F
H fluorophenyl)-8-(3-
~= ~~
N isopropoxYbenzY1)-7-methYl-
\/O\~J
1,3,8-triazaspiro[4.5]dec-3-en-
2-one
Examples 68-78 described in Table 9 are prepared by the procedure as shown
below. In
some cases the benzyl2-methyl-4-oxopiperidine-l-carboxylate used to prepare
XXXII was resolved (see
Example 11, Step 3, prep of 11-3S). XXXII and the corresponding amine / or
amine salt (conunercial
available or the preparation described above) are dissolved in DMSO or DMF.
The resulting mixture is
heated at 80 C -100 C until the reaction is complete. The desired invention
compounds are purified by
preparative HPLC. In some cases chiral HPLC was used to isolate the products.
O 0
HN-~ /N
HN~,,.. :nt RJ
F
N==~,, F or neat N "'",
O-Tl- I / O--r
X)OCII
-123-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Table 9
Ex # Intermediate Structure Chemical Name Mass
Spec
(M+H)t
68 XXIII --f (5R,7S)-4-{[(1R,2R)-2- 525
nN
H fluorocyclohexyl]amino}-1-(3-
N ==-- fluorophenY1)-8-(3-
isopropoxybenzyl)-7-methyl-2-
oxo-1,3-diaza-8-
o azoniaspiro[4.5]dec-3-ene
N~ N F trifluoroacetate and
H
F (5R,7S)-4-{[(1S,2S)-2-
0 fluorocyclohexyl]amino}-1-(3-
fluorophenyl)-8-(3-
isopropoxybenzyl)-7-methyl-2-
oxo-1,3-diaza-8-
azoniaspiro[4.5]dec-3-ene
trifluoroacetate
69 XXIII 0 (5R,7S)-4-{[(1R,2R)-2- 525.6
IIIJ N N F fluorocyclohexyl]amino}-1-(3-
H~ fluorophenyl)-8-(3-
N isopropoxybenzyl)-7-methyl-
~ Or 1,3,8-triazaspiro[4.5]dec-3-en-2-
one
70 XXIII O (5R,7S)-4-{[(1S,2S)-2- 525.6
fluorocyclohexyl]amino}-1-(3-
N/; NF
F fluorophenyl)-8-(3-
H i
N isopropoxybenzyl)-7-methyl-
I O,/ 1,3,8-triazaspiro[4.5]dec-3-en-2-
~ I one
- 124 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Ex # Intermediate Structure Chemical Name Mass
Spec
M+H *
71 XxVI (5R,7S)-1-(3-fluorophenyl)-8-(3- 507
N sopropoxybenzyl)-4-[(2-
--~O F i
HJ%-. N \ / isopropylcyclopropyl)amino]-7-
methyl-1,3,8-triazaspiro[4.5]dec-
N
-Ir0 3-en-2-one Nz~ 72 XXVII 0 (5R,7S)-4-{[(1R,2R)-2- 511
~N N~ fluorocyclopentyl]amino}-1-(3-
N F
F H fluorophenyl)-8-(3-
N isopropoxybenzyl)-7-methyl-
OV 1,3,8-triazaspiro[4.5]dec-3-en-2-
~,0 one and
N
N , N I F (5R,7S)-4-{[(1S,2S)-2-
F
NJ fluorocyclopentyl]amino}-1-(3-
OI/ ~ fluorophenyl)-8-(3-
isopropoxybenzyl)-7-methyl-
1,3,8-triazaspiro[4.5]dec-3-en-2-
one
73 XXVIII (5R,7,S)-1-(3-fluorophenyl)-8-(3- 507
0 isopropoxybenzyl)-4-[(2-
JN N
N F isopropylcyclopropyl)amino]-7-
H ~ methyl-1,3,8-triazaspiro[4.5]dec-
NJ 3-en-2-one
olr
74 XXIX O (5R,7S)-4-{[(1R)-2,2- 543
N JN difluorocyclohexyl]amino}-1-(3-
N~
F F H IIJ~ fluorophenyl)-8-(3-
O F
N isopropoxybenzyl)-7-methyl-
1,3,8-triazaspiro[4.5]dec-3-en-2-
one
-125-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
Ex # Intermediate Structure Chemical Name Mass
Spec
M+H
75 xxix 0 (5R,7S)-4-{[(1S)-2,2- 543
N4 F difluorocyclohexyl]amino}-1-(3-
N J', N~
F F H fluorophenyl)-8-(3-
N ~isopropoxYbenzY1)-7-methyl-
\/O\~J
~1 ~I' 1,3,8-triazaspiro[4.5]dec-3-en-2-
i
one
76 xxx 0 (5R,7S)-4-{[(1R)-2,2- 529
N--~ -1-
difluorocyclopentyl]amino}
~NJ N F
F F H (3-fluorophenyl)-8-(3-
N isopropoxYbenzY1)-7-methyl-
-yo~ 1,3,8-triazaspiro[4.5]dec-3-en-2-
i
one
77 XXX 0 (5R,7S)-4-{[(1S)-2,2- 529
Q ~N N4 F difluorocyclopentyl]amino}-1-
J%, N
F F H (3-fluorophenyl)-8-(3-
N isopropoxYbenz1'1)-7-methYl-
\/O\~J
~I ~U 1,3,8-triazaspiro[4.5]dec-3-en-2-
i
one
78 xxO o (5R,7S)-4-{[(1R,2S)-2- 525
~ N4 fluorocyclohexyl]amino}-1-(3-
N
F Hn fluorophenyl)-8-(3-
N isopropoxybenzyl)-7-methyl-
O
TI V 1,3,8-triazaspiro[4.5]dec-3-en-2-
0 one and
O. N N N F (5R,7S)-4-{[(1S,2R)-2-
F ~ fluorocyclohexyl]amino}-1-(3-
N
O fluorophenyl)-8-(3-
YI V isopropoxybenzyl)-7-methyl-
1,3,8-triazaspiro[4.5]dec-3-en-2-
one
- 126 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
The example in Table 10 was prepared from the appropriate commercially
available or
custom-made amine and the thiohydantoin Intermediate XV above, using methods
similar to that
described for Example 64. The amine or amine salt was heated with the
thiohydantoin neat or with an
appropriate base like N-methylmorpholine as the base/cosolvent and in some
instances an additional
appropriate solvent like toluene was used.
Table 10
.Ex # Intermediate Structure Chemical na:me Mass
Spec
(M+H)
79 0 (5R,7S)-8-benzyl-l-(3- 451.3
Commercially
N fluorophenyl)-7-methyl-4-
available ~ N N '==-, /
H trimethylpropyl]amino}-1,3,8-
N triazaspiro[4.5]dec-3-en-2-one
F
and (5S,7R)-8-benzyl-l-(3-
~ fluorophenyl)-7-methyl-4-
{[(1S)-1,2,2-
trimethylpropyl] amino } -1, 3 , 8 -
triazas iro 4.5 dec-3-en-2-one
EXAMPLE 80
(5R,7S)-4-(cyclohexylimino)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-3,7-
dimethyl-1,3, 8-
triazaspiro [4.5] decan-2-one
O F
\N'\
N 6
aN
y N
O &
(5R,7S)-4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-7-methyl-
1,3, 8-
triazaspiro[4.5]dec-3-en-2-one 11-10, 0.5 g, 0.1 mmoles) was dissolved in THF
(2 mL) in an oven-dried
flask and the solution was cooled under nitrogen to -78 C in a dry ice/
acetone bath. To the cooled
- 127 -
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
reaction was added a 1 M solution of Lithium bis(trimethylsilyl)amide in THF
(0.3 mL, 0.3 mmoles)
dropwise, and the solution was warmed to -20 C for 10 min. The solution was
cooled to -50 C and
iodomethane (0.014 g, 0.1 mmole) was added and the reaction stirred for 30 min
at -50 C. The reaction
was then allowed to warm to rt. A drop of acetic acid was added and the volume
was reduced. The
residue was partitioned between saturated aqueous sodium bicarbonate (5 mL)
and methylene chloride (5
mL). The organic layer was dried over sodium sulfate, filtered and reduced to
a residue which was
chromatographed on silica gel eluting with a gradient elution of 100%
methylene chloride going to 30%
methylene chloride/methanol/10% NH4OH solution over 20 min. The desired
fractions were combined
and the solvents removed to give the product.
(major conformer) 1H NMR (600 MHz, CD2C12) 7.38 (dd, J= 8, 14.8 Hz, 1H), 7.13
(m, 2H), 7.0 (m,
2H), 6.75 (m, 3H), 4.5 (m, 1H), 4.14 (m, 1H), 3.93 (d, J=13.7, 1H), 2.94(s,
3H), 2.75 (d, J=13.7, 1H),
2.54 (m, 1H), 2.4 (m, 1H), 2.22 (m, 1H), 2.1 (m, 2H), 2.0-1.6 (m, 7H), 1.4 (m,
4H), 1.3 (m, 1H), 1.29 (d, J
= 5 Hz, 6H), 1.05 (m, 3H).
(minor conformer) 1H NMR (600 MHz, CD2C12) 7.38 (dd, J= 8, 14.8 Hz, 1H), 7.13
(m, 2H), 7.0 (m,
2H), 6.75 (m, 3H), 4.5 (m, 1H), 4.0 (m, 1H), 3.86 (d, J=13.4, 1H), 2.58 (d,
J=13.4, 1H), 2.46 (m, 1H), 2.1
(m, 3H), 1.9-1.6 (m, 8H), 1.4 (m, 5H), 1.33 (d, J = 6Hz, 3H), 1.26 (d, J 6 Hz,
6H), 1.1 (m, 3H).
LCMS ion fragment = 507.11
The following abbreviations are used throughout the text:
Me: methyl
Et: ethyl
t-Bu: tert-butyl
Ar: aryl
Ph: phenyl
Bn: benzyl
Ac: acetyl
TMSCN: trimethylsilyl cyanide
DMSO: dimethylsulfoxide
EDTA: ethylene diamine tetraacetic acid
Boc: tert-butyloxy carbonyl
CHAPS: 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-l-propanesulfonate
BSA: bovine serum albumin
TFA: trifluoracetic acid
DME : dimethoxyethane
DPPA : diphenylphosphorlyazide
DIEA : diisopropylethylamine
TBAF : tetrabutylammonium fluoride
-128-
CA 02615656 2008-01-16
WO 2007/011833 PCT/US2006/027594
TEA : triethylamine
DCE : dichloroethane
DCM : dichloromethane
TPP: triphenyl phosphine
OTs: toluene sulfonate
BOP: benzotriazolyl-N-oxy-tris(dimethylamino)phosphonium hexaflurophosphate
DIPEA: diisopropylethylamine
DMF: dimethylformamide
DIAD: diisopropylazodicarboxylate
MTBE: methyltertbutylether
LAH: lithium aluminum hydride
DIBAL: diisobutylaluminum hydride
rt: room temperature
aq: aqueous
HPLC: high performance liquid chromatography
MS: mass spectrometry
While the invention has been described and illustrated with reference to
certain
particular embodiments thereof, those skilled in the art will appreciate that
various adaptations, changes,
modifications, substitutions, deletions, or additions of procedures and
protocols may be made without
departing from the spirit and scope of the invention. It is intended,
therefore, that the invention be
defined by the scope of the claims that follow and that such claims be
interpreted as broadly as is
reasonable.
-129-
